Pattern recognition receptor activity at the maternal fetal interface: Implications for preterm labour. by Aled Huws, Bryant
  Swansea University E-Theses                                     
_________________________________________________________________________
   
Pattern recognition receptor activity at the maternal fetal interface:
Implications for preterm labour.
   
Bryant, Aled Huws
   
 
 
 
 How to cite:                                     
_________________________________________________________________________
  
Bryant, Aled Huws (2014)  Pattern recognition receptor activity at the maternal fetal interface: Implications for preterm
labour..  thesis, Swansea University.
http://cronfa.swan.ac.uk/Record/cronfa42934
 
 
 
 Use policy:                                     
_________________________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence: copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder. Permission for multiple reproductions should be obtained from
the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
Please link to the metadata record in the Swansea University repository, Cronfa (link given in the citation reference
above.)
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/
 Pattern recognition receptor activity at 
the maternal-fetal interface: 
Implications for preterm labour
Aled Huws Bryant
Submitted to Swansea University in 
fulfilment of the requirements for the 
Degree of Doctor of Philosophy
Swansea University 
2014
ProQuest Number: 10821324
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this reproduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a co m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria l had to be rem oved,
a no te  will ind ica te  the de le tion .
uest
ProQuest 10821324
Published by ProQuest LLC(2018). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C o de
M icroform  Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 4 81 06 - 1346

Summary
Interest in the innate immune response at the maternal-fetal interface has developed 
due to the association between intrauterine infection, inflammation and adverse 
pregnancy outcomes. Pattern recognition receptors (PRRs) offer a link between 
microbial derived agonists and the production of inflammatory mediators by 
gestation-associated tissues (placenta, choriodecidua and amnion). An improved 
understanding of these receptors and the signal transduction cascades they initiate 
in these tissues might explain why some pregnancies are complicated by preterm 
labour (PTL) and preterm premature rupture of the membranes (PPROM) whereas 
others are only affected by PPROM. However while this may be the eventual aim of 
this field of study; a greater understanding of PRR expression and activity in term 
non-laboured tissues is required to provide a baseline comparison for these 
receptors, in order to determine any potential role they may play in normal term 
labour but also in preterm labour and other adverse pregnancy outcomes.
Examination of PRRs in term non-laboured gestation-associated tissues 
demonstrated the expression of transcripts for Toll-like Receptors (TLRs), NOD-like 
receptors (NLRs), RIG-l-like Receptors (RLRs) and C-type lectin Receptors (CLRs). 
A functional role for TLRs 1-7, NOD1, NOD2, RIG-I/MDA5 and Dectin-1 can be 
inferred by an increase in the production of IL-6 and IL-8 following stimulation with 
receptor specific agonists. IL-1p production and activation of the caspase-1 and/or 
caspase-8 inflammasome was observed in the placenta and choriodecidua in 
response to fungal (3-glucan and bacterial flagellin. The anti-inflammatory cytokines 
IL-4, IL-10 and IL-13 are able to down-regulate the lipopolysaccharide-stimulated 
cytokine responses by the placenta, choriodecidua and amnion. This highlights the 
potential utility of these cytokines in preventing preterm birth.
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Chapter 1
Introduction
1 Introduction
1.1 Overview
Labour is the climax of pregnancy resulting in the expulsion of the fetus from the 
uterus. It is a complex process and the mechanisms involved in the initiation of 
labour are poorly understood despite decades of investigation. Generally, labour is 
not a sudden occurrence but one for which the body prepares: numerous 
physiological, endocrinological, biochemical and immunological events take place at 
the maternal-fetal interface and in both mother and fetus in the lead up to parturition 
[1-5]. These same processes might be accelerated or other pathways brought into 
play when labour occurs prematurely. The bulk of perinatal morbidity and mortality is 
associated with premature labour and delivery of a preterm infant [6, 7]. 
Understanding the mechanisms of labour in healthy and in adverse obstetric 
outcomes should provide insight into the pathogenesis of preterm birth (PTB).
1.2 Human labour
Human labour and delivery have been compared to an inflammatory response [8-10] 
of at least three physiologically interdependent processes (Figure 1.1): remodelling 
of the cervix to allow it to stretch open to the width of the reproductive tract, 
weakening and rupture of the membranes in the region that overlies the cervix, and 
the initiation of rhythmic contractions of increasing amplitude and frequency that 
ultimately force the fetus and placenta from the uterus. Pro-inflammatory cytokines 
produced primarily by gestation associated tissues (placenta and fetal membranes; 
Figure 1.2) have a role in most of these processes, suggesting that the immune 
privileges that the fetal-placental unit has enjoyed during pregnancy might be 
revoked at the time of labour [9]. Beneficial effects of strong pro-inflammatory 
activity during labour could include removal of placental fragments and a heightened 
innate immune response in the postpartum uterus to combat the pathogens 
undoubtedly encountered at this time.
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Figure 1.1 Overview of human labour.
Increased production and release of inflammatory cytokines is caused by a triggering event (e.g. 
microbial stimuli). This leads to the recruitment of inflammatory cells and the increased production of 
other inflammatory mediators. These events facilitate the three physiological process of human labour; 
cervical ripening, membrane rupture and myometrial contractions. These events can also be hindered 
by several inhibitors including IL-10, progesterone and tissue inhibitor of metalloproteinsase (TIMP). 
Adapted from Patni et al [11].
3
Decidua
Fetal
Membranes
Myometrium O!
Placenta
Umbilical Cord
Cervix
Figure 1.2 Gestation associated tissues.
During pregnancy the fetal environment includes the gestation associated tissues - placenta and the 
fetal membranes (amnion and choriodecidua).
1.2.1 Cervical ripening
Re-modelling of the extracellular matrix, including decreased collagen concentration 
and the dispersion of collagen fibrils, is a feature of cervical ripening [12, 13]. This is 
facilitated by increased local production of many pro-inflammatory cytokines and 
chemokines, such as interleukin-1 (3 (IL-1p), IL-6, IL-8, monocyte chemotactic 
protein-1 (MCP-1; CCL2) and tumour necrosis factor a (TNFa) [14, 15]. There is 
also an influx of neutrophils and macrophages that also secrete cytokine and 
chemokines and amplify the inflammatory response via the recruitment of other 
inflammatory cells to the cervix [16-18]. Cytokines such as TNFa and IL-1(3 activate 
the nuclear factor (NF)-kB pathway, leading to increased production of proteases, 
cathepsins and matrix metalloproteinase (MMPs),that allow for the digestion of 
collagen [19]. Inhibitors of MMP are down-regulated by IL-1(3 which also increases 
production of cyclooxygenase (COX)-2 and prostaglandin E2 (PGE2) and this further 
increases production of proteinases and modulates leukocyte trafficking [20]. Murine
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models show that mechanisms regulating cervical ripening might differ in preterm 
and term birth, and with underlying cause of labour: preterm birth subsequent to 
progesterone withdrawal in the absence of infection was comparable to term 
cervical ripening but preterm ripening in response to infection (using 
lipopolysaccharide (LPS)) was associated with a robust pro-inflammatory response 
including neutrophil influx and activation of the prostaglandin synthesis cascade 
[21].
1.2.2 Membrane rupture
Membrane rupture is characterised by extracellular matrix remodeling: fibronectin is 
degraded by MMPs and other proteases [22, 23] facilitating separation of the 
previously fused chorioamniontic membranes and deciduas. Fetal fibronectin 
present in vaginal secretions during early pregnancy can be used as a marker for 
PTB [24]. Similar to the cervix, production of MMPs is increased in response to the 
augmented production of pro-inflammatory cytokines such as IL-8, IL-6, TNFa and 
IL-1 (3 [25-27]. Collagen, particularly collagen I and collagen IV are responsible for 
the strength of the fetal membranes. Specific MMPs modulated by tissue inhibitors 
of matrix metalloproteinases (TIMPs) control collagen degradations, thus the ratio of 
MMPs to TIMPs can be used as an indicator of collagen degradation [28]. It has also 
been noted that inflammatory cytokines can weaken the fetal membranes. This is 
achieved by production of reactive oxygen species (ROS), which has been 
associated with the induction of prostaglandins and MMP-9 [29]. TIMP-1, which 
modulates the activity of MMP-9, is decreased with labour and premature rupture of 
the membranes (PROM) [30, 31].
1.2.3 Myometrial contractions
A similar pattern of cytokine activity is observed in the myometrium: increased levels 
of IL-6, IL-13, TNFa and IL-8 result in increased production of COX-2 and PGE2 [32, 
33]. IL-6 in particular promotes increased production of oxytocin and expression of 
the oxytocin receptor by myometrial cells [34]. Contractions of the uterine smooth 
muscle are primarily facilitated by intracellular calcium and phosphorylation of 
myosin light chains [35]. Oxytocin and prostaglandins are key in this process, 
whereby activation of uterine contractility either directly or indirectly by oxytocin via 
PGF2 results in the activation of phospholipase C, and subsequently the activation of 
calcium channels, resulting in increased intracellular calcium levels [36, 37]. 
Additionally oxytocin facilitates gap junction formation between cells by increasing
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the expression of connexion-43, a gap junction protein, resulting in enhanced cell­
cell coupling, facilitating the synchronisation of the uterine contractions [38].
1.3 Preterm birth
Preterm Birth (PTB) as defined by the World Health Organisation (WHO) is “all 
births prior to 37 completed weeks of gestation or fewer than 259 days since the first 
day of a woman’s last menstrual period” and can be further sub-divided based on 
gestational age [39, 40] (Table 1-1).
Table 1-1 Preterm deliveries subdivided by gestation.
PTB Sub-Category Gestation (Weeks) Occurrence (%)
Extremely Preterm < 2 8 5%
Very Preterm 28 -  < 3 2 12%
Moderate to late Preterm 32 -  < 37 83%
Adapted from March of Dimes [39], Hamilton & Tower [40] and Goldenberg et al [41]. PTB, preterm 
birth.
PTB is the leading cause of perinatal morbidity and mortality in the Western world; 
75% of perinatal mortality and nearly 50% of long-term neurological morbidity are 
associated with PTB [41]. Preterm infants are prone to higher rates of complications 
of the gastrointestinal, renal and respiratory systems [42]. Increasing PTB rates over 
the past 30 years in industrialised countries reflects increased indicated preterm 
births for reasons such as preeclampsia and intrauterine growth restriction (IUGR), 
and the fallout of multiple gestations associated with assisted reproductive 
technologies (ART). Other risk factors for preterm birth include ethnicity, previous 
preterm birth, extremes of maternal body mass index (BMI), genetic variation, 
infection including periodontal disease, and adverse behaviours [41] (Figure 1.3). 
Annual estimates currently suggest that 12.9 million infants worldwide (about 10%) 
are born prematurely [43]. The prevention and management of PTB is one of the 
major challenges of contemporary obstetrics and gynaecology. PTB also has a large 
economic impact. The cost of preterm birth to the UK is £939 million per year, with
the average the cost of a preterm baby is more than one and half times that of a full 
term neonate [44]. Recent decades have seen improvements in the survival rates of 
preterm infants due to advances in neonatal care and the increased use of antenatal 
steroids but little change in the ability to prevent PTB [45].
There are three obstetric precursors leading to PTB. The primary precursor is 
spontaneous preterm labour (sPTL) with intact membranes, defined as uterine 
contractions and cervical changes before 37 weeks gestation, which accounts for 
45% of preterm births. Accounting for 25% of preterm births is preterm premature 
rupture of the membranes (PPROM), characterised by spontaneous membrane 
rupture before 37 weeks gestation [41]. Both sPTL and PPROM are the outcome of 
maternal and/or fetal inflammation that can have a systemic component or remain 
localised to the reproductive tract. The final precursor, accounting for 30% of 
preterm births, is when the infant is delivery by caesarean section before 37 weeks 
for reasons including preeclampsia, placental abruption and growth restrictions. This 
is referred to as delivered for maternal or fetal indications [40].
Intrauterine infection is a common mechanism of preterm labour accounting for 25 -  
40%  of all sPTL cases, although limitations in microbiological culture techniques 
might make this a conservative estimate [46]. Several routes have been suggested 
for microbial invasion into the intrauterine cavity. The most common route is the 
ascension of microorganisms from the vagina through the cervix and into the uterus. 
The infection can ultimately gain access to the amniotic fluid thereby exposing the 
fetus to infection [47]. Other routes of infection include hematogenous spread 
through the placenta of non-genital tract infections such as those from the oral cavity
[48]. Irrespective of the route, microbial invasion results in infection at various sites 
including the placenta, the fetal membranes, the amniotic fluid, the umbilical cord, 
and the fetus itself. Many microorganisms have been associated with PROM, sPTL 
and PTB. Microorganisms resulting in intrauterine infection include Escherichia coli
[49], Ureapiasma urealyticum [50], Streptococcus agalactiae [51], Chlamydia 
trachomatis [51] and Candida albicans [52] among many others. For example, 
genital mycoplasmas have been associated with a higher maternal white blood 
count and C-reactive protein (CRP), and more leukocytes in the amniotic fluid [53].
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Figure 1.3 Risk factors for preterm birth.
Adapted from Goldenberg et al [41]. BMI, body mass index; PTB, preterm birth; UTI, urinary tract 
infection.
1.4 Inflammation and cytokines in healthy and adverse pregnancy 
outcomes
A wealth of evidence indicates that labour is an inflammatory process [10]. 
Inflammation is a primary response mechanism resulting from the biological activity 
of cytokines and other mediators produced in response to harmful stimuli of both 
infectious and non-infectious origins. Cytokines are small ( - 5 - 2 0  kDa) proteins 
secreted by many cells types that function as extracellular signalling molecules to 
facilitate communication between various cells of the body, a response induced by 
binding to specific receptors expressed by target cells. Cytokines including IL-6, IL-8 
and TNFa are key immunological and inflammatory mediators which can act in an 
autocrine, paracrine or endocrine manner [54, 55].
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The pathophysiological mechanisms underlying preterm birth are largely unknown 
but might relate to premature activation of the normal labour process or the 
response to an insult. Proposed triggers of preterm birth include: uterine over­
distension [56], stress [3, 57, 58], infection and inflammation [53, 59-61], and other 
immunologically-mediated processes e.g allergy/hypersensitivity [62-64]. 
Irrespective of the triggering event, local and systemic inflammation tends to be a 
feature of preterm labour and delivery. Understanding the inflammatory pathways 
that contribute to the initiation and maintenance of preterm (and term) labour could 
be used to develop strategies to: (i) identify those women most at risk of preterm 
labour and birth, and (ii) prevent preterm birth. Whilst infection-associated PTB is 
the focus of this thesis, clinical studies have revealed an association between 
infection and other pregnancy complications such as preeclampsia and IUGR [65, 
66].
A burgeoning body of- literature implicates numerous cytokines in the normal 
physiological processes of pregnancy (e.g. implantation, placental function, 
parturition) and in the inflammatory response during infection associated preterm 
labour [10, 67-72]. The analysis of changes in candidate cytokines has proved 
worthwhile in identifying potential underlying mechanisms of PTB. IL-1, the first 
cytokine implicated is up-regulated in the human decidua in response to microbial 
products (e.g. lipopolysaccharide (LPS)), resulting in the production of 
prostaglandins by the amnion and decidua [73-75]. Mid-trimester amniotic fluid 
levels of IL-1 (3 are associated positively with preterm delivery [76], and IL-6 
concentrations in amniotic fluid are considered a marker for infection [77, 78]. Other 
cytokines including IL-10 [79], TNFa [80], granulocyte colony stimulating factor (G- 
CSF) [81] and IL-18 [82] among others have been linked to infection associated 
preterm labour. There are now a number of groups developing strategies to identify 
cytokine and other protein signatures that might rapidly identify those women most 
at risk of delivering prematurely especially in the setting of intrauterine infection. 
Mass spectrometry-based proteomic profiling of amniotic fluid from women with PTL 
or PROM found an inverse relationship between time to delivery and severity of 
intra-amniotic inflammation as determined by measurement of 4 biomarkers 
(neutrophil defensins-1 and -2  and calgranulins A and C). While even minimal 
inflammation was also associated with preterm birth, the extent of intra-amniotic 
inflammation correlated with negative outcomes for the neonate [83]. The potential 
of proteomic profiling of cervico-vaginal fluid also has been evaluated in a non­
human primate model of intra-amniotic infection. Differential expression of proteins 
was observed in control versus infected samples and this might offer a relatively 
non-invasive strategy for detection of infection via signatures created by specific 
biomarkers [84]. Numerous novel predictors of intra-amniotic infection; including 
immune modulators and acute-phase reactants, have been identified using a 
comprehensive proteome analysis of vaginal fluid from a cohort of pregnant women 
in spontaneous preterm labour. In the intraamniotic infection group, an increase in 
amniotic fluid proteins (e.g. vitamin D binding proteins and insulin-like growth factor 
binding protein-1) and a decrease of extracellular matrix-signalling proteins (e.g. 
fatty acid binding protein) were noted when compared to women in preterm labour 
who lacked evidence of infection. This suggests that the mechanisms of preterm 
birth may differ in the presence of infection [85].
The cytokines of interest are produced by cells normally present in the gestation- 
associated tissues such as trophoblast cells (syncytiotrophoblast and 
cytotrophoblast) and macrophages, and by leukocytes that infiltrate these tissues in 
response to inflammatory stimuli. An accumulation of leukocytes evident upon 
histological analysis of the placental membranes, so-called chorioamnionitis, occurs 
in around one-third of preterm deliveries. Chorioamnionitis was once considered a 
hallmark of infection but it was soon recognised to occur in the absence of any 
detectable signs of infection. Now, two types of chorioamnionitis have been 
classified: acute chorioamnionitis (ACA) associated with infection, and chronic 
chorioamnionitis (CCA) of immunologic origin related to maternal anti-fetal allograft 
rejection and graft-versus-host disease in the placenta [86]. The local cytokine 
profile differs with the type of chorioamnionitis: IL-6 is the prototypic cytokine 
elevated in amniotic fluid in ACA whereas for CCA amniotic fluid levels of CXCL10 
(IP-10 -  interferon-inducible protein-10) are increased and there is elevated gene 
expression of not only CCL10 but also CXCL9 (MIG -  monokine induced by 
interferon gamma) and CXCL11 (l-TAC - interferon-inducible T-cell alpha 
chemoattractant) [87].
While chorioamnionitis is generally associated with adverse pregnancy outcomes, 
around 9 - 20% of term deliveries have evidence of histologic chorioamnionitis and 
the duration of labour might impact on the occurrence of this [86, 88]. Notably 
chorioamnionitis is also increased in spontaneous versus induced preterm birth [87]. 
Preterm chorioamnionitis is accompanied by villitis in around 40%  of cases [87].
Placental villous macrophages (Hofbauer cells) in particular increase when there is 
evidence of chorioamnionitis. It has been suggested that fibroblast production of 
MCP-1 in response to bacterial products such as LPS or inflammatory cytokines 
such as IL-1 (3 or TNFa might drive the accumulation of macrophages within 
placental villi in this setting [89].
1.5 The innate immune response and inflammation: pattern 
recognition receptors and cytokine production
Changes in cytokine production at the maternal-fetal interface are a feature of both 
term and preterm labour. This has generated much interest in the mechanisms of 
cytokine production in the placenta and attached membranes; and whether such 
changes precede labour or are simply a consequence of it. Signalling pathways of 
the innate immune system which produce a defined cytokine output in response to 
microbial stimuli have been postulated as central to this. Several studies have found 
a link between the treatment of various gestation-associated tissues with microbial 
stimuli and cytokine outputs [45, 59, 90-92]. These studies have shown that 
microbial products such as LPS can trigger the production of key molecular events 
ultimately leading to the production of relevant cytokines such as IL-1 (3, IL-6 and 
TNF-a, the roles of which have been noted above.
The innate immune system uses evolutionary conserved germline encoded 
receptors, termed pattern recognition receptors (PRRs), to recognise and respond to 
a variety of pathogenic and non-pathogenic microorganisms. Identification of PRRs 
was demonstrated initially by work on the Drosophila protein Toll, a protein involved 
in the development of dorsoventral polarity during embryonic growth. However, 
Hoffman and colleagues demonstrated that Toll was also required for an effective 
immune response to Aspergillus fumigates in the fly [93]. This realisation inspired a 
search for mammalian homologues of Toll, which lead to the discovery initially of 
Toll-like receptor 4 (TLR4), and consequently the remainder of the Toll-like receptor 
family (TLRs) [94]. As increasing research attention has been placed on the 
mechanisms of innate immune recognition and signalling, other pattern recognition 
families have been discovered. These include; RIG-I (retinoic acid-inducible gene I)- 
like receptors (RLRs) [95], NOD (nucleotide oligomerisation domain)-like receptors 
(NLRs) [96], C-type lectin receptors (CLRs) [97] and Cytosolic DNA sensors (CDS) 
[98]. Each family of PRRs has numerous members (Table 1-2).
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PRRs detect conserved molecular patterns called pathogen associated molecular 
patterns (PAMPs) on a wide range of pathogens. Detection of a PAMP by its 
specific PRR, activates intracellular signalling, leading to cytokine gene expression 
and eventual activation of inflammatory and antimicrobial responses [99]. Examples 
of PAMPs include LPS, a cell wall component of Gram-negative bacteria, and 
peptidoglycan (PGN), a component of Gram-positive bacteria cell walls [100]. PRRs 
have also been implicated in the recognition of endogenous danger signals by the 
host, referred to as both damage associated molecular patterns (DAMPs) and 
alaramins [101]. However, no consistent terminology has been adopted, with some 
using these terms interchangeably, while others consider DAMPs as an umbrella 
term for both exogenous PAMPs and endogenous alarmins [102].
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Table 1-2 Pattern recognition receptors and their ligands.
PRR Name Group Ligand /  PAMP Localization
TLR1 TLR Triacyl Lipopeptides Plasma Membrane
TLR2 TLR
Peptidoglycan (PGN), Lipopeptides, 
Glycolipids, B-glucan
Plasma Membrane
TLR3 TLR Viral double-stranded RNA Endosome
TLR4 TLR Bacterial lipopolysaccharide (LPS) Plasma Membrane
TLR5 TLR Flagellin Plasma Membrane
TLR6 TLR Diacyl Lipopeptides Plasma Membrane
TLR7 TLR
Single-stranded RNA of viral and bacterial 
origin
Endosome
TLR8 TLR
Single-stranded RNA of viral and bacterial 
origin
Endosome
TLR9 TLR CpG motifs common in bacterial and viral DNA Endosome
TLR 10 TLR Unknown Plasma Membrane
RIG-1 RLR Short dsRNA Cytoplasm
MDA5 RLR Long dsRNA Cytoplasm
NOD1 NLR Distinct PGN Motifs e.g. iE-DAP Cytoplasm
NOD2 NLR Distinct PGN Motifs e.g. MDP Cytoplasm
NLRP3 NLR
Adenosine-5'-triphosphate (ATP), 
Monosodium Urate (MSU), Nigericin
Cyoplasm
Dectin-1 CLR B-glucan Plasma Membrane
Dectin-2 CLR High-mannose structures Plasma Membrane
MINCLE CLR
a-mannose, trehalose-6’6’-dimycolate (TDM), 
SAP130
Plasma Membrane
DAI CDS cytosolic dsDNA Cytoplasm
AIM2 CDS cytosolic dsDNA Cytoplasm
Adapted and modified from Takaoka & Akira [103]. ATP, adenosine-5'-triphosphate; CDS, cytosolic 
DNA sensor; CLR, C-type lectin receptor; CpG, "—C—phosphate—G— "; dsDNA, double stranded 
deoxyribonucleic acid; dsRNA, double stranded ribonucleic acid; iE-DAP, y-D-Glu-mDAP; LPS, 
lipopolysaccharide; MDA5, melanoma differentiation-associated protein 5; MSU, monosodium urate; 
NOD, nucleotide-binding oligomerisation domain; NLR, NOD receptor; NLRP, NOD-like receptor 
containing a PYD domain; PAMP, pathogen associated molecular pattern; PGN, peptidoglycan; PRR, 
pattern recognition receptor; RIG-I, retinoic acid-inducible gene 1; RLR, RIG-I like receptor; SAP, 
splicesome associated protein; TDM, trehalose-6’6’-dimycolate; TLR, toll-like receptor.
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1.5.1 Toll-like receptors
The first characterised mammalian TLR was TLR4, and a further 12 mammalian 
TLRs have since been identified [104]. Only TLRs 1 -  10 are expressed and 
functional in humans. TLRs 1-9 are functional in both human and mice, however 
TLR10 is likely non-functional in mice due to substitution of the C-terminal half of the 
mouse TLR10 gene with a non-productive sequence. In contrast, a stop codon in 
the human TLR11 gene results in the gene not being expressed, while mouse 
TLR11 is functional and has a role in urogenital tract infections in particular [105]. 
Stimulation of TLRs by their specific PAMPs initiates an intracellular signalling 
cascade involving numerous proteins, most notably MyD88. Activation of these 
signalling molecules ultimately leads to the activation of NF-kB and other 
transcription factors to induce the production of inflammatory cytokines.
TLRs are type I transmembrane glycoproteins. The extracellular N-terminal end of 
all TLRs is composed of leucine-rich repeats (LRRs), which mediate PAMP binding 
and receptor dimerisation [104]. The LRR domain is composed of 19-25 tandem 
LRR motifs, of 24-29 amino acids in length [106]. The mechanisms by which TLRs 
can differentiate between PAMPs or how any one TLR can respond to multiple 
PAMPs are only now being revealed. It has been suggested that specific ligand 
binding sites are created in each TLR by specific insertions of the PAMP into the 
LRR [107]. The conserved cytoplasmic region of each TLR is termed the Toll/IL-1 
receptor (TIR) domain due its similarity to the cytoplasmic domains of the 
interleukin-1 receptor family. The TIR domain varies between 135 and 160 amino 
acids in length and functions as a binding site for downstream adapter molecules
[108].
TLRs can be characterised into two groups based on their cellular location and 
ligand specificity: plasma membrane localised TLRs - 1, 2, 4, 5, 6 and 10 -  that 
generally recognise lipid based PAMPs; however no ligand has yet been identified 
for TLR10. TLRs localised to intracellular endosomes - 3, 7, 8 and 9 -  that recognise 
nucleic acid based PAMPs.
The most extensively studied member of the TLR family is TLR4. TLR4 is expressed 
on various haematopoietic cells including monocytes, macrophages, 
polymorphonuclear (PMN) cells, dendritic cells, and B cells. It is also expressed by 
non-haematopoietic cells including epithelial cells and fibroblasts [109]. TLR4
predominantly recognises LPS, a cell wall component of Gram-negative bacteria, 
composed of O-antigen, lipid A (endotoxin) and an oligosaccharide core [110]. TLR4 
recognition of LPS requires formation of a complex with CD14 and MD2 [111]. MD2 
binds to the extracellular region of TLR4, enabling it to bind to the lipid A component 
of LPS. CD14, a glycosyl phosphatidylinositol (GPI)-anchored, high affinity 
membrane protein, binds LPS in the presence of LPS-binding protein (LBP). LBP 
exchanges monomers of LPS for other lipids bound in its lipid binding site prior to 
transferring the LPS monomers to CD14. This enables CD14 to concentrate the LPS 
which is released from the bacterium in small amounts prior to presenting the LPS to 
the TLR4-MD2 complex [112]. TLR4 also has been implicated in the detection of 
fungal PAMPs including glucuronoxylomannan from Cryptococcus neoformans, and 
mannan derived from Saccharomyces cerevisiae and Candida albicans [113].
TLR2, which has a similar expression profile to TLR4, recognises a variety of 
PAMPs from both Gram-positive and Gram-negative bacteria including 
lipoproteins/lipopeptides and peptidoglycan, glycolipids, lipoteichoic acid and non- 
endobacterial LPS [114]. TLR2 also recognises fungal PAMPs including cell surface 
phospholipomannan of Candida albicans, and Saccharomyces cerevisiae derived 
zymosan [113, 115]. TLR2 forms a heterodimer with its structural relatives, TLR1 or 
TLR6 [116, 117], These heterodimers - TLR2/TLR1 and TLR2/TLR6 - can detect 
subtle variations in the lipid component of lipoproteins: tri-acetylated lipopeptides by 
TLR2/TLR1 and di-acetylated lipopeptides by TLR2/TLR6 [117, 118]. Recognition of 
di-acetylated lipopeptides by TLR2/TLR6, is facilitated by the co-receptor CD36, a 
class II scavenger protein [119]. Expression patterns of TLR1 and TLR6 are similar 
to that of TLR2, however both are highly expressed on B cells; while TLR2 is not 
[109]. The regulation of TLR2 expression differs between various cell types 
depending on their specific function and this is not the case for TLR1 and TLR6
[109].
TLR5 recognises bacterial flagellin, a structural protein which is the major 
component of flagella of Gram-negative bacteria [120]. Recognition of flagellin by 
TLR5 is possibly via highly conserved regions in the flagellin protein [121]. A 
common stop codon in TLR5 is associated with loss of signalling to flagellin and 
increased susceptibility to pneumonia caused by Legionella pneumophila [122]. In 
addition to the conventional expression of TLR5 by haematopoietic cells, TLR5 is 
expressed on the basolateral surface of healthy human intestinal epithelium,
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suggesting that bacterial recognition by TLR5 only occurs as the bacteria invade 
across the epithelium [123].
TLR3 is involved in the recognition of double-stranded RNA (dsRNA) from double­
stranded viruses, such as reovirus, or that generated during viral replication of single 
stranded viruses [124, 125]. Multiple haematopoietic, such as dendritic cells, and 
non-haematopoietic cells, such as epithelial cells, express TLR3 which is located 
within endosomes. Recognition of dsRNA by TLR3 was first demonstrated in TLR3 
deficient mice, which showed susceptibility to mouse cytomegalovirus [126]. The 
type I interferon (IFN) inducing dsRNA synthetic analog, polyinosine-deoxycytidylic 
acid (poly l:C) is often used in vitro to induce TLR3 activity [124].
TLR7 and TLR8 are structurally highly conserved and recognise uridine or 
guanosine-rich single stranded RNAs from a variety of viruses, including the 
influenza virus and human immunodeficiency virus (HIV) [127-129]. Additionally, 
they can recognise several synthetic imidazoquinoline-like molecules, such as 
resiquimod, which have potent antiviral activities due to their structural similarity to 
ribonucleic acids. While TLR7 and TLR8 recognise viral nucleic acid structures [129, 
130] their expression within endosomes prohibits, under normal circumstances, 
interaction with host derived ssRNA.
TLR9 recognises the unmethylated CpG motifs common in single-stranded DNA 
present in the genomes of many viruses and bacteria [131-133]. DNA viruses shown 
to induce inflammatory cytokine and type I IFN production via TLR9, include herpes 
simplex virus-1 (HSV-1), HSV-2 and murine cytomegalovirus (MCM). Two 
structurally different forms of CpG exist: A-type CpG oligodeoxynucleotides (ODNs) 
which stimulate plasmacytoid DCs (pDCs) to produce IL-12 and IFNa and B-type 
CpG ODNs, which induce IL-6, IL-12 and TNFa production by pDCs. B-type CpG 
ODNs also up-regulate expression of MHC Class II and the costimulatory molecules 
CD80 and CD86 on B cells and pDCs [131, 134]. TLR9 might also recognise host 
derived CpGs but these are weak inducers of activation due to the presence of 
highly methylated cytosine bases.
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Figure 1.4 Overview of Toll-like receptor (TLR) signalling.
Activation of TLRs by their specific PAMPs (pathogen associated molecular patterns) initiates an 
intracellular signalling cascade involving numerous adapter proteins (MyD88, TRIF, TRAM, TIRAP), 
ultimately leading to the activation of several transcription factors (NF-kB, ISRE3, ISRE7, AP-1) to 
induce the production of inflammatory cytokines. Adapted from O’Neill et al [135], Kawai & Akira [136] 
and Kopp and Medzhitov [137], AP1, activator protein 1; CD, cluster of differentiation; CpG, "—C— 
phosphate—G— dsRNA, double stranded ribonucleic acid; IFN, interferon; IkB, inhibitor of kappa B; 
IRF, interferon regulatory factor; ISRE, interferon stimulated gene factor; LPS, lipopolysaccharide; 
MD2, lymphocyte antigen 96; MKK, Mitogen-activated protein kinase kinase; MyD88, myeloid 
differentiation primary response 88; NF-kB, nuclear factor-kappa B; PGN, peptidoglycan; ssRNA, 
single stranded ribonucleic acid; TIR, toll/interleukin-1 receptor; TIRAP, TIR domain-containing adapter 
protein; TLR, toll-like receptor; TRAM, TRIF related adapter molecule; TRIF, TIR-domain-containing 
adapter-inducing interferon-p.
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1.5.1.1 TLRs: recognition and response
Binding of PAMPs leads to the dimerisation of TLRs, which triggers the activation of 
the TLR mediated signalling pathways and the expression of various genes involved 
in the immune response. As previously described TLR2 forms a heterodimer with 
both TLR1 and TLR6, the remaining TLRs form homodimers [138]. TLR signalling 
originates from the TIR domain of the receptor, which associates with an adapter 
containing a TIR domain. Various adapters have been characterised including 
MyD88 (Myeloid differentiation primary response gene 88), TRIF (TIR domain- 
containing adapter proteins inducing IFN|3), TRAM (TRIF related adapter molecule) 
and TIRAP (TIR domain-containing adapter protein); each are involved in slightly 
different signalling pathways, dependent on which TLR is activated [139]. Two main 
TLR signalling pathways have been described: the MyD88-dependent pathway and 
the MyD88-independent pathway also known as the TRIF-dependent pathway.
The adapter MyD88, which has a C-terminal TIR domain in addition to an N-terminal 
death domain, associates with the TIR domain of the TLR. Upon activation of a TLR, 
MyD88 recruits IRAK-4, a member of the IL-1 receptor associated kinase (IRAK) 
family, via interactions between the death domains of both molecules. This enables 
activation of IRAK-1 by IRAK-4 mediated phosphorylation. IRAK-1 then associates 
with TRAF6 (TNF receptor associated factor 6), resulting in the eventual activation 
of the IkB kinase (IKK) complex, which consists of IKKa, IKKp and NEMO/IKKy. The 
IKK complex induces the phosphorylation of IkB, resulting in translocation of the 
nuclear transcription factor NF-kB, from the cytosol to the nucleus. Once in the 
nucleus NF-kB can induce expression of multiple inflammatory cytokines [140-142]. 
Alternatively, activation of TRAF6 can lead to the activation of MAP kinases, 
resulting in AP-1 transcription factor activation. As shown in MyD88-deficient mice, 
MyD88 is vital for signalling via this pathway. A second adapter, TIRAP/Mal 
(MyD88-adapter-like) has been shown to be associated with the MyD88-dependent 
pathway for signalling via TLR2 and TLR4 [143].
Evidence for a My88-independent pathway was first shown in MyD88-deficient 
macrophages, in which NF-kB activation was not observed but production of 
inflammatory cytokines was [144]. Further investigation noted that TLR4 stimulation 
results in IRF3 (interferon regulatory factor) activation, a transcription factor involved 
in the production of IFNa [145]. Additionally IRF3 was activated in response to
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dsRNA or viral infection, via TLR3, suggesting that both TLR3 and TLR4 can utilise 
a common MyD88-independent pathway [146].
Two main adapters have been identified as involved in the MyD88-independent 
pathway: TRIF also known as TICAM-1 (TIR domain containing molecule), and 
TRAM or TICAM-2. TRIF has been associated with MyD88-independent signalling 
via TLR3, while TRIF and TRAM are associated with MyD88-independent signalling 
via TLR4 [147-149]. The TIR domain of TRIF is located in the centre of the molecule 
and the flanking N-terminal and C-terminal regions can both mediate the activation 
of NF-kB but by two different actions: the N-terminal region associates with TRAF6, 
while the C-terminal region associates with RIP1 (receptor interacting protein) [150, 
151]. Activation of the IFNa promoter is exclusively via the N-terminal region in 
association with the non-canonical IKKs, TBK1 (TANK-binding kinase) and 
IKKi/IKKe, which mediate the phosphorylation and nuclear translocation of IRF3, 
resulting in the induction of IRF-3 dependent IFN(3 production.
1.5.1.2 TLRs: negative regulation
Excessive production of inflammatory cytokines in response to PAMPs by TLRs can 
lead to detrimental outcomes including sepsis and autoimmune disease. Thus 
negative regulatory mechanisms have developed in response to TLR-mediated 
signalling. Once such mechanism is the phenomenon known as tolerance, in which 
a subsequent challenge by a PAMP results in a reduced response. This was first 
document in relation to LPS; however the exact mechanisms are not yet fully 
understood. A number of inhibitors of TLR signalling have also been described. 
One such molecule is IRAK-M. IRAK-M lacks kinase activity and prevents the 
dissociation of IRAK-1/IRAK4 from MyD88 which in turn prevents the IRAK-1/TRAF6 
complex forming [152, 153]. Another inhibitor SOCS1 (suppressor of cytokine 
synthesis 1) has been shown to directly modulate TLR signalling [154].
1.5.2 Nod-like receptors (NLRs)
NLRs (also known as CATERPILLERs) consist of a large family of 23 human 
intracellular (cytosolic) PRRs, which recognise both PAMPs and/or DAMPs. 
Activation via NLRs leads to cytokine production via NF-kB, or the inflammasome 
(see section 1.4.3.1) [155-157]. NLRs have also been implicated in autophagy, a 
lysosomal degradation and cell death pathway that follows infection [158]. 
Structurally, NLRs are characterised by the presence of a trimodular structure: a
19
central nucleotide binding domain (NBD) flanked by leucine rich repeats (LRRs) at 
the C-terminal and a protein binding domain - caspase activation and recruitment 
domain (CARD), baculovirus inhibitor of apoptosis protein repeat (BIR), death 
effector domain (DED) or pyrin domain (PYD) - at the N-terminal. These N-terminal 
domains, also termed the effector region, are responsible for the protein-protein 
interactions needed to activate downstream signal transduction. NLRs can be 
categorised into subfamilies based on this effector domain including: NLRC (Nod­
like receptor containing a CARD domain) and CIITA or NLRA (class II, major 
histocompatibility complex, transactivator) all contain CARD effector domains, while 
NLRPs contain a pyrin effector domain, and NAIPs or NLRBs contain three BIR 
domains [155,159].
The first identified and most widely studied NLRs are NOD1 and NOD2. These 
belong to the NLRC subfamily and are highly expressed in monocytes, 
macrophages and dendritic cells, in addition to other hematopoietic cells and 
epithelial cells [160]. Both NOD1 and NOD2 recognise peptidoglycan (PGN) an 
essential building block of Gram-positive bacteria cell walls and to lesser extent 
Gram-negative bacteria. PGN consists of glycan chains cross-linked via short 
peptides [161], NOD1 and NOD2 recognise different motifs in this structure: NOD2 
recognises the conserved muramyl dipeptide (MDP) motif found in all PGNs [162], 
whereas NOD1 recognises D-y-glutamyl-meso-DAP dipeptide (iE-DAP), which is 
present in all Gram-negative, but only some Gram-positive PGNs [163, 164]. NOD2 
can also recognise viral ssRNA and mycobacterial N-glycolylmuramyl dipeptides 
[165,166]. Thus both NOD1 and NOD2 are involved in the recognition of a variety of 
pathogenic bacteria including: E. coli, Chlamydia spp, Haemophilus influenza by 
NOD1, and M. tuberculosis and Streptococcus pneumonia by NOD2 [159]. Since 
the majority of these bacteria replicate outside of the cytoplasm where NOD1 and 
NOD2 are located, a mechanism by which PGN can cross the cell membrane to 
activate them is required. Although numerous transport proteins including PepT1, 
PepT2, and pannexin have been identified to facilitate MDP passage into the 
cytoplasm, an exact mechanism is not fully understood [167-169].
In general, activation of NOD1 and NOD2 by their respective ligands results in a 
conformational change allowing interaction with CARD domain containing receptor- 
interacting serine-threonine kinase 2 (RIP2) in a homophilic CARD-CARD manner. 
Cellular inhibitors of apoptosis 1 and 2 (clAP1 and 2) are also involved [170]. RIP2
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can then mediate the ubiquitination of NF-kB essential modulator (NEMO)/IKK, 
subsequently leading to the activation of NF-kB and the production of pro- 
inflammatory cytokines and antimicrobial peptides [171]. Activation of NOD2 by 
MDP also can result in the activation of the MAP kinase pathways via the adapter 
CARD9 [172].
Other NLRs including NLRX1 and NLRC5 have gained interest as regulators of PRR 
signalling pathways. The mitochondrial protein NLRX1 has the ability to inhibit RIG-I 
signalling by interacting with mitochondrial antiviral-signalling protein (MAVS) a 
mitochondrial adapter [173]. NLRX1 can trigger the generation of reactive oxygen 
species (ROS) thereby amplifying NF-kB and JNK signalling [85]. NLRC5 inhibits 
NF-kB and IRF mediated signalling by interacting with the NF-kB signalling 
intermediates IKKa and IKK(3, NLRC5 blocks the phosphorylation of these proteins 
and thus inhibits NF-kB signalling. Inhibition of IRF driven type I interferon response 
via RLRs occurs by interaction of NLRC5 with RIG-I and MDA5 [3].
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Figure 1.5 Overview of NOD signalling.
Activation of NOD1/NOD2 by their ligands facilitates the interaction with the adapter protein RIP2 and 
the subsequent activation of transcription factors to induce the production of pro-inflammatory 
cytokines. Adapted from Shaw et al [157] and Kanneganti et al [155]. AP1, activator protein 1; CARD9, 
caspase activation and recruitment domain 9; IFN, interferon; IkB, inhibitor of kappa B; MDP, muramyl 
dipeptide; MKK, mitogen-activated protein kinase kinase; NF-kB, nuclear factor-kappa B; NOD, 
nucleotide binding oligomerisation domain; PGN, peptidoglycan; RIP2, Receptor-interacting 
serine/threonine-protein kinase 2; Tri-DAP, L-Ala-gamma-D-Glu-mDAP.
1.5.2.1 The inflammasome
Certain members of the NLR family detect microbial components in the cytosol and 
trigger the assembly of a multiprotein oligomer termed the inflammasome. This 
complex supports the autocatalytic cleavage of caspase-1 which enables the 
processing and secretion of proforms of IL-1 (3 and IL-18. NLRP1, NLRP3, NLRC4 
and the adapter apoptosis-associated speck-like protein containing a CARD (ASC) 
are critical components of the inflammasome but components of emerging interest 
include NLRP6 [174-176]. While much of the focus has been on the caspase-1
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inflammasome, caspase-8 and caspase-11 (in mice) are also associated with an 
inflammasome-triggered response in a caspase-1-independent manner [177,178].
The NLRP3 inflammasome (Figure 1.6) is the most extensively studied: it comprises 
NLRP3, ASC, and caspase-1 [179]. Like other NLRP family members, NLRP3 is 
composed of a C-terminal LRR domain, a central NOD domain and an N-terminal 
PYD domain. NLRP3 is expressed in many types of hematopoietic cells, in addition 
to osteoblasts, skin keratinocytes and transitional epithelium of the urinary tract 
[180]. A wide variety of pathogens of bacterial, fungal and viral origin can initiate 
NLRP3 inflammasome formation: Listeria monocytogenes, Staphylococcus aureus, 
Candida albicans, Saccharomyces cerevisiae, and adenovirus and influenza 
viruses. A number of host-derived DAMPs indicative of cellular injury, including 
extracellular ATP and uric acid among others, have been shown to activate the 
inflammasome [181, 182]. The mechanisms involved in the recognition of these 
stimuli by NLRP3 are currently not fully understood, but may involve cellular 
mediators e.g. reactive oxygen species (ROS) relaying signals to NLRP3 [180]. 
However physical interaction between NLRP3 and the PAMPs/DAMPs has not been 
ruled out [183]. Following activation, NLRP3 oligomerisation leads to the clustering 
of PYD domains which can then recruit the CARD containing adapter ASC which by 
a CARD-CARD interaction can then recruit pro-caspase-1. The clustering of pro- 
capase-1 results in its autocleavage to the active caspase-1 p10/p20 tetramer 
enabling the processing of cytokine proforms to yield mature molecules for 
secretion. Production of these proforms depends on NF-kB driven transcriptional 
activity resulting from signalling from other PRRs such as NOD2 and TLRs [184].
Less is known about the NLRP1 inflammasome, which is comprised of ASC, 
caspase-1, caspase-5, and NLRP1 and induced by the NOD2 agonist MDP [179]. 
NLRP1 is expressed in various haematopoietic cells including: T and B cells, 
monocytes, dendritic cells and granulocytes, as well as on neurons and non- 
haematopoietic cells within the testes [180]. The structure of NLRP1 is different to 
that of NLRP3, as NLRP1 contains a C-terminal CARD domain, allowing NLRP1 to 
interact directly with pro-caspase-1. However ASC forms part of the inflammasome 
complex, allowing for the recruitment of caspase-5 providing additional 
inflammasome activity [179].
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Figure 1.6 Overview of the NLRP3 inflammasome.
Upon TLR activation an inactive pro-IL-13 precursor is produced that must ultimately be cleaved into 
the bioactive mature IL-1 (3, a process that is regulated by the inflammasome. A second signal for 
example the microbial toxin nigericin activates NLRP3 resulting in the autocatalytic cleavage of pro- 
caspase-1 to active caspase-1, which in turn enables the processing of pro-IL-1 p (and pro-IL-18) and 
secretion of mature IL-1 (3 (and IL-18). Adapted from Schroder et al [184] and Franchi et al [185]. ASC, 
apoptosis-associated speck-like protein containing a CARD (caspase activation and recruitment 
domain); IkB, inhibitor of kappa B; IL-1 (3, interleukin-1 (3; NF-kB, nuclear factor-kappa B; NLRP, NOD- 
like receptor containing a PYD domain; PAMP, pathogen associated molecular pattern; TLR, toll-like 
receptor.
NLRC4 (also known as IPAF) is expressed primarily in lymphoid tissue. Like NOD1
and NOD2 it has a C-terminal LRR domain, a central NOD domain, and an N-
terminal CARD domain [186]. Activation of the NLRC4 by microbial flagellin leads to
the activation of caspase-1, IL-1 (3 secretion and pyrotosis, a rapid form of cell death
[187, 188]. Similar to NLRP1, NLRC4 can interact directly with pro-caspase-1 via its
CARD domain. The role of ASC in the NLRC4 inflammasome remains inconclusive:
ASC cannot interact with NLRC4 which lacks a PYD domain but a role for ASC in
regulation of this inflammasome has been suggested [184].
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1.5.3 C-type Lectin receptors (CLRs)
CLRs are a family of receptors that recognise and bind carbohydrates in a calcium- 
dependent manner. Binding is mediated via a conserved carbohydrate recognition 
domain (CRD) first identified on circulating mannose binding lectin (MBL). Other 
than MBL, CLRs are primarily expressed on antigen presenting cells (APCs) such 
as macrophages and dendritic cells, and are involved particularly in fungal 
recognition and modulation of the anti-fungal innate immune response. CLR 
intracellular signalling is activated via immunoreceptor tyrosine-based activation 
motif (ITAM) present in the cytoplasmic tail of the receptor or on ITAM containing 
adapters. Examples of such CLRs include;- Dectin-1, Dectin-2, macrophage- 
inducible C-type lectin (MINCLE), DC-SIGN and the mannose receptor [97].
Mannose binding lectin has two to six clusters of CRDs which facilitate the 
identification of an attachment to repetitive mannose and fucose residues found on 
various microorganisms. The fixed orientation of the CRDs requires not only the 
presence of these residues but their specific spatial arrangement to initiate 
interaction between MBL and the target micro-organism. Recognition of mannose 
and fucose by MBL leads to the activation of the lectin complement pathway and 
enhanced polymorphonuclear cell uptake [189-191 ].
The mannose receptor (MR) has similar recognition strategies to MBL. Primarily 
expressed by macrophages and dendritic cells, the mannose receptor is a type-1 
membrane protein with eight tandemly arranged CRD domains. These allow the 
recognition of various carbohydrates terminating in L-fucose, D-mannose and N- 
acetyl glucosamine [192]. In addition to CRDs at the extracellular region, MR has 
two additional domains, an N-terminal cysteine-rich domain and a fibronectin II 
domain; these are involved in calcium-independent binding to sulphated sugars and 
collagen, respectively. Unlike the CRDs, these additional domains are only involved 
in the recognition of endogenous ligands and not those of microbial origin [192, 
193]. The role of the MR in host defence remains a mystery: animal knockout 
models do not demonstrate an increased susceptibility to pathogens such as 
Candida albicans and mycobacteria which are known to contain MR ligands [194, 
195].
The most widely studied CLR is Dectin-1. Dectin-1, also known as C-type lectin 
domain family 7 member A (CLEC7A), is a small (33kDa) type II glycosylated
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transmembrane receptor with an extracellular CRD connected to a cytoplasmic 
ITAM-like motif by a stalk domain. Two functional isoforms exist - Dectin-1 A, and 
Dectin-1 B which lacks the stalk domain, due to alternative splicing [196]. Dectin-1 
expression in humans can be found on myeloid cells, including neutrophils, 
monocytes/macrophages and dendritic cells, however limited expression has been 
noted on other cell types [196]. Dectin-1 recognises specifically the glucose 
polymers (3-1-3 and/or -1-6-glucans primarily found in the cell walls of fungi, 
including Candida albicans and Saccharomyces cerevisiae, but which can also be 
found in the cell walls of some plants [197]. Upon binding of the appropriate PAMP, 
phosphorylation of Dectin-1 occurs by a non-receptor tyrosine kinase, Src, via 
interaction with its ITAM motif. This leads to the activation of another kinase, Syk 
(spleen tyrosine kinase), which induces the activation of the CARD9-Bcl10-Malt1 
adapter complex leading ultimately to the activation of NF-kB and the production of 
pro-inflammatory cytokines [198]. In addition, activation of Dectin-1 mediates the 
production of reactive oxygen species (ROS), which can trigger the NLRP3 
inflammasome and further modulation of cytokine expression occurs via the NFAT 
(nuclear factor of activated T-cells) pathway [199, 200]. Attenuation of the Dectin-1 
mediated pro-inflammatory response has been linked to internalisation of the 
receptor [201]. It has been shown that signalling via Dectin-1 and TLR2/TLR6 
combined enhances the response triggered by each receptor alone [202].
Similarly to Dectin-1, Dectin-2 which can be found on myeloid cells, has a role in 
antifungal immunity, particularly in hyphal recognition by detecting high mannose 
structures [97]. However unlike Dectin-1, Dectin-2 must associate with an 
Fc receptor y-chain (FcRy), leading to of the CARD9 complex and NF-kB activation 
[203]. In response to Candida albicans, Dectin-2 induces the production of TNFa, 
and has been implicated in Th17 inducing activity [204].
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Figure 1.7 Overview of Dectin-1 signalling.
Activation of Dectin-1 by (3-glucans initiates several intercellular signalling pathways via the adapter 
protein syk to induce cytokine production. Similar pathways are activated by Dectin-2 and MINCLE. 
Adapted from Taylor et al [205], Brown et al [206] and Reid et al [207], ASC, apoptosis-associated 
speck-like protein containing a CARD; BcMO, B cell lymphoma/leukemia 10; CARD9, caspase 
activation and recruitment domain 9; IkB, inhibitor of kappa B; IL-1 (3, interleukin-1 (3; MALT1, mucosa 
associated lymphoid tissue lymphoma translocation gene 1; NFAT, nuclear factor of activated T-cells; 
NF-kB, nuclear factor-kappa B; NLRP, NOD-like receptor containing a PYD domain; ROS, reactive 
oxygen species; Syk, spleen tyrosine kinase.
MINCLE which is structurally similar to Dectin-2 recognises numerous exogenous
PAMPs and endogenous DAMPs, including those from mycobacteria, C. albicans
and necrotic cells [208, 209]. The identification of necrotic and damaged cells is
mediated via recognition of splicesome-associated protein 130 (SAP130), secreted
by these cells. MINCLE was the first known example of a CLR that can interact with
PAMPs and DAMPs. MINCLE and another CLR, Galectin-3, have a role in anti-
Candida defence, by recognition of a-mannose [209]. MINCLE also recognises the
immunostimulatory component of Mycobacterium tuberculosis - trehalose-6’6’-
dimycolate better known as cord factor [210].
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DC-SIGN expressed primarily on monocyte-derived dendritic cells, is a type II 
transmembrane receptor with only one C-type lectin domain and has been 
implicated in the recognition and uptake of Candida albicans by detecting high 
mannose structures [211]. DC-SIGN, also interacts with Leishmania but has gained 
increasing interest because of its involvement in the recognition of several viruses 
including human immunodeficiency virus (HIV) [212-214].
1.5.4 RIG-I like Receptors (RLRs)
The cytoplasmic RNA helicases that comprise the RIG-I like family of receptors play 
a major role in host anti-viral defence. RLRs include the well characterised RIG-1 
(retinoic acid-inducible gene I), MDA5 (melanoma differentiation associated factor 5) 
and LGP2 (laboratory of genetics and physiology 2). These are able to detect a 
variety of viral RNA ligands present in the cytoplasm and triggering the activation of 
transcription factors resulting in the production of type I IFNs in addition to 
expression of other anti-viral genes [215]. Viral recognition also occurs via TLR3. It 
seems that RIG-1 and MDA5 play a greater role in viral recognition by fibroblasts, 
macrophages and myeloid dendritic cells whereas TLR3 plays a more important role 
in viral recognition by plasmacytoid dendritic cells (pDCs) [216].
Both RIG-1 and MDA5 share a number of structural similarities. They contain a 
central DExD/H box RNA helicase domain flanked by an N-terminal of tandem 
CARD domains and a C-terminal domain (CTD). In the case of RIG-1 the CTD also 
contains a repressor domain (RD), involved in autoregulation, which is not present in 
the CTD of MDA5. Despite their similar structures, RIG-1 and MDA5 are able to 
detect distinct viral species: RIG-1 is involved in the recognition of Paramyxoviridae, 
Filoviridae and Rhabdoviridae among others, whereas MDA5 is important in the 
recognition of Picornaviruses [217], More is known about RLR signalling in regard to 
RIG-1 however it’s believed that both RIG-1 and MDA5 share a common signalling 
pathway, involving the adapter ISP-1/MAVS (mitochondrial antiviral signalling 
protein) [218]. Prior to recognition of RNA by the RD or CTD region, RIG-1 is 
inactive in a ’’closed” conformation, where the CARD domain is bound to the RD. 
Activation of RIG-1 results in a conformational change whereby CARD is released 
from the RD, allowing the CARD domain to interact with the adapter ISP-1 [217]. 
ISP-1 can then initiate two distinct signalling routes resulting in the activation of 
various transcription factors including NF-kB which induces the production of pro- 
inflammatory cytokines, and IRF3 and IRF7 which are responsible for the
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expression of type 1 IFNs [218]. Unlike RIG-1, MDA5 does not contain a RD to 
regulate its activation and when expressed ectopically signalling occurs in the 
absence of RNA recognition [219]. Unlike RIG-I and MDA5, LGP2 lacks the N- 
terminal CARD domain, consisting only of the RNA helicase domain and the C- 
terminal domain containing an RD. It has been suggested that LGP2 is involved in 
the negative regulation of RIG-1 and possibly MDA5 [217]. This negative feedback 
is thought to take place on many levels including acting as a competitor for dsRNA, 
interaction with ISP-1, and maybe direct binding to RIG-1 via RD interactions [219].
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Figure 1.8 Overview of RLR signalling.
Activation o f RIG-l/MDA-5 by dsRNA triggers a signal cascade via the adapter ISP-I resulting in the  activation of 
several transcrip tion  factors including ISRE and N F -k B to  induce the production o f p ro -in flam m atory  cytokines 
and type I interferons. A th ird  RLR, LGP2 is thought to  act as a negative regulator o f this system. Adapted from  
Creagh et al [220], Yoneyama et al [95] and Loo e t al [217]. dsRNA, double stranded ribonucleic acid; IFN, 
in te rfe ron; Ik B, inh ib ito r o f kappa B; I PS-1, m itochondria l an tiv ira l signalling prote in (MAVS); IRF, in te rfe ron  
regulatory facto r; ISRE, in terferon stim ulated gene facto r; LGP2, laboratory o f genetics and physiology 2; MDA5, 
melanoma d ifferentia tion-associa ted prote in 5; N F -k B, nuclear factor-kappa B; RIG-1, retino ic acid-inducible 
gene 1; RNA, ribonucleic acid; RLR, RIG-1 like receptor.
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1.5.5 Other pattern recognition receptors
Other groups of pattern recognition receptors have also been described, including 
cytosolic DNA sensors (CDS) and scavenger receptors (SR).
DNA-dependent activator of IFN-regulatory factors (DAI, also known as DLM-1 and 
ZBP1) was the first CDS to be described. It was first identified in murine 
macrophages and murine tumour stromal cells. DAI is up-regulated by exposure to 
cytosolic DNA or IFNy suggesting that DAI functions as a DNA sensor [221, 222]. A 
human homologue containing two N-terminal Za domains and a C-terminal domain 
has since been described but it is of unknown function [223]. Activation of DAI by 
either microbial or host derived DNA, results in the activation of both the NF-kB 
pathway and the IRF pathway [224]. Additional CDS including LRRFIPI, I F116, 
DDX41, cGAS and AIM2 have now been described [225]. RIG-1, a RLR family 
member has also been characterised unexpectedly as a CDS. However RIG-1, 
unlike other CDSs does not recognise cytosolic DNA directly but rather a dsRNA 
intermediate produced by RNA polymerase III mediated transcription [226].
Two pathways that mediate the response to cytosolic DNA have been described; 
activation of STING dependent signalling and activation of caspase-1 [225]. The 
primary pathway induced by cytosolic DNA is the production of type I IFNs and IFN 
stimulated genes via the transcription factor IRF3. A key upstream molecule of this 
is STING (stimulator of IFN genes). STING which is located on the endoplasmic 
reticulum, acts as a platform for the phosphorylation of IRF3 via TBK1 [227]. As 
described above (see 1.4.3.1) activation of caspase-1 occurs through a multi protein 
complex called an inflammasome. AIM2 (absent in melanoma 2), in response to 
cyctosolic DNA, actively promotes the formation of an inflammasome (AIM2 
inflammasome), interacting with the adapter ASC, leading to the cleavage of pro- 
caspase-1 to activate the caspase and formation and secretion of mature forms of 
IL-1 (3 and IL-18 [228].
Scavenger receptors (SRs) are a group of cell surface transmembrane receptors 
that are important in the clearance of several pathogens, host modified molecules, 
and apoptotic cells by endocytotic internalisation. These receptors also play a role in 
lipid metabolism. Expressed primarily on myeloid cells and some endothelial cells, 
both their expression and structure are regulated by various cytokines including IL-6 
and TNFa [229]. Numerous SRs have been shown to play a role in innate immunity,
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including SR-A I, SR-A II, CD36, LOX-1, MARCO, SR-CL I, SR-CL II, SCARF1 and 
DSR-C1 [230, 231].
1.6 Pattern recognition receptors at the maternal-fetal interface
The discovery of an association between intrauterine infection, inflammation and 
certain adverse pregnancy outcomes has led to increased interest in the innate 
immune response at the maternal-fetal interface [232]. The production by gestation- 
associated tissues of cytokines in response to microbial products has been well 
documented. Since pattern recognition receptors are a key component of the innate 
immune response, linking infection by various microorganisms to the production of 
inflammatory mediators, a role for PRRs at the maternal-fetal interface has been 
postulated. To date studies have principally focused on the role of TLRs and most 
recently NLRs, primarily in the placenta and the trophoblast.
1.6.1 Placenta
Expression of transcripts for TLR 1-10 in the term placenta has been demonstrated 
with all but TLR9 shown to be functional (note that TLR10 function has not been 
studied due to the lack of an identified ligand) [233]. Changes were observed in both 
mRNA expression and functional cytokine outputs in response to labour at term. An 
increase in TNFa in response to LPS and R848 (TLR7/8 ligand) were associated 
with labour, however a significant difference in expression of transcripts was noted 
only with TLR2 and TLR5 [233]. TLR2 and TLR4 protein has been localised to term 
syncytiotrophoblast and intermediate cytotrophoblast cells and both receptors are 
highly expressed in first trimester placental tissue [90, 234]. First trimester 
trophoblast cells also express TLR6. TLR6 blocks apoptosis induced by PGN via 
TLR1 and TLR2 and mediates NF-kB activation and secretion of IL-6 and IL-8 
leading to the postulate that TLR6 might regulate the balance of apoptosis and 
inflammation in response to Gram-positive infection [235].
The NLRs, NOD1 and NOD2 are both expressed in the first trimester placenta 
where they are localised to the syncytiotrophoblast and cytotrophoblast. In contrast 
only NOD1 is expressed in term trophoblast cells. This corresponds to the functional 
outputs of first versus third trimester trophoblast cells; first trimester cells respond to 
both MDP and iE-DAP, and third trimester cells only respond to iE-DAP [60, 236]. 
The NOD1 ligand iE-DAP can induce preterm delivery in a murine model. When 
lower doses that did not induce preterm delivery were used there was heightened
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inflammation at the maternal-fetal interface and in the fetus itself [237]. 
Inflammasome components including caspase-1, the adapter PYCARD and NLR 
members, NLRP1, NLRP3 and NLRC4 are expressed in first trimester 
cytotrophoblasts. Moreover in the presence of LPS, expression of these was 
enhanced and IL-1 (3 secretion induced. When compared to the other NLRs, a 2-fold 
up-regulation of NLRP3 expression was observed [238].
Immunohistochemical studies have shown that the CLR DC-SIGN is expressed by 
fetal macrophages (Hofbauer cells) within the chorionic villi of the term placenta 
[214]. Viral ssRNA also activates cytokine, chemokine, and type I IFN production by 
primary first trimester trophoblast cells. This ligand also induces apoptosis in 
trophoblast cells in an IFNy-dependent fashion [239].
1.6.2 Amnion
Amniotic epithelial cells represent the first line of defence against intra-amniotic 
infection. Earlier studies were restricted to TLR2 and TLR4 and found that both of 
these receptors are up-regulated in the amnion from women with chorioamnionitis 
compared to those without [59], although not all studies support this finding [240]. 
Transcripts for TLRs 1-10 have been detected in human amniotic epithelial cells. 
However only TLR2/6, TLR4 and TLR5 have been reported to be functional: 
activation of TLR2/6 and TLR5 resulted in increased production of IL-6 and IL-8, 
while activation of TLR4 reduced cell viability via apoptosis [241]. 
Immunohistochemical studies of human fetal membranes have shown that the 
expression of TLR4 is greater in the chorion than the amnion, that expression 
decreases with gestational age but that expression does not differ by anatomic 
location within the uterus [240].
1.6.3 Decidua
Despite its juxtaposition to the myometrium the expression and function of PRRs 
within the maternally derived decidua is not studied extensively. Initially transcripts 
for TLRs 1-6 were detected in term decidual cells but only TLR1, TLR2, TLR4 and 
TLR6 were shown to be functional via production of IL-8 in response to stimulation 
with LPS or PGN [242]. Transcripts for TLRs 1-10 have since been detected in both 
first trimester and term decidual cells [243]. Despite no significant change in mRNA 
levels between first and third trimester cells, it was observed that expression levels 
of all TLRs other than TLR3, 7 and 9 were lower at term. In contrast to previous
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studies no functional response via production of IL-8 was observed resulting from 
TLR2 and TLR4 in response to PGN or LPS. However LPS induced IL-6 was 
observed in addition functional TLR3 by poly(l:C) induced IL-6 and IL-8 [243].
Immunohistochemical studies have demonstrated the expression of NOD1 and 
NOD2 in first trimester decidualised stroma [244]. Similarly to first trimester 
trophoblasts, the NLRP1, NLRP3 and NLRC4 inflammasomes are expressed in first 
trimester decidual stromal cells and, in the presence of LPS, their expression is 
enhanced and IL-1 (3 secretion induced [238]. DC-SIGN has also been detected on 
decidual macrophages [245].
1.7 PRRs and adverse pregnancy outcomes
PRRs expressed at the maternal-fetal interface could play an important role in the 
pathogenesis of infection-associated preterm birth and other adverse pregnancy 
outcomes [246]. This possibility has been studied mostly with regards to TLRs, 
especially TLR4. LPS from Gram-negative bacteria has been implicated in infection 
associated preterm birth and there have been a number of studies exploring the 
possible role of TLR4 in preterm labour. Functional TLR4 has been implicated in 
preterm labour triggered by administration of heat killed E.coli in mice [92]. Evidence 
for a role for TLRs in infection-associated preterm birth also comes from genetic 
studies. A polymorphism (Asp299Gly) known to be associated with impaired TLR4 
function and an increased likelihood of Gram-negative sepsis [247] was carried 
more often by preterm infants than term infants or by mothers delivering preterm 
than at term [248]. Genetic variation in TLRs is also associated with other adverse 
obstetric outcomes: TLR4, TLR9 and TLR1 but not TLR2 variants are associated 
with placental malaria (low birth weight and maternal anaemia; no difference in 
parasite densities) [249]. Other genetic variants are also associated with risk of PTB: 
maternal genetic variants in extracellular matrix metabolism with risk of PPROM and 
fetal genetic variation (e.g. IL-6R1) are associated with risk of PTB [250].
While LPS has been used as the model for infection associated PTB for many years 
it is worth noting that LPS from different species of bacteria might differentially 
regulate inflammatory responses from gestation-associated tissues such as the 
amniochorion [251]. Also tissue processing for ex vivo investigations can impact on 
cytokine measurements. For example, in a comparison of punch biopsies of amnion 
or choriodecidua versus dual compartment transwells, the punch biopsies typically
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made greater amounts of cytokines [252]. Such observations highlight the need to 
take these factors into account when designing studies and when comparing data 
from different studies.
In addition to the direct pro-inflammatory effects initiated by exposure to infection, 
disturbances in the regulation of apoptosis might also be associated with sub- 
optimal pregnancy outcome [253]. Increased trophoblast apoptosis is seen during 
the first trimester of pregnancies complicated with IUGR or preeclampsia [81, 254], 
and elevated trophoblast apoptosis has been observed in preterm births [255, 256]. 
It has been suggested that the direct or indirect effects of infectious microorganisms 
upon trophoblast cell survival might depend upon which TLRs are activated with 
TLR2-mediated events apparently favoring apoptosis [235].
Recently there has been growing interest in how a viral infection might itself cause 
preterm birth but also how it might increase the risk of pregnancy failure during 
subsequent or concurrent bacterial infection. In a murine model, intraperitoneal 
injection of a synthetic TLR3 ligand, poly l:C, caused preterm delivery within 24 
hours. This was associated with inflammation in multiple gestation-associated 
tissues (polymorphonuclear cell infiltrate, necrosis and haemorrhage), infiltration of 
NK cells and macrophages into the placenta, and placental cytokine (e.g. IL-6) and 
chemokine (e.g. MCP-1) production that could also be detected systemically. This 
did not occur in TLR3 knock out animals. The cytokine response could be replicated 
in vitro by polyl:C treatment of primary murine trophoblast and a human trophoblast 
cell line and involved activation of NF-kB [257]. In contrast, intra-peritoneal injection 
of murine herpes virus was associated with evidence of inflammation in the placenta 
and spleen but no adverse pregnancy outcomes. Evidence of viral infection in the 
placenta and decidua but not the fetus led the investigators to postulate that these 
tissues act as a barrier to capture virus and prevent infection of the fetus. However, 
this might not prevent developmental impacts on the fetus. Human primary first 
trimester trophoblast also can be infected with herpes virus in vitro but unlike the 
response to poly l:C treatment, cytokine and chemokine production tended to be 
down-regulated. Viral infection but not polyl:C induced increased expression of 
TLR2 and TLR4 in human trophoblast cells and in the accompanying mouse model, 
viral infection sensitised for a response -  preterm delivery in less than 24hrs in all 
mice accompanied by 100% fetal death - to intraperitoneal infection of LPS [258,
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259]. These observations have highlighted a need for better understanding of the 
expression and activity of viral detecting PRRs at the materno-fetal interface.
Preeclampsia, a pregnancy specific hypertensive disorder, also is characterised by 
inflammation. Pathways related to stress, inflammation (including TLR signalling 
pathways), growth, tissue remodelling, and metabolism are all altered during 
preeclampsia [260]. The differences might reflect acute inflammation secondary to 
microbial infection versus chronic inflammation secondary to oxidative stress. 
Possible involvement of the inflammasome in preeclampsia has been suggested. 
Uric acid is known to activate the NLRP3 inflammasome: circulating uric acid levels 
increase prior to clinical manifestations of preeclampsia and levels relate to disease 
severity. Components of the inflammasome, including ASC, are expressed in first 
and third trimester trophoblasts and monosodium urate (MSU) up-regulates IL-1(3 
production in an inflammasome-dependent manner [261]. However it must be noted 
that despite an observed up-regulation of IL-1(3 in response to MSU this was only 
slight and experimental design was sub optimal as a priming first signal, such as 
LPS, prior to MSU stimulation was not used. There is also interest in the potential 
role of viral PAMPs or related DAMPs from necrotic cells in preeclampsia. Activation 
via TLR3 or the RLRs RIG-1 and MDA-5 leading to downstream inflammation, anti- 
angiogenesis and oxidative stress converging on endothelial dysfunction has been 
postulated [262]. A proposed role for TLR9 has also been implicated in 
preeclampsia and preterm birth. In complicated pregnancies significantly elevated 
levels of circulating free fetal DNA is found in the maternal plasma [263]. Since 
TLR9 recognises hypomethylated microbial DNA, it has been suggested that it may 
also be able to recognise fetal DNA which itself is hypomethylated [264]. Additionally 
higher circulating levels of mitochondrial DNA (mtDNA) are observed during 
pregnancies with preeclampsia. An evolutionary conserved relationship between 
bacteria and mitochondria may facilitate recognition of mtDNA via TLR9 [265].
1.8 Regulating the inflammatory response at the materno-fetal 
interface
The resolution of inflammation is essential for immune homeostasis. It has become 
apparent that there are intracellular stress proteins that have extracellular properties 
related to the regulation of the innate immune response and inflammation. These 
so-called RAMPs (resolution-associated molecular patterns [266]) have anti­
inflammatory activity or the ability to resolve inflammation and counterbalance the
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activity of PAMPs and DAMPs. HSP10, HSP27, aB-crystallin and BiP have been 
suggested as founding members of this family of molecules [266]. There is keen 
interest in the potential therapeutic use of these [267].
There are also a number of cytokines well recognised for their anti-inflammatory 
activity. These include IL-4, IL-10 and IL-13. IL-10 can down-regulate LPS- and LTA 
(lipoteichi acid)-induced cytokine/chemokine responses by the healthy term placenta 
[268]. Paradoxically, IL-10 is increased in amniotic fluid from women in term labour 
and women with intra-amniotic infection at term and preterm, and is also increased 
in those without infection who delivered preterm rather than term [269]. Elevated IL- 
10 in these circumstances might represent a compensatory mechanism that has 
failed. Similarly, an anti-inflammatory cytokine (IL-4, IL-10 and IL-13) bias within the 
cervix prior to 16 weeks of gestation might identify those women most likely to suffer 
microbial invasion of the utero-placental unit and then spontaneous preterm labour 
and delivery [270]. Whether the greater anti-inflammatory milieu permits ascending 
infection or is a compensatory response to a pro-inflammatory response to existing 
infection that when no longer controlled tips in favour of pro-inflammatory response 
and the initiation of labour remains to be determined.
A key component of PRR signalling pathways, essential for the expression of 
cytokines and other immune response gene is the transcription factor NF-kB. NF-kB 
pathway intermediates including IKK-a, IKK-(3, IKK-y and kB -a  have been identified 
in first trimester decidua, while binding activity has been reported in a variety of 
intrauterine cells and tissues, including first trimester placenta, amnion epithelial 
WISH cells and nuclear extracts prepared from term amnion, choriodecidua and 
placenta [271]. The functionality of NF-kB is determined by several heterodimer 
combinations of various subunits including p50, p52, Rel-A (p65), Rel-B and c-Rel 
[272], Several of these subunits have been reported in nuclear extracts from first 
trimester trophoblast, term cytotrophoblast and term amnion, choriodecidua and 
placenta [271].
With labour characterised by an increase in pro-inflammatory cytokine production, it 
might be expected that during pregnancy, NF-kB activity would be supressed. The 
expression of several pathway intermediates responsible for NF-kB inactivation has 
been shown to increase in the decidua in response to increased progesterone 
production [273]. More so in term cytotropholasts the DNA binding activity of NF-kB
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is suppressed by the production of glucocorticoids [274]. An important role for NF-kB 
during labour has also been shown. Following term labour, increased activity of p65 
in the amnion, but not choriodecidua has been noted; with binding of p65 to the kBa  
gene promoter also increased in response to labour in the amnion [275, 276], with 
varying degrees of p65 expression in preterm samples [272]. Additionally, activation 
of NF-kB is critical for the activation of numerous genes associated with labour, 
including MMPs and COX-2 [277]. In the myometrium, increased expression and 
DNA binding activity of p65 is observed during labour. However other investigators 
have been unable to record any changes in p65 activity in amnion or choriodecidua, 
but this might relate to differences in experimental approaches especially explants 
models versus primary cultures of isolated cells [278]. Considering its central role in 
inflammation and labour, directed targeting may have the potential as an effective 
treatment for preterm labour. However considering the broad role of NF-kB the 
identification of labour specific components of this pathway is key, in order to 
minimise toxicity [277].
1.9 Aims and Objectives
The study of PRR-mediated inflammation at the maternal-fetal interface has only 
just begun. Ultimately, a better understanding of these receptors and the signal 
transduction cascades they initiate might explain why some pregnancies are 
complicated by PTL and PROM whereas others are only affected by PROM. 
Moreover, investigations into the endogenous activators of PRRs might explain how 
PTL and PROM can occur in the absence of infection (e.g. preeclampsia, multiple 
gestation, teenage pregnancy, or excessive tobacco and alcohol consumption). 
These molecules (either the receptors or their signalling molecules) might therefore 
be excellent targets for therapeutic strategies because they are upstream mediators 
of the pro-inflammatory cascade that ultimately results in premature labour and 
preterm birth.
However while this may the eventual aim of this field of study; a greater 
understanding of PRR expression and activity in term non-laboured tissues is 
required to provide a baseline comparison for these receptors, in order to determine 
any potential role they may play in normal term labour but also in preterm labour and 
other adverse pregnancy outcomes. With this in mind the primary aim of this thesis 
is to determine the expression and activity of PRRs in term non-laboured gestation- 
associated tissues. Secondary to this, the work presented here will start to examine
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the signalling pathways involved upon PRR activation and to try and identify 
molecules that may reduce PRR mediated responses in these tissues. With this in 
mind the objectives are as follows:-
(i) To investigate PRR expression and activity in the term non-laboured 
placenta, choriodecidua and amnion.(Chapter 3 & 4)
(ii) To examine inflammasome activity in the term non-laboured placenta, 
choriodecidua and amnion. (Chapter 4 & 5)
(iii) To examine the impact of anti-inflammatory cytokines on PRR mediated 
responses in the term non-laboured placenta, choriodecidua and amnion. 
(Chapter 6)
Chapter 2
Materials and Methods
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2 Materials and methods
2.1 Samples and recruitment
Informed written consent was obtained from all participants for the collection of 
peripheral blood and the placenta following delivery in the case of pregnant women. 
Ethical approval for this study was given by the South West Wales Research Ethics 
Committee (REC 11/WA/0060, 11/WA/0040 and 04/W MW 02/68). Documents 
(participant information sheet, questionnaires and consent forms) are shown in 
Chapter 8.1.
2.1.1 Participant groups
The following participant groups were recruited:
1. Term non-laboured women (gestational age > 37 weeks) -  During pre­
operative assessment at the antenatal day assessment unit at Singleton 
Hospital, Swansea, healthy pregnant women scheduled for elective 
caesarean section (ESC) at term were approached. Women undergoing 
elective section for fetal or maternal anomalies were not recruited therefore 
samples were typically from women scheduled for section because of breach 
presentation, cephalo-pelvic disproportion or emergency section at previous 
delivery. Maternal blood was collected into sodium heparin containing tubes 
during the pre-operative assessment at the same time as samples for routine 
clinical care. Following liaison with midwives on the delivery suite, the 
placenta was collected after the ESC.
2. Healthy Adults -  Peripheral blood was collected from healthy adult donors 
into sodium heparin containing tubes (Vacutainer, Greiner Bio-One) at the 
Institute of Life Science, Swansea University.
Exclusion Criteria: Women with documented evidence of infection such as HIV or 
hepatitis C, autoimmune diseases, severe medical conditions or stillborn births. 
Women with poor English language skills were also excluded.
2.1.2 Sample collection
The placenta was collected into a sealed clean plastic bag and placed into a clean
plastic bucket immediately following delivery. Samples were transported to the
laboratory at ambient temperature in specialised transport bag and processed within
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1.5 hours of delivery. Blood was collected into sodium heparin containing tubes and 
processed within 30 minutes of collection.
2.2 Processing of gestation-associated tissues
A. When handling the placenta and the attached membranes, care was taken to 
minimise contamination by LPS/endotoxin. All procedures are performed in a 
class II tissue culture cabinet using disposable sterile consumables; 
including surgical grade sterile equipment for dissection. Reagents used 
were determined by manufactures to be endotoxin free.
B. Total weight (placenta and attached membranes) was recorded prior to 
preparation of explant cultures.
2.2.1 Placental explant cultures
The deciduas basalis, overlaying the maternal side of the placenta was removed 
with scissors. Pieces of placenta tissue (1 cm3) were then cut from various sites 
across the placenta and placed into sterile calcium and magnesium free PBS 
(phosphate buffered saline; Life Technologies, UK). Tissue was washed repeatedly 
with PBS to remove any contaminating blood. Tissue was then minced into smaller 
pieces and washed further. Pieces of tissue (1 mm3 pieces to a total of 0.2 g) were 
transferred into the required number of wells of a standard 12-well tissue culture 
plate (Greiner Bio-one, Germany; Figure 2.1) containing 1 ml Ultraculture medium 
(Lonza, UK), supplemented with 2 mM Glutamax (Life Technologies, UK) and 100 
U/ml penicillin, 100 pg/ml streptomycin sulphate and 0.25 pg/ml amphotericin B 
(PSF; Life Technologies, UK).
Explant cultures were exposed to different stimuli as detailed in individual chapters; 
an unstimulated control was always included. All treatments were performed in 
duplicate. Cultures were incubated for 24 hours at 37°C in 5% CO 2 . Tissue free 
supernatants were collected by centrifugation for 7 minutes at 4°C, 515 x g and 
stored at -20°C until analysis.
2.2.2 Fetal membrane explant cultures
Pieces of membranes were cut away from the placenta. Choriodecidua and amnion
were separated from each other by blunt dissection and placed separately into PBS.
Tissue was washed repeatedly with PBS to remove any contaminating blood. Each
membrane was cut with an 8 mm biopsy punch (Steifel; Medisave, UK). Biopsies of
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amnion, six pieces, were transferred into each individual well of a 12-well tissue 
culture plate containing 1ml Advanced DMEM (Life Technologies, UK) 
supplemented with 2 mM Glutamax and 2% FBS (Fetal Bovine Serum, Hyclone; 
Fisher-Scientific, UK), or three pieces into each individual well of a 24-well tissue 
culture plate containing 0.5 ml of the same medium. Biopsies of choriodecidua, four 
pieces, were transferred into each individual well of a 12-well tissue culture plate 
containing 1 ml Advanced RPMI supplemented with 2-Mercaptoethanol (2-ME), 2 
mM Glutamax and 2% FBS, or two pieces into each individual well of a 24-well 
tissue culture plate containing 0.5 ml of the same medium (Figure 2.1).
Once prepared, explants cultures were exposed to different stimuli as detailed in 
individual chapters; an unstimulated control was always included. All treatments 
were performed in duplicate. Cultures were incubated for 24 hours at 37°C in 5% 
CO2 . Tissue free supernatants were collected and stored at -20°C until analysis.
Figure 2.1 Gestation associated tissues -  Placenta and fetal membranes.
(A) Fetal side of the placenta showing umbilical cord. (B) Maternal side with attached fetal membranes 
(choriodecidua & amnion). (C) Placental explant culture. (D) Choriodecidua explant. (E) Amnion 
explant.
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2.2.3 Storage of gestation-associated tissues for RNA extraction
PBS washed tissue (0.2 g) was placed into a 2ml tube containing Lysing Matrix D 
(Fisher Scientific Ltd, UK) with 600 pi TRI reagent (Sigma-Aldrich, USA) within 30 
minutes of collection. Specimens were stored at -20°C until extraction.
2.2.4 Lactate dehydrogenase (LDH)-cytotoxicity assay
Cytotoxicity was evaluated using the LDH-Cytotoxicity Assay Kit II (Abeam, UK), 
utilising a WST (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)- 2/-/-5-tetrazolio]-1,3-benzene 
disulfonate sodium salt)reagent, a tetrazolium salt substrate, for detection of LDH 
released from damaged cells (Figure 2.2). In a 96 well plate, 100 pi of LDH reaction 
mix working solution (49 parts LDH assay buffer, 1 part WST substrate mix) was 
added to either, 10 pi of supernatant or 10 pi of the appropriate control (background 
control; cell culture medium, negative control; dH20, positive control; LDH). All tests 
were performed in triplicate. The reaction was then incubated for 30 minutes at room 
temperature. Following this, the absorbance of all samples and controls at 450 nm 
was read using a plate reader (POLARStar; BMG) and the levels of LDH calculated 
as a comparison to the unstimulated.
IJ
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Fyruvate NADH WST
Lactate NAD* Yellow
Dye
Figure 2.2 Lactate dehydrogenase cytotoxicity assay.
During cell death the plasma membrane is damaged resulting in the release of LDH, an enzyme that 
oxidises lactate, generating NADH. The cytotoxicity assay takes advantage of this process by utilising 
a WST substrate mix, which interacts with NADH generating a yellow colour. LDH, lactate 
dehydrogenase; NAD/NADH, Nicotinamide adenine dinucleotide; WST, 4-[3-(4-iodophenyl)-2-(4- 
nitrophenyl)- 2/-/-5-tetrazolio]-1,3-benzene disulfonate sodium salt. Adapted from Sarker et al [279].
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2.3 Processing of adult peripheral blood
To limit contamination, handing of adult peripheral blood took place in a class II 
tissue culture cabinet. Manufacture endotoxin tested reagents and disposable sterile 
consumables were used.
2.3.1 Isolation of mononuclear cells (MNCs) by density gradient 
centrifugation
Whole anti-coagulated blood (10 ml) was layered onto 10 ml Histopaque 1077 
(Sigma-Aldrich, Poole, UK) in a 50 ml falcon tube (Greiner, Bio-One, Germany) and 
centrifuged at 800 x g for 20 minutes with no brake (Figure 2.3). The plasma was 
removed and discarded. The mononuclear cell layer was removed and placed in a 
30 ml Universal (Greiner, Bio-One, Germany), topped up with RPMI 1640/Glutamax 
(Life Technologies, UK) and centrifuged at 500 x g for 10 minutes at room 
temerature. The supernatant was discarded and the cell pellet resuspended in RPMI 
1640/Glutamax and centrifuged at 500 x g for 7 minutes. The supernatant was 
discarded and the cell pellet resuspended in RPMI 1640/Glutamax supplemented 
with 5% FBS and 2-ME -  the volume of this was dependent on the stating volume of 
blood. MNCs were then counted using the Countess® automated cell counter (Life 
Technologies, UK).
Blood
Histopaque-
CENTRIFUGE
V
Plasma
'M ononuclear
Cells
Histopaque
Red Blood 
Cell Pellet
Figure 2.3 Density gradient centrifugation of whole blood.
Diagram illustrating the isolation of mononuclear cells by density gradient centrifugation.
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2.3.2 Mononuclear cell culture
Isolated MNCs were cultured at 0.5 x 106 cells in 500 |jl of RPMI 1640/Glutamax/5%  
FBS/2-ME in a 4.5 ml culture tube (Greiner Bio-One, Germany; Figure 2.4). Optimal 
levels of all agonists were then added as detailed in individual chapters. An 
untreated sample was always included. All treatments were performed in duplicate. 
Cultures were then incubated for 24 hours. Following incubation, cultures were 
centrifuged for 7 minutes at 4°C, 515 x g. Cell free supernatants were removed and 
stored at -20°C until analysis.
Stimulus: Unstim Unstim LPS LPS
0 .5x l06 cells in 
0.5ml RPMI + 
Glutamax + 5% 
+ 2ME
-c
i 2 3 4
Incubation; 24 hours
Figure 2.4 Mononuclear cell cultures.
Diagram illustrating the set up and principle of MNC cultures. Unstimulated/LPS example.
2.4 Gene expression
2.4.1 RNA extraction from gestation-associated tissue samples
The Trizol method of RNA extraction was used. Previously archived samples 
(section 2.2.3) were thawed and placed into a FastPrep FP120A Homogeniser 
(Bio101 Savant, Qbiogene, The Netherlands) and homogenised for 45 seconds at 
speed setting 5. Lysates were then centrifuged at 20,000 x g for 5 minutes at 4°C. 
The supernatant were then transferred to a 1..5 ml tube (Greiner, Bio-One, 
Germany), prior to incubation for 5 minutes at room temperature. Chloroform (150 
pI:- Sigma-Aldrich, Poole, UK) was added, mixed vigorously and incubated at room 
temperature for a further 15 minutes, prior to centrifugation at 18,000 x g at 4°C for 
15 minutes. Following centrifugation, 3 phases are present (Figure 2.5). The upper 
aqueous phase which contains RNA was removed and mixed with 250 pi
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isopropanol (Sigma-Aldrich, Poole, UK) prior to incubation at room temperature for 
10 minutes. This was then centrifuged for 5 minutes at 4°C, 18, 000 x g. An RNA 
pellet forms on the bottom of the tube. Supernatant was removed and the RNA 
pellet washed with 500 pi 70% ethanol, vortexed and centrifuged for 5 minutes at 
4°C, 11,000 x g. On removing ethanol the pellet was allowed to dry for 5 -  10 
minutes at room temperature, with care taken to ensure that the pellet doses not dry 
out completely. The pellet was then reconstituted in 50 pi RNase-free water 
(Ambion, UK).
To ensure that the RNA was free of genomic DNA, the RNA extract was processed 
using the DNA free DNase Kit (Ambion, UK) as per manufacturer’s instructions. 
Spectrophotometric quantification of DNA free RNA was performed using a 
NanoDrop (ND-3300 fluorospectrometer, NanoDrop Technologies, USA). Optical 
density ratios (OD260/OD280) were determined with a ratio of > 1.8 accepted as 
satisfactory.
Chloroform
Supernatan t —
C entrifugation >>
A queous Phase 
(conta in ingR N A )
Interphase  
(co n ta in in g D N A )
} O rganicPhase  (con ta in in g P ro te in )
Figure 2.5 RNA separation.
After centrifugation, three phases are present: a lower red organic phase (containing protein), an 
interphase (containing DNA) and a colourless upper aqueous phase (containing RNA).
2.4.2 Reverse transcription polymerase chain reaction (RT-PCR) -  
Complementary cDNA synthesis
Reverse transcription was performed using the RETROscript kit (Ambion, UK) as 
per manufacturer’s instructions. Briefly, using random decamers and murine 
leukaemia virus reverse transcriptase, 1 pg of RNA was transcribed into cDNA. The 
reaction was incubated at 44°C for 60 minutes then 92°C for 10 minutes in a 
polymerase chain reaction (PCR) thermal cycler (DNAEngine, Bio-Rad, UK). A
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positive control of mouse liver RNA provided in the kit was used as a positive 
control. A no template control (NTC) of water and reverse transcriptase was 
performed to ensure that all reagents were DNA free.
For confirmation of successful cDNA synthesis a “check” PCR was performed with 
products analysed by gel electrophoresis (see 2.4.3.2).
2.4.3 Polymerase chain reaction (PCR)
Polymerase chain reaction was performed using the Platinum® Taq DNA 
Polymerase kit and 10 mM dNTP Mix (both Life Technologies, UK). cDNA (1 pi) was 
added to a master mix of 10X PCR buffer, dNTP, specific forward and reverse 
primers for the gene of interest, optimised concentration of MgCh, nuclease free 
water and a thermostable Taq DNA polymerase for a total reaction mix of 20 pi. A 
no template control (NTC) of water and PCR master mix was performed to ensure 
that all reagents were DNA free. Human spleen cDNA (prepared from total human 
spleen RNA as in section 2.4.2; Clontech, UK) was used as a positive control. PCR 
reaction was performed in a DNAEngine thermal cycler. Cycling parameters were 
95°C for 5 minutes, 40 cycles of (94°C for 30 seconds, reaction specific annealing 
temperature for 30 seconds, 72°C for 30 seconds), 72°C for 4 minutes. Primer 
sequences and optimised conditions are detailed in the appropriate chapters.
2.4.3.1 Optimisation of PCR primers
To ensure a successful PCR reaction, each primer pair was optimised for a specific 
annealing temperature and magnesium concentration by performing a 
temperature/MgCh gradient using human spleen cDNA (Figure 2.6). Primer 
information is detailed in individual chapters.
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MgCI2 
Concentration
Non-Specific 
Bands(NSB)
MgCI2
Concentration
Non-Specific 
Bands(NSB)
1.5nM 2.5nM
3.5nM
Temperature (58-72°C)
Figure 2.6 Example temperature/MgCb gradients.
PCR reactions of different MgCb were placed on a temperature gradient in thermal cycler. Under 
optimum conditions non-specific bands (NSB) are no longer present.
2.4.3.2 “Check” PCR
For confirmation of successful cDNA synthesis a “check” PCR was performed. For 
each sample a reaction mix of 20 pi containing 10X PCR buffer, dNTP and control 
primers from the RETROscript kit, a thermostable Taq DNA polymerase, nuclease 
free water and cDNA as per manufacturer’s instructions. A “check” PCR was 
performed on the experimental samples cDNA produced during the RT, in addition 
to the corresponding RNA from the experimental samples to ensure that each 
sample was free of genomic DNA. The NTC and positive control from the RT step 
and a negative control containing all PCR reagents with water substituted for the 
cDNA were also included.Cycling parameters were 95°C for 1 minutes, 30 cycles of 
(94°C for 30 seconds, 59°C for 30 seconds, 72°C for 30 seconds), 72°C for 4 
minutes.
If each stage of the RNA extraction and RT-PCR were successful, upon analysis by 
gel electrophoresis, bands of the appropriate size should be present in the positive 
control and for all experimental samples, but not in the NTC or negative control or 
the corresponding RNA from the experimental samples. If bands were present in the 
RNA samples, RNA was subjected to further DNase treatment until RNA was DNA 
free.
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2.4.4 Agarose gel electrophoresis
Agarose gels (2%) were prepared (agarose tablets; Bioline, UK; Tris-Borate-EDTA 
(TBE); Sigma-Aldrich, Poole, UK) and allowed to set for 30 minutes at room 
temperature. PCR products were loaded alongside DNA standard (Tracklt; Life 
Technologies, UK) and run for a minimum of 30 minutes at 120 V. Gels were 
subsequently visualised under UV light (Gel Doc XR, Bio-Rad).
2.5 Protein expression
2.5.1 Protein extraction from gestation-associated tissue samples
PBS washed tissue (0.2 g) was place into a 2ml tube containing Lysing Matrix D 
with 500 pi RIPA Buffer (150 mM NaCI, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with Protease Inhibitor 
Cocktail (104 mM AEBSF, 80 pM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM 
Leupeptin, 1.5 mM Pepstatin A) and Phosphatase Inhibitor Cocktail (all Sigma- 
Aldrich, Poole, UK).
Specimens were placed into a FastPrep homogeniser and homogenised for 45 
seconds at speed setting 5. Lysates were then centrifuged for 20 minutes at 4°C, 
12,000 x g. Supernatants were transferred to a clean 1.5ml tube with the remaining 
cellular debris discarded. A small volume of supernatant was aliquoted for protein 
estimation. Lysates were stored at -20°C until needed.
2.5.2 Protein estimation
Protein content of each sample was estimated using the Bicinchoninic acid (BCA) 
Assay. In a 96 well plate (Greiner, Bio-One, Germany), 80 pi of a working solution 
(50 parts bicinchoninic acid solution, 1 part copper (II) sulphate pentahydrate 4%  
solution, all Sigma-Aldrich, Poole, UK) was added to either, 10ul of protein sample 
or 10 pi protein standard (Bovine serum albumin [BSA], 0.2 -  1 mg/ml; Sigma- 
Aldrich, Poole, UK, blank of distilled water also included). The reaction was then 
incubated for 30 minutes at 37°C. Following this, the absorbance at 562 nm of all 
samples and standards was measured using a plate reader (POLARstar Omega; 
BMG LABTECH, Germany).
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2.5.3 Western blotting
2.5.3.1 Preparation of protein samples
Previously quantified protein (50 pg) was added to 5ul LDS samples buffer (Life 
Technologies, UK) and sufficient deionised water to make a total volume of 25 pi. All 
samples were then incubated for 10 minutes at 70°C.
2.5.3.2 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis)
Polyacrylamide running gels (7.5-15%) were prepared (see Table 2-1) and placed 
into a 1.5 mm gel mould (Bio-Rad,- UK). Water saturated butanol was added to 
ensure a clean top edge and the gel left to polymerise for 30 minutes at room 
temperature. Once set, the butanol was washed off, stacking gel (1.75 ml H20 , 0.75 
ml Tris + SDS, 0.5 ml 30% acrylamide, 100 pi 10% APS [ 0.1 g APS in 1 ml dH20], 
3 pi TEMED) was added and comb inserted before leaving gel for 20 minutes at 
room temperature. Un-polymerised staking gel was removed by washing with dH20 
and gels placed into a mini tank (Mini-PROTEAN Tetra Cell, Bio-Rad, UK) filled with 
1 X SDS-PAGE running buffer (900 ml deionised water, 100 ml 10 X SDS-PAGE  
running buffer; 500 ml Tris-Glycine, 5 g SDS, both Sigma-Aldrich, Poole, UK). 
Protein samples were loaded alongside a protein standard (All Blue; Bio-Rad, UK) 
and run for 50 minutes at 200 V.
2.5.3.3 Semi-dry membrane transfer
Once the gel has run, proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad, UK) using a transfer dock (Bio-Rad TransBlot SD) for 75 
minutes at 15V. PVDF membrane was pre-soaked (methanol for 30 seconds, water 
for 2 minutes, transfer buffer for at least 5 minutes) then placed upon three pre­
soaked pieces of filter paper on the transfer dock. The SDS-PAGE gel was then 
placed on top of the PVDF membrane followed by three further pieces of filter paper. 
Care was taken to ensure no air bubbles. Protein was then transferred using the 
Trans-Blot SD Semi-Dry Electrophoretic Transfer cell (Bio-Rad, UK). Following 
transfer each membrane was treated with Ponceau S stain (Sigma-Aldrich, Poole, 
UK) to visualise the protein to ensure that the transfer was successful. The 
membrane was then washed in 1 X TBS-Tween-20 (Both Sigma-Aldrich, Poole, UK) 
to remove the stain before continuing.
Table 2-1 Polyacrylamide running gels.
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Reagent 7.50% 10% 12% 15%
Water 5 ml 4.2 ml 3.5 ml 2.5 ml
4 X Tris and 
SDS
2.5 ml 2.5 ml 2.5 ml 2.5 ml
30% acrylamide 2.5 ml 3.3 ml 4 ml 5 ml
APS
100 pi of 10% 
solution
100 pi of 10% 
solution
100 pi of 10% 
solution
100 pi of 10% 
solution
TEMED 10 pi 10 pi 10 pi 10 pi
Different percentage 1.5 mm polyacrrylamide gels (7.5-15%) were prepared by varying the 
concentration of acrylamide in the mixture. The polymerising agents APS and TEMED were not added 
until ready to cast to minimise the amount of oxidation the mixture undergoes, as this will impair 
polymerisation. 10% APS -  0.1 g APS in 1 ml dhteO. APS, ammonium persulfate; TEMED. 
Tetramethylethylenediamine.
2.5.3.4 Membrane blocking and antibody staining
PVDF membrane was blocked for 1 hour at room temperature in 5% non-fat milk in 
TBS. Blocking buffer was then removed and 2ml of primary antibody (diluted in 
either 5% BSA, 0.1% Tween-20 in TBS or 5% non-fat milk in TBS to the appropriate 
concentration as noted in each chapter) was added to the PVDF membrane which 
was then sealed in a plastic bag and incubated over-night at 4°C. The following 
morning, the primary antibody was removed and the membrane washed in TBS- 
Tween-20 three times for 7 minutes each. Secondary antibody as indicated in each 
chapter was prepared and the membrane incubated with 2 ml of this preparation for 
1-2 hours at room temperature in a sealed plastic bag. The membrane was then 
washed in TBS-Tween-20 three times for 7 minutes as before and TBS for a 
minimum of 5 minutes before visualisation.
2.5.3.5 Enhanced chemiluminesence (ECL)
PVDF membrane was incubated face down in ECL for 1-5 minutes at room 
temperature -  time varied depending on the ECL reagent used; 1 minute for 
Amersham ECL Select Western blotting detection reagent (GE Healthcare, UK) and 
5 minutes for West PICO Chemiluminescent substrate (Fisher Scientific, UK). The
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membrane was then visualised using a ChemiDoc XRS (Bio-rad, UK) at several 
different time points (1 ,10 , 30, 60, 90, 270 seconds).
2.5.3.6 Stripping and re-probing of PVDF membrane
The membrane was placed in room temperature TBS-Tween-20 for 10 minutes, 
prior to being sealed in a plastic bag with 2 ml stripping buffer (Fisher-Scientific, UK) 
for 15-20 minutes. Following incubation the membrane was washed in TBS-Tween- 
20. The membrane was then ready to be reprocessed as described above (see
2.5.3.4 -  2.5.3.5).
2.6 Enzyme linked immunoabsorbant assay (ELISA)
Production of cytokines/chemokines were examined in the supernatants of placenta, 
choriodecidua and amnion explant cultures and whole blood culture supernatants 
collected after 24 h using commercially available ELISA kits as per manufactures 
instructions. The different cytokines analysed are listed in Table 2-2.
An overview of a general ELISA protocol can be seen in Figure 2.7. Briefly, a half­
area 96 well plate (Greiner Bio-one, Germany) is coated with a capture antibody and 
incubated overnight at 4°C. The coating antibody is discarded and the plate 
incubated for 1 hour at room temperature with 1% BSA in PBS (150 pi per well). The 
plate is subsequently washed 3 times with wash buffer (1% BSA in PBS 0.005%  
Tween-20) using an ELx50 Microplate Strip Washer (BioTek, UK) and supernatants 
of interest in addition to known standards are added for 2 hours at room 
temperature. Following incubation the plate is washed 4 times before the addition of 
detection antibody at room temperature for 2 hours. The plate is once again washed 
4 times, before the addition of strepdavidin horseradish peroxidase (HRP) linked 
secondary antibody for 20 minutes’ at room temperature and once again washed 6 
times. A substrate solution is prepared according to manufactures instructions 
(TMB, BD Bioscience, USA) and added allowing for the development of a blue 
colour. A yellow is then produced followed the addition of 1M H2SO4 to stop the 
reaction. The intensity of the colour is measured at 450 nm using a plate reader 
(POLARstar Omega; BMG LABTECH, Germany), with the concentration of the 
cytokine calculated based on the standard curve.
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Table 2-2 ELISA kits used in this body of work.
Cytokine/Chemokine Manufacturer Sensitivity (pg/ml)
IL-1 (3 R&D Systems 3.91 pg/ml
IL-6 R&D Systems 9.38 pg/ml
IL-8 (CXCL8) R&D Systems 31.2 pg/ml
MIP-1a (CCL3) R&D Systems 7.81 pg/ml
Sensitivity is listed as provided by manufacturers.
Substrate
Streptavidin 
HRP
Detection
Antibody
Antigen
Acid
Capture
Antibody
0 ^ 0
o o o o
Y Y Y Y Y
l ~ n  l~ B ~ |  |~ C ~ |  f ~ D ~ |  | ~ E ~ | m
Figure 2.7 Overview of ELISA protocol.
(A) Capture antibody is immobilised on plastic. (B) Antigen is added and binds to the capture antibody. 
(C) Biotin-conjugated detection antibody is added and binds the antigen. (D) HRP linked streptavidin 
binds to biotin on the detection antibody. (E) TMB is added and catalysed by the HRP producing a blue 
colour. (F) Acid is added, stopping the reaction producing a yellow colour.
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2.7 Caspase activity assay
Caspase activity was evaluated using the Caspse-1 Colorimetic Assay Kit and 
Caspase-8 Colorimetic Assay Kit (both Abeam, UK), utilising a caspase specific 
substrate, which in the presence of active caspase is cleaved releasing a 
chromophore. Spectrophotometric detection of light emitted by the chromophore is 
relative to the amount of active caspase. In a 96 well half-area plate 100 pg of 
protein in 25 pi was added with 25 pi of 2X reaction buffer (containing 10 mM DTT) 
and 5 pi substrate (200 pM; YVAD-p-NA, Caspase-1 substrate; lETD-p-NA, 
Caspase-8 substrate). All tests were performed in duplicate. Commercially available 
active Caspase-1 and Caspase-8 (both Abeam) were used as positive controls. The 
reaction was incubated at 37°C for a minimum of 2 hours. Following this, the 
absorbance of all samples and controls at 405nm were read using a plate reader 
(POLARstar Omega; BMG LABTECH, Germany). Protein and buffer without 
substrate were included permitting background correction.
2.8 Statistical analysis
All experiments were performed a minimum of three times (i.e. a minimum of three 
biological replicates) in duplicate (two technical replicates) with data presented as 
mean ± SEM.
Since the data sets contained small sample numbers it was important to consider 
which statistical test would be most appropriate. To choose a parametric test, the 
data must be normally distributed i.e. following a Gaussian distribution; if the data is 
not normality distributed type II error will occur. However, tests used to determine 
normality do not have the power to determine if a data set comes from a Gaussian 
population, when the sample number is small. Since normality cannot be 
determined, the alternative is to perform non-parametic testing. However, it should 
be noted that applying non-parametric tests to a data set without knowing if it is 
normally disturbed could increase the chances of type I errors occurring. As 
normality could not be determined, all data was therefore treated as non-parametric. 
The Wilcoxon matched pairs signed rank test was applied when comparing to 
groups (e.g treated and untreated), and the Freidman’s test with Dunn’s posthoc test 
when comparing three or more groups (e.g. untreated, treatment 1 and treatment 2). 
A p vaule of < 0.05 was determined significant. Statistical significance was 
calculated using GraphPad Prism (Version 6, GraphPad Software Inc, USA).
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Chapter 3
Expression and activity of TLRs, 
NLRs and RLRs in human 
gestation-associated tissues
3 Expression and activity of TLRs, NLRs and RLRs in human 
gestation-associated tissues
3.1 Introduction
It is now well established that a number of cytokines and chemokines play a role in 
the normal physiological process of pregnancy including parturition. In particular the 
cytokines IL-1J3, IL-6, IL-8 and TNFa among others are produced by gestation- 
associated tissues (placenta and attached membranes) both constitutively and/or in 
response to an insult [10, 67-72]. Pattern recognition receptors (PRRs) have been 
identified as a link between both exogenous microbial agonists (pathogen 
associated molecular patterns, PAMPs) and endogenous host derived agonists 
(damage associated molecular patterns, DAMPs) [103, 280]. However, the study of 
PRR expression and activity by gestation-associated tissues is still in its infancy.
The study of PRRs expression and activity by gestation-associated tissues has 
principally focused on Toll-like receptors (TLRs) and more recently Nod-like 
receptors (NLRs). Transcripts for TLRs 1-10 have been demonstrated in the term 
placenta, decidua and amnion [233, 241-243]. Functional activity of TLRs 1-9 have 
been reported for the term placenta, with only functional activity for TLRs 2/6, 4 and 
5 in amniotic epithelial cells and TLRs 1-4 and 6 in the decidua [233, 241-243]. 
Expression of the NLRs, NOD1 and NOD2 has been demonstrated by the term 
decidua, while only NOD1 is expressed by the term placenta [60, 244]. However, 
NOD2 in addition to NOD1 has been shown to be expressed in the first trimester 
placenta with a corresponding functional output; functional NOD1 and 2 in first vs. 
functional NOD1 at term [281]. NLR activity by the amnion has not been examined 
to date.
Other families of PRRs have also been described namely RIG-l-like receptors which 
are associated with recognition of viral RNAs and C-type lectin receptors, which are 
associated with recognition of fungal derived carbohydrates [196, 217]. However the 
expression and activity of these PRRs by gestation associated tissues remains 
unknown. It is therefore clear that a great deal remains to be understood regarding 
PRR activity in gestation-associated tissues.
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3.2 Aims
The aim of this chapter is to examine the expression and activity of Toll-like 
receptors (TLRs), NOD-like receptors (NLRs) and RIG-l-like receptors (RLRs) in the 
term non-laboured human placenta, choriodecidua and amnion. The activity of oC- 
type lectin receptors (CLRs) will be examined in the following chapter.
3.3 Methods
3.3.1 Samples
Healthy pregnant women scheduled for elective caesarean section (ESC) were 
approached in the antenatal day assessment unit at Singleton Hospital, Swansea, 
during their pre-anaesthetic assessment. Informed written consent was obtained 
following explanation of the study. After delivery, the placenta and attached fetal 
membranes (n = 3-11) from these women were collected and processed within 1.5 
hours of delivery (see Chapter 2.1 for details).
3.3.2 PCR
Gestation associated tissue samples (placenta, choriodecidua and amnion) were 
stored in TRI reagent and frozen within 30 minutes of collection of the tissue. RNA 
was extracted using the Trizol method and was cDNA subsequently produced 
following DNase treatment (see Chapter 2.4 for method). PCR was performed for 
TLRs, NLRs and RLRs using the primers tested in Table 3-1 and 3-2.
3.3.3 Gestation-associated tissues explants
Placenta, choriodecidua and amnion tissue explants were cultured as described in 
chapter 2.2. Cultures were initially stimulated with several PRR specific agonists (all 
Invivogen) at a range of concentrations (Table 3-3) to identify an optimum 
concentration of each agonist. Once identified the optimised concentration was used 
in subsequent in vitro culture experiments.
3.3.4 Cytokine production
IL-6 and IL-8 in the tissue free supernatants of placenta, choriodecidua and amnion 
explant cultures collected after 24 h were measured using commercially available 
ELISA kits (DuoSet, R&D Systems) as per manufacturer’s instructions.
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3.3.5 Statistical analysis
Agonist mediated cytokine production by non-laboured tissues was evaluated by 
Wilcoxon matched pairs signed rank test or Freidman’s test with Dunn’s posthoc test 
for multiple comparisons. A p-value of £ 0.05 was considered significant.
Table 3-1 TLR and Housekeeping primer sequences.
Gene Primer
Mg2+
Cone
(nM)
Annealing 
Temp (°C)
Fragment 
Size (bp)
Ref
TLR1
F
R
5' CAGTGTCTGGTACACGCATGGT 
5' TTT CA AA AACCGT GTCTGTTAG AG A
3 63 104 [233]
TLR2
F
R
5' GGCCAGCAAATTACCTGTGTG 
5' AGGCGGACATCCTGAACCT
2 69 67 [233]
TLR3
F
R
5' CCTGGTTTGTTAATTGGATTAACGA 
5' TGAGGTGGAGTGTTGCAAAGG
1.5 63 82 [233]
TLR4
F
R
5' C AG AGTTT CCTG C A AT G GAT C A 
5' GCTTATCTGAAGGTGTTGCACAT
3.5 60 88 [233]
TLR5
F
R
5' TGCCTTGAAGCCTTCAGTTATG 
5' CCAACCACCACCATGATGAG
1.5 59 77 [233]
TLR6
F
R
5’ GAAGAAGAACAACCCTTTAGGATAGC 
5' AGGCCAAACAAAATGGAAGCTT
2.5 68 88 [233]
TLR7
F
R
5' TTTACCTGGATGGAAACCAGCTA 
5' TCAAGGCCTGAGAAGCTGTAAGCTA
2 66 73 [233]
TLR8
F
R
5’ TTATGTGTTCCAGGAACTCAGAGAA 
5' TAATACCCAAGTTGATAGTCGATAAGTTTG
3 66 83 [233]
TLR9
F
R
5' GGACCTCTGGTACTGCTTCCA 
5' A AG CTCGTTGTACACCC AGT CT
2 66 151 [233]
TLR10
F
R
5' TGTTATGACAGCAGAGGGTGATG 
5' G AGTT G A A A AAGG AGGTTATAGG AT A A AT C
1.5 63 151 [233]
UBE2D2
F
R
5' GATCACAGTGGTCTCCAGCA 
5' TCCATTCCCGAGCTATTCTG
3 65 156 [282]
Sequences and optimum conditions for each pair of Toll-like receptor (TLR) and housekeeping primers 
used for PCR. TLR primers sequences obtained from Patni et al 2009 [233] and UBE2D2 sequences 
from Popov et al 2010 [282]. Bp, base pairs; F, forward primer sequence; nM, nanomolar; R, reverse 
primer sequence; TLR, Toll-like receptor; UBE2D2, ubiquitin-conjugating enzyme E2 D2.
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Table 3-2 NLR and RLR primer sequences.
Gene Primer
Mg2+
Cone
(nM)
Anneling 
Temp (°C)
Fragment 
Size (Bp)
Accession
Number
NOD1
F
R
5' AGGCTGAGTACCATGGGCTA 
5' GCCCGTTTAGTCACCCTTCA
2 66 184 NM_006092
NOD2
F
R
5‘ CAGGCAGCACAGGTCAGCCC 
5' GTTGTGCGGCTCGGCCTTCT
2 71 300 NM_001293557
NLRP1
F
R
5' ATACGAAGCCTTTGGGGACT 
5' CACCGCTTCTCTCATCACAA
3 65 164 NM_014922
NLRP3
F
R
5' ACCGGAGCCAGCAGGAGAGG 
5' GAAGGCTGCCCTGGCTTGGG
1.5 71 659 NM_001127461
NLRC4
F
R
5' GCCTCAGGCTGCAAATAAAG 
5' CCA AGCT GTC AGT C AG ACC A
2 68 213 NM_001199139
NLRX1
F
R
5' GCTCCATGGCTTAGAGCATC 
5' ACGTACTTGCTGGGGATACG
1.5 62 189 NM_001282358
NAIP
F
R
5' TTCTTGCCCTGAAAACTGCT 
5’ CGTATTGGGAAGTGGATGCT
3 66 169 NM_004536
RIG-I
F
R
5' TGTTTCCAGGGATCCCAGCAATGA 
5' ACTTCACATGGATCCCCCAGTCATGGC
1.5 70 839 NM_014314
MDA5
F
R
5' GCT C AC AGTGG AT CCG G AGTTAT CG A A 
5' C ACC AT C ATGG AT CCCC AAGCCT G G CC
2 59 420 NM_022168
LGP2
F
R
5‘ GTGGTGGTGCAGGCGAGACC 
5' GCTGGGGGCAGCAGTTCTGG
3 70 752 NM_024119
Sequences and optimum conditions for each pair of NOD-like receptor (NLR) and RIG-1 like receptor 
(RLR) primers used for PCR. Bp, base pairs; F, forward primer sequence; LGP2, laboratory of genetics 
and physiology 2; MDA5, melanoma differentiation-associated protein 5; NAIP, NLR family apoptosis 
inhibitory protein; nM, nanomolar; NOD, nucleotide-binding oligomerisation domain; NLRC, NOD-like 
receptor containing a CARD domain; NLRP, NOD-like receptor containing a PYD domain; R, reverse 
primer sequence; RIG-1, retinoic acid-inducible gene 1.
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Table 3-3 TLR, NLR and RLR ligands.
Ligand
Receptor
Targeted
Concentrations
Tested
Pam3CSK4 TLR2/1 100 n g -  1 ug/ml
HKLM TLR2 10*6 -1 0 *8  cells/ml
FSL1 TLR2/6 1 ng -  1 ug/ml
Poly(l:C)HMW TLR3 5 - 2 5  |Jg/ml
Poly(l:C)LMW TLR3 5 - 25 pg/ml
LPS TLR4 1 ng -  10 pg/ml
Flagellin TLR5 1 ng - 1 0 0  ng/ml
Imiquimod TLR7 10 ng -  1 pg/ml
ssRNA40 TLR8 10 ng -  1 pg/ml
Tri-DAP NOD1 100 ng -  10 pg/ml
MDP NOD2 100 ng -1 0  pg/ml
Poly(l:C)LyoVec RIG-1 & MDA-5 10 ng -1 pg/ml
Ligands at a range of concentrations were tested on placenta, choriodecidua and amnion to identify an 
optimum concentration of each agonist. HKLM, heat killed Listeria monocytogenes; HMW, high 
molecular weight; LMW, low molecular weight; LPS, lipopolysaccharide; MDA5, melanoma 
differentiation-associated protein 5; MDP, Muramyl dipeptide; NOD, nucleotide-binding oligomerisation 
domain; NLR, NOD receptor; Poly(l:C), polyinosine-polycytidylic acid; RIG-1, retinoic acid-inducible 
gene 1; RLR, RIG-I like receptor; ssRNA, single stranded RNA; TLR, toll-like receptor; Tri-DAP, L-Ala- 
y-D-Glu-mDAP.
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3.4 Results
3.4.1 Expression of transcripts for TLRs, NLRs and RLRs by gestation- 
associated tissues
To investigate whether transcripts for a variety of pattern recognition receptors, 
including TLRs, NLRs and RLRs are expressed in gestation associated tissues, 
PCR was performed using five individual samples of each tissue type (placenta, 
choriodecidua and amnion). Three of these five samples are shown in Figure 3.2 -  
Figure 3.4. Transcripts for each PRR examined were present in all five samples of 
each of the tissues.
L S - ve P P P C C  C A A A
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Figure 3.1 Transcripts for TLR1-10 in gestation-associated tissues.
Each TLR was present in all five of the samples tested from each of the tissues examined, three 
representative samples are shown; placenta (P), choriodecidua (C) and amnion (A). Human spleen (S) 
was used as a positive control and UBE2D2 was used as a housekeeping gene. L = 100 base pair 
ladder and the negative control (-ve) was with water replacing cDNA in the reaction mix.
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Figure 3.2 Transcripts for NLR family members in gestation associated tissues.
Each NLR family member was present in all five of the samples tested from each of the tissues 
examined, three representative samples are shown; placenta (P), choriodecidua (C) and amnion (A). 
Human spleen (S) was used as a positive control and UBE2D2 was used as a housekeeping gene. L = 
100 base pair ladder and the negative control (-ve) was with water replacing cDNA in the reaction mix.
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Figure 3.3 Transcripts for RLR family members in gestation associated tissues.
Each RLR family member was present in all five of the samples tested from each of the tissues 
examined, three representative samples are shown; placenta (P), choriodecidua (C) and amnion (A). 
Human spleen (S) was used as a positive control and UBE2D2 was used as a housekeeping gene. L = 
100 base pair ladder and the negative control (-ve) was with water replacing cDNA in the reaction mix.
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3.4.2 Optimisation of PRR agonists
In order to investigate the functional activity of PRRs in the placenta, choriodecidua 
and amnion, preliminary investigations (n=3) were performed in order to determine 
an optimised concentration of each agonist for subsequent experiments. In doing so 
a range of concentrations, based on the manufacturer’s recommendations was 
tested for each agonist (Table 3-3) on all three tissues. If no significant outcome was 
observed at any concentration, a concentration for further experiments was chosen 
based on its ability to provide the greatest increase for both IL-6 and IL-8 for all 
three tissues. Optimised concentrations of each agonist are summarised in Table 3- 
4 with each dose response shown in the appendix (Chapter 8.3, Figure 8.1 -  8.14). 
Table 3-4 Optimised concentrations of TLR agonists.
Ligand
Receptor
Targeted
Optimised
Concentration
Pam3CSK4 TLR2/1 100 ng/ml
HKLM TLR2 10*7 cells/ml
FSL1 TLR2/6 10 ng/ml
Poly(l:C)HMW TLR3 25 pg/ml
Poly(l:C)LMW TLR3 25 pg/ml
LPS TLR4 10 ng/ml
Flagellin TLR5 100 ng/ml
Imiquimod TLR7 1 pg/ml
ssRNA40 TLR8 1 pg/ml
Tri-DAP NOD1 10 pg/ml
MDP NOD2 10 pg/ml
Poly(l:C)LyoVec RIG-1 & MDA-5 1 pg/ml
Optimised concentrations of PRR agonists as determined following preliminary investigations. HKLM, 
heat killed Listeria monocytogenes; HMW, high molecular weight; LMW, low molecular weight; LPS, 
lipopolysaccharide; MDA5, melanoma differentiation-associated protein 5; MDP, Muramyi dipeptide; 
NOD, nucleotide-binding oligomerisation domain; NLR, NOD receptor; Poly(l:C), polyinosine- 
polycytidylic acid; RIG-I, retinoic acid-inducible gene 1; RLR, RIG-I like receptor; ssRNA, single 
stranded RNA; TLR, toll-like receptor; Tri-DAP, L-Ala-y-D-Glu-mDAP.
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3.4.3 Response of term non-laboured gestation associated-tissues 
explants to TLR agonists
3.4.3.1 TLR1/2/6
Since TLR2 can form both a homodimer and heterodimer complex with TLR1 and 
TLR6, distinct agonists were used to determine if these receptors are functional in 
the placenta, choriodecidua and amnion. The agonists Pam3CSK4 (100 ng/ml), a 
synthetic triacylated lipopeptide, and FSL-1 (10 ng/ml), a synthetic lipoprotein, were 
used to examine the TLR2/1 and TLR2/6 heterodimers respectively. A freeze-dried 
heat-killed preparation of Listeria monocytogenes (HKLM; 107 cells/ml) was used as 
a general activator of TLR2. As shown in Figure 3.4, a significant increase in IL-6 
and IL-8 production was observed by both the placenta and choriodecidua in 
response to all three agonists. A significant increase in cytokine production was also 
observed by amnion to all three agonists with the exception of HKLM induced IL-8.
3.4.3.2 TLR3
To investigate if TLR3, a receptor involved in the recognition of dsRNA is functional 
in the placenta, choriodecidua and amnion both a high molecular weight (HMW, 1.5- 
8 kb) and a low molecular weight (LMW, 0.2-1 kb) version of the synthetic dsRNA 
analogue Poly(l:C) (Polyinosine-polycytidylic acid) was used at a optimised 
concentration of 25 pg/ml. As shown in Figure 3.5, a increase in both IL-6 am IL-8 
production was observed in response to both HMW and LMW Poly(l:C) in the 
placenta and choriodecidua, however a significant increase in cytokine production 
was only observed by these tissues in response to treatment with LMW Poly(l:C). 
Similarly increased IL-6 and IL-8 was observed by the amnion following treatment 
with both agonists, with only LMW induced IL-8 significant.
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Figure 3.4 TLR2 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua (E-F) amnion 
following stimulation with Pam3CSK4 (100 ng/ml), HKLM (107 cells/ml) and FSL-1 (10 ng/ml) (n=10). 
Statistical significance compared to unstimulated control as determined by Freidman’s test with Dunn’s 
posthoc test are shown: * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 3.5 TLR3 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua (E-F) amnion 
following stimulation with Poly(l:C)HMW and Poly(l:C)LWM (both 25 pg/ml; n=5). Statistical 
significance compared to unstimulated control as determined by Freidman’s test with Dunn’s posthoc 
test are shown: * p < 0.05, ** p £ 0.01.
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3.4.3.3 TLR4
To investigate if TLR4 is functional in the placenta, choriodecidua and amnion an 
ultrapure form of LPS isolated from E. coli 0111:B4 was used. Since LPS is routinely 
used within the group a concentration of 10 ng/ml has been determined previously 
[233]. A significant increase in both IL-6 and IL-8 production in response to LPS is 
observed in all three tissues (Figure 3.6).
3.4.3.4 TLR5
To investigate if TLR5 is functional in the placenta, choriodecidua and amnion an 
ultrapure form of flagellin isolated from Salmonella typhimurium was used at a 
concentration of 100 ng/ml.A significant increase in both IL-6 and IL-8 production in 
response to flagellin is observed in all three tissues (Figure 3.7).
3.4.3.5 TLR7/8
To investigate if TLR7 and TLR8 were functional in the placenta, choriodecidua and 
amnion the agonists imiquimod (R837) and ssRNA40/LyoVec were used at an 
optimised concentration of 1 pg/ml (n=5). Imiquimod is a small synthetic antiviral 
molecule specific to TLR7 composed of an imidazoquinoline amine analogue to 
guanosine, while ssRNA40/LyoVec is a single stranded GU-rich oligonucleotide 
complexed with the transfection reagent LyoVec, specific for TLR8. In response to 
both Imiquimod and ssRNA40 a statistically significant increase in IL-8, but not IL-6 
was observed in the placenta. In the choriodecidua only a statistically significant 
increase was observed for ssRNA40 induced IL-6, there was no significant increase 
in IL-8 in response to either agonist. Similarly to the placenta, the amnion produced 
a statistically significant increase in IL-8 in response to both agonists. Additionally, a 
significant increase in IL-6 production in response to imiquimod, but not ssRNA40 
was observed in the amnion.
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Figure 3.6 LPS induced cytokine response by the term non-laboured placenta, choriodecidua 
and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following stimulation with 10 ng/ml of LPS (n=11). Statistical significance compared to 
unstimulated control as determined by Wilcoxon matched pairs signed rank test are shown: *** p < 
0.001.
68
B
200000
150000
E 100000 
"52
50000
* * 400000
300000
E 200000 
*Sa
100000
Unstim Flagellin Unstim Flagellin
125000
100000
2  75000
o. 50000
25000
Unstim Flagellin
D
250000
200000
S
S  150000
100000
50000
* *
Unstim Flagellin
10000 n
E 5000
160000
120000
E 80000
*sa
40000
* *
Unstim Flagellin Unstim Flagellin
Figure 3.7 Flagellin induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following Flagellin (100 ng/ml; n=9). Statistical significance compared to unstimulated control 
as determined by Wilcoxon matched pairs test are shown: ** p £ 0.01.
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Figure 3.8 TLR7/8 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua (E-F) amnion 
following stimulation with either imiquimod or ssRNA40 (both 1 pg/ml; n=5). Statistical significance 
compared to unstimulated control as determined by Freidman’s test with Dunn’s posthoc test are 
shown: * p < 0.05, ** p < 0.01.
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3.4.4 Response of term non-laboured gestation-associated tissues 
explants to NLR agonists
To investigate if the NLRs, NOD1 and NOD2 were functional in the placenta, 
choriodecidua and amnion, the agonists L-Ala-Y-D-Glu-mDAP (Tri-DAP) and 
muramyl dipeptide (MDP) which are specific for NOD1 and NOD2 respectively were 
used. As shown in Figure 3.9, a significant increase in IL-6 and IL-8 production by 
the placenta is observed in response to Tri-DAP treatment. An increase in MDP 
induced IL-8 is also observed, however this was not significant. An increase in 
cytokine production is observed in response to both agonists by the choriodecidua, 
with a significant increase in Tri-DAP induced IL-6 and MDP induced IL-8. In the 
amnion, a significant increase in MDP induced IL-6 and Tri-DAP induced IL-8. 
Elevated IL-8 induced by MDP treated amnion is also observed.
3.4.5 Response of term non-laboured gestation-associated tissue 
explants to RLR agonists
To investigate if the RLRs, RIG-I and MDA5 were functional in the placenta, 
choriodecidua and amnion the agonist Poly(l:C)/LyoVec, a complex between the 
transfection reagent LyoVec and poly(l:C) was used. Transfected Poly(l:C) has been 
shown previously to be recognised by RIG-I/MDA5, unlike naked Poly(l:C) which is 
recognised by TLR3 [216, 283]. The results are shown in Figure 3.10. Elevated IL-8 
production was observed in all three tissues in response to treatment with 
Poly(l:C)LyoVec, however this was not significant. In contrast, no difference was 
observed in relation to IL-6 production, by the placenta and amnion. Elevated IL-6 
production was observed by the choriodecidua, but this was not significant.
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Figure 3.9 N0D1/2 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua (E-F) amnion 
following stimulation with either Tri-DAP or MDP (both 10 pg/ml; n=6). Statistical significance compared 
to unstimulated control as determined by Freidman’s test with Dunn’s posthoc test are shown: * p < 
0.05, **p<0.01.
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Figure 3.10 RIG-I/MDA5 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following treatment with Poly(l:C)LyoVec (1 pg/ml; n=5). Statistical significance was 
determined by Wilcoxon matched pairs test. No significant difference was observed.
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3.5 Discussion
Since changes in cytokine production at the maternal-fetal interface are a feature of 
both term and preterm labour, the mechanisms involved in their production by the 
placenta and attached membranes have gathered much interest. PRRs play a key 
role in the production of inflammatory mediators in response to microbial stimuli, it 
has therefore been suggested that PRRs have a central role in cytokine production 
by these tissues. With this in mind, the aim of this chapter was to examine whether 
several families of PRRs, including Toll-like receptors (TLRs), NOD-like receptors 
(NLRs) and RIG-l-like receptors (RLRs) were expressed and were able to elicit a 
cytokine response (IL-6 and IL-8) following stimulation with known agonists. The 
cytokines IL-6 and IL-8 were chosen due to their documented role in both term and 
preterm labour [11, 15, 25, 27] and as key cytokine produced following PRR 
activation [233, 284-286].
Work previously reported by the group had demonstrated the expression of TLR 1 -  
10 in the term placenta with TLR 2-5 and 7/8 shown to be functional based on a 
significant increase in one or more of the cytokines analysed (IL-6, IL-8, IL-10 and 
TNFa) [233]. The data generated here mainly corresponds to this in regards to 
expression and function of TLRs by the placenta. In relation the functional response 
of the placenta to TLR agonists, the data shown here, demonstrates a significant 
increase in the production of either IL-6, IL-8 or both in response to Pam3CSK4 
(TLR2/1), FSL-1 (TLR2/6), HKLM (TLR2) Poly(l:C)LWM (TLR3), LPS (TLR4), 
Flagellin (TLR5) and Imiquimod (TLR7), thus implying functional TLR 1-7 in the 
placenta. In comparison to previous studies where PGN is used as an activator of 
TLR2, this work utilised the specific agonists for the TLR2 heterodimers TLR2/1 and 
TLR2/6, thus implying for the first time that both are functional in the term placenta. 
However, neutralisation experiments are required to confirm this. While functional 
TLR7 and 8 has been previously reported utilising a dual agonist for both receptors, 
the work presented here would suggests that TLR8 is not functional as significant 
increase in cytokine production was not observed to the TLR8 agonist ssRNA40. 
However, this is likelya result of heterogeneity within the small sample population 
examined. Similarly, low sample number may offer an explanation as to why no 
significant cytokine production was observed to the TLR3 agonist Poly(l:C)HMW in 
comparison to Poly(l:C)LMW. However, it is not entirely surprising that a difference 
was observed between the two agonists, as these synthetic dsRNA molecules differ 
in size, therefore it’s possible that the smaller LMW (0.2 -  1 kb) poly(l:C) gains
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access to the endosomose located TLR3 with greater ease that the larger HMW (1.5 
- 8  kb) poly(l:C).
Similarly to the term placenta, the work in this chapter demonstrates expression of 
transcripts for TLR 1 -  10 by the term choriodecidua and amnion, corresponding to 
that previously reported in decidual cells and amnion epithelial cells [240, 243, 287]. 
Functional TLR 1-6 and 8 are implied in the term choriodecidua as suggested by the 
significant increase in the production of either IL-6, IL-8 or both in response to 
Pam3CSK4 (TLR2/1), FSL-1 (TLR2/6), HKLM (TLR2) Poly(l:C)LWM (TLR3), LPS 
(TLR4), Flagellin (TLR5) and ssRNA40 (TLR8). In response to ssRNA40 only a 
significant increase in IL-8 was observed, possibly due to heterogeneity within low 
sample number examined. This is the first time functional response to ligands for 
TLR5 and TLR8 within these tissues have been described. Previous investigation 
showed only functional TLR1-4 and 6 in term decidual cells, while functional TLR5 
and TLR8 have been shown in fetal membranes explant [242,243 ,288].
The difference in the response of isolated decidual cells in comparison to explants of 
choriodecidua or whole fetal membrane to TLR5 and TLR8 agonists highlights the 
importance of the model of investigation used. While a dissociated cell model has 
the advantage of greater efficiency and reproducibility, resulting from the generation 
of millions of cells from a single source, the activity of these cells in isolation is 
artificial and does not factor in the interactions between various cells found in any 
given tissue or how utilisation of signalling pathways may differ. The response to 
TLR5/TLR8 agonists might be the result of resident leukocytes (macrophages and 
neutrophils) within the choriodecidua. Leukocyte recruitment from the maternal 
circulation into the choriodecidua accomplished by selective chemotaxis has been 
proposed as a key step in the preparation for labour [14, 289, 290]. These resident 
leukocytes have been shown to secrete various pro-inflammatory cytokines 
including IL-1 (3, IL-8 and TNFa at both term and preterm, contribution to the 
inflammatory environment during labour [289, 291]. Since the expression of TLRs by 
macrophages and neutrophils has been well documented [292], it’s more than likely 
that these cells contribute to the TLR agonist induced cytokine production by the 
choriodecidua. Alternatively, this might suggest differential expression of these 
receptor between the chorion and decidua at the protein level. Immunohistochemical 
studies would be needed to confirm protein expression and the cell populations 
expressing these receptors.
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To date, TLR2/6, TLR4 and TLR5 have been reported to be functional in amnion 
epithelial cells, based on increased IL-6 an IL-8 in addition to the translocation of the 
NF-kB, p65 subunit. No induction of IL-6 or IL-8 was observed in response to 
agonist for TLR1/2, 7 and 9, while no TLR8 agonist was used [287]. The data 
presented here implies functional TLR2/1, TLR2/6, TLR3, TLR4, TLR5 and TLR7 as 
suggested by the significant increase in the production of IL-6, IL-8 or both in 
response to specific agonists. This data therefore verifies a functional response to 
TLR2/6, TLR4 and TLR5 agonists in the term amnion, in addition to showing a 
functional response TLR2/1, and TLR7 agonists.
While a functional response to TLR9 agonists (CpG ODN) was not examined during 
initial investigations, preliminary data recently generated (Chapter 8.3 -  Figure 8.15) 
implies that TLR9 is not functional in the term non-laboured placenta, corresponding 
to previously published work by the research group [233]. While no impact was 
observed on IL-6 production in response to CpG ODN by the choriodecidua and 
amnion, a down-regulation of constitutive IL-8 was observed. A recent report noted 
and increase in MCP-1 and a inhibitory effect on the constitutive production of G- 
CSF, IFNy, MIP-1a, MIP-1(3, RANTES and VEGF in response to CpG ODN by 
human fetal membrane explants [288]. Therefore, activation of TLR9 may play a 
regulatory role within human fetal membranes.
Previous investigations of NLR expression by the placenta have been limited to 
primary first and third trimester trophoblast noting expression of transcripts and 
protein for both NOD1 and NOD2 in first trimester trophoblast, but only NOD1 in 
third trimester trophoblast. A corresponding functional response was observed [60, 
236]. The data generated here show transcripts for both NOD1 and NOD2 in the 
term placenta. In response to treatment with Tri-DAP (NOD1) and MDP (NOD2) a 
significant increase in both IL-6 and IL-8 production was observed in response to 
Tri-DAP but not MDP. This data implies that in the term placenta that only NOD1 is 
functional, while NOD2 is not, corresponding to response of the third trimester 
trophoblast. It should be noted however that an increase in IL-8 production was 
noted in response to the NOD2 agonist MDP in the term cytotrophoblast, in a NOD2 
independent manner [60]. Elevated levels of IL-8 in response to MDP were also 
observed here. In addition to NOD2, MDP has been shown to activate human 
NLRP1 and NLRP3; however these NLRs are primarily involved in inflammasome 
activation [293, 294]. While the data herein shows transcripts for both NLRP1 and
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NLRP3 in the term placenta and others have demonstrated transcripts in both the 
first and third trimester trophoblast [238, 295], no significant induction of IL-1 (3 was 
observed (See Chapter 8.3 -  Figure 8.16) in response MDP stimulation of the term 
placenta, likely resulting from low sample. Additionally the term placenta expresses 
transcripts for other NLRs including NLRC4, NAIP and NLRX1 (Figure 3.3). 
Transcripts for NLRC4 have been reported previously reported in first trimester 
trophoblasts [238].
Recently, expression of both NOD1 and NOD2 has been reported in the fetal 
membrane, with expression of both up-regulated following spontaneous labour 
[286]. Further examination at the protein level noted expression of NOD1 and NOD2 
by chorionic cytotrophoblasts and decidual cells. However, only protein for NOD1 
was shown in amnion epithelial cells. Additionally fetal membrane explants in 
response to NOD agonist resulted in production of IL-6 and IL-8 [286]. The data 
generated here shows that both the term choriodecidua and amnion express 
transcripts for NOD1 and NOD2. Significantly elevated IL-6 production is observed 
in response to Tri-DAP by the choriodecidua, while elevated IL-8 is observed in 
response to MDP, implying both receptors are functional in the choriodecidua. Only 
Tri-DAP induced IL-8 is observed by the amnion, implying functional NOD1. 
Heterogeneity within the small sample population examined likely is the cause of the 
discrepancy between cytokines observed.
Transcripts for the inflammasome associated NLRs, NLRP1, NLRP3 and NLRC4 
have been reported in the first trimester decidual stromal and endothelial cells [238]. 
The data reported here demonstrate the expression of these NLRs in the term 
choriodecidua and amnion in addition to the NLRs, NAIP and NLRX1.
To date, the examination of the expression and function of RLRs in human gestation 
associates tissues is relatively limited. It has previously been reported that third 
trimester placenta and decidua express RIG-I, MDA5 and LGP2 [296]. This work 
demonstrates the expression of transcripts for the three described RLRs by the 
placenta, choriodecidua and amnion. Immunohistochemical studies are needed to 
confirm protein expression and the cell populations expressing these receptors. 
Tissues stimulated with the agonist Poly(l:C)LyoVec (RIG-I/MDA5) did not elicit a 
significant production of their IL-6 or IL-8, implying that the RLRs are not functional 
is gestational tissues. However elevated levels of IL-8 were observed by all three
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tissues in response to treatment, and with increased sample number may be 
significant. RLR induced IL-8 production may play a role in neutrophil recruitment to 
gestational tissues. IL-8 is a key chemokine involved neutrophil chemotaxis [297]. 
During infection neutrophils are one of the first leukocytes to be recruited from the 
circulation into tissues, to mediate bacterial clearance. Neutrophil recruitment is 
also a feature of viral infection, were they have been implicated in providing 
protection from viral infection by the release of neutrophil extracellular traps and the 
production of type I interferons [298, 299]. Therefore IL-8 production by RLRs and 
other viral sensing PRRs (TLR3/7/8) which also upon activation induce IL-8 
production, maybe a key step in promoting viral clearance in gestational tissues. 
Since Poly(l:C)LyoVec is a dual agonist neutralisation experiments would be 
required to determine if either RIG-I, MDA5 or both are potentially functional. 
Additionally quantitative PCR would be required to examine the role of LGP2, as 
there is no agonist for this receptor due to regulatory function in RIG-I and MDA5 
signalling [217].
In summary, this work clearly demonstrates that human term gestation associated 
tissues mount a functional response to known ligands of a variety of PRRs. Further 
work is required to reveal the PRR expressing cells within these tissues. In addition, 
work is required to examine in detail PRR-mediated signalling pathways in these 
tissues in response to each PRR agonist and the cross-talk resulting from the 
activation of multiple receptors. Subsequent chapters will start examining.these, 
focusing on C-type lectin receptors (CLRs) and the signalling pathways involved in 
flagellin recognition in addition to examining modulators of cytokine production 
induced by PRRs.
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Chapter 4
Expression and activity of CLRs, in 
human gestation-associated 
tissues and the innate immune 
response to Candida albicans
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4 Expression and activity of CLRs in human gestation associated 
tissues and the innate immune response to Candida albicans
4.1 Introduction
Vulvovvaginal candidiasis (W C ) or vaginal thrush is a common reproductive 
infection and only second to bacterial vaginosis as a cause of vaginal inflammation 
[300]. More than 75% of women of reproductive age will be diagnosed with W C  at 
least once during their lifetime, with recurrence occurring in 40-50% of women, while 
5-8% will suffer with recurrent (R) W C  (three or more episodes) [301, 302]. 
Candida albicans are a frequent cause of W C  [303]. Several risk factors have been 
described for W C , including steroid and immunosuppressive therapy, diabetes and 
pregnancy [302, 304]. The higher occurrence of W C  and R W C  in pregnant women 
compared to non-pregnant is associated with changes in reproductive hormone 
levels e.g. estrogens. As the concentrations of estrogens increase, glycogen 
production in vaginal tissues increases, providing Candida species a source of 
carbon for growth [305, 306]. Additionally estrogens enhance the adherence of 
Candida to the muscosal surface of the vagina [301]. While colonisation of the 
amniotic cavity by Candida is rare, the consequences of intra-amniotic Candida 
infections include preterm labour (PTL) and preterm rupture of membranes (PROM), 
neonatal infection and fetal death [52, 307].
Candida albicans and other Candida species are dimorphic fungal organisms that at 
any given time asymptomatically colonises 30-50% of healthy individuals; however 
under certain conditions they can cause a broad spectrum of muscosal and 
systemic infections [308]. While several virulence factors are important in the 
pathogenesis of Candida, the role of the cell wall is critical, as the first point of 
contact with the host [309]. The Candida cell wall is composed of numerous 
polysaccharide structures such as mannoproteins (N-linked and O-linked), chitin and 
(3-glucans (|3-1,3 glucan and [3-1,6 glucan) that function as pathogen associated 
molecular patterns (PAMPs) recognised by pattern recognition receptors (PRRs) of 
the innate immunes system [202, 207, 310]. Several groups of PRRs play role in 
anti-candida defence; including Toll-like receptors (TLRs), NOD-like receptors 
(NLRs) and Scavenger receptors, C-type lectin receptors (CLRs) are the primary 
contributors (Table 4-1). Despite the prevalence of Candida albicans infection during 
pregnancy and the possible associated pregnancy complications of intra amniotic
colonisation, very little is in known about CLRs at the maternal-fetal interface.
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Table 4-1 Pattern recognition receptors involved in anti-Candida immunity.
PRR Group Fungal PAMP
TLR2 TLR Phospholipomannan
TLR4 TLR Mannan
TLR9 TLR
CpG
Oligodecoxynucleotides
Dectin-1 CLR p-Glucan
a-mannans, O-linked
Dectin-2 CLR mannobiose rich 
glycoproteins
MINCLE CLR
a-mannos,
glyceroglycolipids
DC-SIGN CLR High Mannose Structures
Mannose
Receptor
CLR
Mannan, N-linked Mannose 
Residues
Galectin-3 CLR (3-Mannosides
SCARF-1 SR p-Glucan
CD36 SR (3-Glucan
NLRP3 NLR
Unknown - activation via 
Dectin-1 induced ROS
Several pattern recognition receptors from the Toll-like receptor, C-type lectin receptor, NOD-like 
receptor and scavenger receptor families have been implicated in the innate immune response to 
Candida albicans. Adapted from [97] and updated with information from [311-314], CLR, C-type lectin 
receptor; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; F, 
forward primer sequence; MINCLE, macrophage-inducible C-type lectin; NLR, NOD-like receptor; 
NLRP, Nod-like receptor containing a PYD domain; ROS, reactive oxygen species; SCARF-1, 
scavenger receptor class F, member 1, SR, scavenger receptor; TLR, Toll-like receptor.
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4.2 Aims
The aim of this chapter was to examine the innate immune response to fungal- 
derived PAMPs and to Candida albicans, particularly the expression and function of 
CLRs in the term non-laboured human placenta, choriodecidua and amnion.
4.3 Methods
4.3.1 Samples
Healthy pregnant women scheduled for elective caesarean section (ESC) were 
approached in the antenatal day assessment unit at Singleton Hospital, Swansea, 
during their pre-anaesthetic assessment. Informed written consent was obtained 
upon explanation of the study. Following delivery, placenta and attached fetal 
membranes (n = 3-12) from these women were collected and processed within 1.5 
hours of delivery. Peripheral blood (n = 3) was also collected from healthy adults at 
the Institute of Life Science, Swansea University who were approached and 
consented as controls.
4.3.2 PCR
Gestation associated tissue samples (placenta, choriodecidua and amnion) were 
stored in TRI reagent and frozen within 30 minutes of collection. RNA was extracted 
using the Trizol method and cDNA was subsequently produced following DNase 
treatment (see Chapter 2.4 for method). PCR was performed for CLRs and 
scavenger receptors (see Chapter 2.4 for method and Table 4-2 for primer details).
4.3.3 Gestation-associated tissue explants
Placenta, choriodecidua and amnion tissue explants were cultured as described in 
Chapter 2.2. Cultures were initially stimulated with several ligands at various 
concentrations (Table 4-3) to identify an optimum concentration of each agonist. 
Once identified the optimised concentration was used in subsequent in vitro culture 
experiments. Cultures were incubated for 24 hours. For inhibition/neutralisation 
experiments cultures were incubated for 30 minutes prior to the addition of agonist 
with the following blocking antibodies or inhibitors; anti-hDectin-1 lgG1 (5 pg/ml, 
Invivogen), Mouse lgG1 isotype (5 pg/ml, Invivogen), piceatannol (Syk inhibitor, 100 
pM, Tocris), BAY11-7082 (kB -a inhibitor, 50 pM, Merck Chemicals), butylated 
hydroxyanisole (BHA, ROS inhibitor, Sigma), Z-W EHD-FMK (Caspase-1 inhibitor, 
5uM, R&D Systems), Z-IETD-FMK (Caspase-8 inhibitor, 5pM, R&D Systems).
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Table 4-2 CLR primer sequences.
Gene Primer
Mg2+
Cone
(nM)
Anneling
Temp
(°C)
Fragment 
Size (Bp)
Accession
Number
Dectin-1 F 5' CTGTGGTCCTGGGTACCATGGCT
1.5 69 388 NM 197947.2
Variant a R 5' ACCTCAGTCTGGGGCCGAGAAAG
Dectin-1 F 5' TCCTGGGTACCATGGGGGTTCT
2 60 234 NM 022570.4
Variant b R 5' GGGGCCGAGAAAGGCCTATCCAA
F 5' ATGGTGAAACTGGCAAAAGG
Dectin-2 2.5 67 205 NM 001007033
R 5' ACCAAATGTGCTCCCATCTC
F 5‘ TGGGTGGACGGCACACCTTTG
MINCLE 1.5 70 88 NM 014358
R 5' TGGCACAGTCCTCCAGGGTAGC
F 5' GACTGCAGCAGCTGGGCCTC
DC-SIGN 1.5 60 147 NM 021155
R 5' GGAGCCCAGCCAAGAGCGTG
F 5' GAGCCAGCCAACGAGCGGAA
Galectin-3 2 70 658 NM 002306
R 5' CTGCAACCTTGAAGTGGTCAGGTTC
Mannose F 5‘ G CCCACGACGACTCCCG AAC
3.5 70 580 NM 002438
Receptor R 5' CCTCTTGCAAAACGCTCGCGC
F 5' CCTCAGCTCCCACAAGCTAC
SCARF-1 1.5 59 152 NM 003693
R 5' GAACCTCATCTGCCTCTCCA
F 5' AGGCCCTGCATTCCTGTCATCCT
CD36 1.5 70 992 NM 001001548
R 5' TGGCGGCTATCATAAGGAGGAGGC
Sequences and optimum conditions for each pair of C-type lectin receptors (CLRs) primers used for 
PCR. Bp, base pairs; CD, cluster of differentiation; DC-SIGN, dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin; F, forward primer sequence; MINCLE, macrophage- 
inducible C-type lectin; R, reverse primer sequence; SCARF-1, scavenger receptor class F, member 1.
Table 4-3 CLR ligands.
Ligand
Receptor
Targeted
Concentrations
Tested
Curdlan Dectin-1 1-100 pg/ml
Depleted Zymosan Dectin-1 1-100 pg/ml
TDB MINCLE 1-100 pg/ml
Ligands at various concentrations were tested on placenta, choriodecidua and amnion to identify an 
optimum concentration of each agonist. MINCLE, macrophage-inducible C-type lectin; TDB, Trehalose- 
6, 6-dibehenate.
4.3.4 Tissue lysates
Total protein was extracted from placenta and choriodecidua explants treated with 
curdlan after 3h, 6h and 18h. An unstimulated control at each time point and TO 
tissue was also included (see chapter 2.5.1 for method). Total protein was estimated 
using the BCA assay (see chapter 2.5.2 for method).
4.3.5 Peripheral blood mononuclear cell cultures
Mononuclear cells (n=3) were isolated as described in chapter 2.3. Cultures were 
stimulated with LPS (10 ng/ml) and a range of Trehalose-6,6-dibehenate (TDB) 
concentrations (1-100 pg/ml).
4.3.6 Cytokine production
IL-1 (3, IL-6 and IL-8 in the tissue free supernatants of placenta, choriodecidua and 
amnion explant cultures collected after 24 h were measured using commercially 
available ELISA kits (DuoSet, R&D Systems) as per manufacturer’s instructions. IL- 
1(3 in tissue lysates and corresponding tissue free supernatants of placenta and 
choriodecidua collected after 3h, 6h and 18h were measured.
4.3.7 Cytotoxicity assay
As outlined in chapter 2.2.4, cytotoxicity of all inhibitors was evaluated utilising a 
WST reagent for detection of LDH in tissue free supernatants (LDH-Cytotoxicity 
Assay Kit II, Abeam).
4.3.8 Caspase-1/8 activity
The activity of caspase-1 and caspase-8 was measured in tissue lysates at TO and 
after 3h, 6h and 18h of culture in the presence of absence of with curdlan using 
commercially available colorimetric kits (Caspase-1 Assay Kit and Caspase-8 Assay 
Kit, Both Abeam) as per manufacturer’s instructions (see chapter 2.7 for method). 
Active caspase-1 and active caspase-8 (Both Abeam) were used as positive 
controls.
4.3.9 Statistical analysis
Agonist mediated cytokine production by non-laboured tissues was evaluated by 
Wilcoxon matched pairs signed rank test or Freidman’s test with Dunn’s posthoc test 
for multiple comparisons. A p-value of £ 0.05 was considered significant.
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4.4 Results
4.4.1 Expression of CLRs and scavenger receptors by gestation- 
associated tissues
To investigate whether transcripts for a variety of CLRs and scavenger receptors, 
including Dectin-1 (variant a & b), Dectin-2, MINCLE, DC-SIGN, Galactin-3, 
Mannose Receptor, SCARF-1 and CD36 are expressed in gestation associated 
tissues, a PCR was performed using 5 individual samples of each tissues type 
(placenta, choriodecidua and amnion); 3 examples of each tissue is shown in Figure 
4.1. Transcripts for each PRR examined were present in all samples in each of the 
tissues.
Dec-la 
Dec-lb 
Dec-2 
MINCLE 
DC-SIGN
Gal-3 
MR 
SCARF-1 
CD36 
UBE2D2
Figure 4.1 Expression of transcripts for CLR and scavenger receptors by gestation Associated 
tissues.
RNA was extracted from placenta (P), choriodecidua (C) and amnion (A), reverse transcribed and then 
used for PCR of CLR and scavenger receptor family member. Three representative examples of a total 
of 5 are shown. Total RNA from human spleen (S) was used as a positive control and UBE2D2 was 
used as a housekeeping gene. L = 100 base pair ladder and the negative control (-ve) was with water 
replacing cDNA in the reaction mix.
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4.4.2 Response of term non-laboured gestation-associated tissue 
explants to CLR agonists
4.4.2.1 Optimisation of CLR agonists
In order to investigate the functional activity of CLRs in the placenta, choriodecidua 
and amnion, preliminary investigations (n=3) were performed using distinct CLR 
agonists, to determine an optimised concentration of each agonist for subsequent 
experiments. In doing so a range of concentrations, based on the manufacturer’s 
recommendations was tested for each agonist (Table 4-4) on all three tissues. If no 
significant outcome was observed at any concentration, a concentration for further
; experiments was chosen based on its ability to provide the greatest increase for
both IL-6 and IL-8 for all three tissues. Optimised concentrations of each agonist are 
summarised in Table 4-4 with each dose response shown in the appendix (Chapter 
I 8.3, Figure 8.17 -  8.20).
i[
iiiI
i
! Table 4-4 Optimised concentrations of Dectin-1 and MINCLE agonists.
Ligand
Receptor
Targeted
Optimised
Concentration
Curdlan Dectin-1 100 pg/ml
Depleted Zymosan Dectin-1 100 pg/ml
TDB MINCLE 100 pg/ml
Concentrations of agonists for Dectin-1, as determined following preliminary investigations. MINCLE, 
macrophage-inducible C-type lectin; TDB, Trehalose-6,6-dibehenate.
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4.4.2.2 Dectin-1
To investigate if Dectin-1, a receptor involved in the recognition of (3-glucans is 
functional in the placenta, choriodecidua and amnion, the agonists depleted 
zymosan, a cell wall preparation from Saccharomyces cerevisiae treated with hot 
alkali to remove TLR2 stimulating properties and curdlan, a |3-1,3-glucan from 
Alcaligenes faecalis and were used. The results are shown in Figures 4.2. Elevated 
IL-6 and IL-8 was observed in response to both depleted zymosan and curdlan in 
the placenta, however a significant increase was not observed for depleted zymosan 
induced IL-8. Similarly, in response to both agonists elevated cytokine levels were 
observed in response to both agonists by the choriodecidua. A difference in the 
responsiveness of the amnion to both agonists was observed, with elevated 
cytokine production only occurring following treatment with curdlan.
4.4.2.3 MINCLE
To investigate if MINCLE, a receptor involved in the recognition of trehalose-6,6- 
dimycolate (TDM), better known as cord factor, the agonist trehalose-6,6-dibehenate 
(TDB), a synthetic analogue of TDM, which has been shown to bind MINCLE was 
used [315]. The results are shown in Figures 4.5. In response to TDB treatment no 
effect was observed in any of the three tissues. To confirm the bioactivity of TDB, 
peripheral blood mononuclear cells (PBMCs) isolated from healthy adult donors 
(n=3) were treated with varying concentrations of TDB. An LPS positive control was 
also included (Figure 4.4). A significant increase in both IL-6 and IL-8 production 
from PBMCs was observed in response to LPS only and not any concentration of 
TDB tested.
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Figure 4.2 Dectin-1 agonist induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following stimulation with depleted zymosan (DZYM) and curdlan (both 100 pg/ml; n=9). 
Statistical significance compared to unstimulated control as determined by Freidman’s test with Dunn’s 
posthoc test is shown: * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 4.3 MINCLE induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following stimulation with 100 pg/ml of trehalose-6,6-dibehenate (TDB; n=11). Statistical 
significance was determined by Wilcoxon matched pairs test. No significant difference was observed.
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Figure 4.4 Cytokine response by peripheral blood mononuclear cells to LPS and varying doses 
of TDB.
IL-6 and IL-8 production (pg/ml mean ± SEM) by peripheral blood mononuclear cells (n=3) in response 
to varying concentrations of TDB (1 -  100 pg/ml) and LPS (10 ng/ml). Statistical significance compared 
to unstimulated control as determined by Freidman’s test with Dunn’s posthoc test are shown: * p £ 
0.05.
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4.4.3 The Dectin-1 signalling pathway
Activation of Dectin-1 by the appropriate agonist leads to a series of signalling 
events involving notably spleen tyrosine kinase (Syk) and the transcription factor 
NF-kB [198, 199, 206].
4.4.3.1 Dectin-1 activation
To confirm the role of Dectin-1 in the pro-inflammatory response triggered by 
curdlan and depleted zymosan, term non laboured tissues were treated with both 
Dectin-1 agonists and LPS in the presence and absence of a neutralising 
monoclonal anti-human Dectin-1 mouse lgG1 antibody (Figure 4.5). Mouse lgG1 
isotype was used as a control. In this preliminary investigation, no inhibition of 
cytokine production was observed in response to either curdlan or depleted 
zymosan treatment in the presence of the neutralising antibody.
4.4.3.2 Spleen tyrosine kinase (Syk) activation
To examine the role of Syk in the curdlan and depleted zymosan induced pro- 
inflammatory response in the placenta, choriodecidua and amnion, tissues were 
treated with both agonists in the presence or absence of the Syk inhibitor, 
piceatannol (PIC) for 24 hours. The optimum concentration of the inhibitor was 
determined following initial dose course (see Chapter 8.3 -  Figure 8.21), 
corresponding to previously published use of the inhibitor [316]. As shown in Figure 
4.6, treatment with piceatannol resulted in decreased agonist induced cytokine 
production by the placenta. However this was not significant. A similar trend is 
observed following piceatannol treatment of both the choriodecidua (Figure 4.7) and 
amnion (Figure 4.8). Treatment with piceatannol did not impact tissue viability as 
observed by LDH assay.
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Figure 4.5 Dectin-1 neutralisation in term non-laboured gestation associated tissues.
Explants of (A-B) placenta, (C-D) choriodecidua, and (E-F) amnion were stimulated with LPS (10 
ng/ml), curdlan (100 pg/ml) and depleted zymosan (DZYM, 100 pg/ml) in the presence (5 pg/ml) of 
anti-human Dectin-1 mouse lgG1 antibody or mouse lgG1 isotype (n=1) and IL-6 and IL-8 levels 
(pg/ml) in tissue free supernatants measured.
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Figure 4.6 Syk inhibition in the term non-laboured placenta.
IL-6 & IL-8 production (pg/ml mean ±SEM) by the placenta, following stimulation with (A-B) curdlan or 
(D-E) depleted zymosan (both 100 pg/ml, n=3) in the presence or absence of 100 pM piceatannol. (C 
&F) Relative lactate dehydrogenase (LDH) levels compared to the unstimulated. Statistical significance 
was determined by Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 4.7 Syk inhibition in the term non-laboured choriodecidua.
IL-6 & IL-8 production (pg/ml mean ±SEM) by the choriodecidua, following stimulation with (A-B) 
curdlan or (D-E) depleted zymosan (both 100 pg/ml, n=3) in the presence or absence 100 pM of 
piceatannol. (C & F) Relative lactate dehydrogenase (LDH) levels compared to the unstimulated. 
Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical 
significance compared to curdlan is shown: * p < 0.05.
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Figure 4.8 Syk inhibition in the term non-laboured amnion.
IL-6 & IL-8 production (pg/ml mean ±SEM) by the amnion, following stimulation with (A-B) curdlan or 
(D-E) depleted zymosan (both 100 pg/ml, n=3) in the presence or absence of 100 pM piceatannol. (C 
&F) Relative lactate dehydrogenase (LDH) levels compared to the unstimulated. Statistical significance 
was determined by Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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4.4.3.3 NF-kB activation
To investigate the role of NF-kB in the curdlan induced pro-inflammatory response in 
the placenta, choriodecidua and amnion, tissues were treated in the presence or 
absence of the irreversible kB -a inhibitor, BAY11-7082, which inhibits kB -a  
phosphroylation causing the inactivation of NF-kB [317]. To determine an optimum 
concentration of the inhibitor an initial dose course was performed based on 
manufacturer’s recommended working concentrations, utilising LPS as a known NF- 
kB activator. No reduction in LPS induced cytokine production was observed at any 
concentration tested in the placenta or choriodeicuda. However a reduction was 
observed in the amnion at 10 pM inhibitor. Following reports in the literature of the 
inhibitor on placental tissue [318, 319], a concentration of 50 pM was tested (see 
Chapter 8.3 - Figure 8.22). A reduction in LPS induced cytokine production was 
observed in all three tissues in the presence of the inhibitor. As a result this 
concentration of BAY11-7082 was used in subsequent experiments, to examine 
curdlan induced NF-kB activation. As seen in Figures 4.9 -  4.11, a reduction curdlan 
induced IL-6 and IL-8 is observed in all three tissues in the presence of the inhibitor. 
However this was not significant. Treatment with BAY11-7082 did not impact tissue 
viability as observed by LDH assay.
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Figure 4.9 NF-kB inhibition in the term non-laboured placenta.
Placental explants were stimulated with curdlan (100 pg/ml, n=3) in the presence or absence of 50 pM 
of BAY11-7082 and (A) IL-6 and (B) IL-8 (both pg/ml mean ± SEM). (C) Relative lactate 
dehydrogenase (LDH) levels compared to the unstimulated. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p < 0.05.
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Figure 4.10 NF-kB inhibition in the term non-laboured choriodecidua.
Choriodecidual explants were stimulated with curdlan (100 pg/ml, n=3) in the presence or absence of 
50 pM of BAY11-7082 and (A) IL-6 and (B) IL-8 (both pg/ml mean ± SEM). (C) Relative lactate 
dehydrogenase (LDH) levels compared to the unstimulated. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 4.11 NF-kB inhibition in the term non-laboured amnion.
Amnion explants were stimulated with curdlan (100 pg/ml, n=3) in the presence or absence of 50 pM of 
BAY11-7082 and (A) IL-6 and (B) IL-8 (both pg/ml mean ± SEM). (C) Relative lactate dehydrogenase 
(LDH) levels compared to the unstimulated. Statistical significance was determined by Freidman’s test 
with Dunn’s posthoc test. No significant difference was observed.
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4.4.4 p-glucan induced inflammasome activation by term non-laboured 
gestation-associated tissue explants
4.4.4.1 Curdlan induced IL-1p production
Elevated levels of IL-1 p present in amniotic fluid are a hallmark of intra-amniotic 
infection during pregnancy [320]. As a result the mechanisms of IL-1 p production by 
the gestation associated tissues have gained interest. To date, p-glucan induced 
activation of dectin-1 and production of IL-1 p in macrophages and dendritic cells, 
have yielded evidence of NLRP3/capase-1 and a non-canonical capase-8 
inflammasome respectively [177, 314]. IL-1 p production by DC’s was independent of 
NLRP3 and caspase-1 [177]. To investigate if p-glucans can induce IL-1 p production 
in the placenta, choriodecidua and amnion, tissue was treated with curdlan for 24 
hours (n=12). A significant increase in IL-1 p production was observed in all three 
tissues (Figure 4.12).
4.4.4.2 Reactive oxygen species (ROS) Production
Generation of reactive oxygen species is associated with activation of the NLRP3 
inflammasome [321]. Furthermore, in macrophages p-glucan triggered IL-1 p 
production is dependent on ROS production in a Syk dependent manner [199, 314]. 
To investigate the role of ROS in p-glucan triggered IL-1 p in the placenta, 
choriodecidua and amnion, the known ROS inhibitor butylated hydroxyanisole (BHA) 
was used [314, 322, 323]. BHA functions as ROS scavenger [324]. Tissues were 
treated with curdlan either in the presence or absence of BHA at various 
concentrations (n=3). As shown in Figure 4.13, no inhibition of IL-1 p production was 
observed in response any of the concentrations of BHA tested in any of the tissue.
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Figure 4.12 Curdlan induced IL-1 (3 production by term non-laboured gestation associated 
tissues.
Explants of (A) placenta, (B) choriodecidua and (C) amnion were treatment with curdlan (100 pg/ml; 
n=12) and IL-1 p production (pg/ml mean ± SEM) measured in tissue free culture supernatants 
measured. Statistical significance compared to unstimulated control as determined by Wilcoxon 
matched pairs signed rank test are shown: ** p < 0.01, *** p < 0.001.
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Figure 4.13 Inhibition of reactive oxygen species (ROS) production.
Explants of (A) placenta, (B) choriodecidua and (C) amnion were treated with curdlan (100 pg/ml) in 
the presence or absence of the ROS inhibitor, BHA at varying concentrations (n=3) and IL-1 (3 levels 
(pg/ml mean ± SEM) in tissue free supernatants measured. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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4.4.4.3 Caspase inhibition & activity
Since p-glucan induced IL-1 (3 production has been associated with both caspase-1 
and caspase-8, the role of both enzymes in the processing of pro-IL-113 was 
examined utilising specific inhibitors. Tissues were treated with curdlan either in the 
presence or absence of the caspase-1 inhibitor, Z-W EHD-FMK or caspase-8 
inhibitor, Z-IETD-FMK for 24 hours (n=3). The optimum concentration of both 
inhibitors was determined following initial dose course (see Chapter 8.3 Figure 8.23 
- 8.24). A reduction in curdlan induced IL-1 (3 production in all three tissues was 
observed in the presence of both inhibitors; however this was not significant (Figure 
4.14 and 4.15). Treatment with either inhibitor did not impact tissue viability as 
observed by LDH assay.
To examine specific caspase activity in these tissues, lysates of placenta and 
choriodecidua were prepared at 3, 6 and 18 hours following curdlan treatment 
(Figure 4.16 and 4.17). Caspase activity at TO was also examined. No discernible 
difference was observed in caspase-1 or caspase-8 activity regardless of time or 
curdlan stimulation. To determine the functionality of the assay, background 
reagents and TO placental lysates were spiked with 1 unit of either active caspase-1 
or caspase-8 (Figure 4.18). When compared with un-spiked controls, both spiked 
reagents and lysates demonstrated increased caspase activity as expected. 
Additionally in order to determine that the recommended incubation time of 2 hours 
was sufficient to observed caspase activity, subsequent time points of 24, 48 and 72 
hours were included. While increasing the incubation time did not impact the 
caspase activity within the treated placental and choriodecidual lysates (Figure 4.16 
and 4.17), increased activity was observed in both the spiked reagents and lysates 
(Figure 4.18). This would confirm that both assays are functional and that there is 
nothing present in the lysate that would interfere with the assay.
In addition to caspase activity, lysates were assayed for IL-1 (3, representing putative 
pro-IL-1 p. IL-1 (3 production was also examined in corresponding tissue free 
supernatants. Lysates showed an increase in putative pro-IL-1 p production in both a 
curdlan and time dependent manner, which was also observed in corresponding 
supernatants (Figure 4.19 - 4.20).. In the placenta, an increase in both putative pro- 
IL-1 p and IL-1 p were observed from 3 hours and continued to increase over time. In 
the choriodecidua, however an increase both putative pro-IL-1 p and IL-1 p were not 
observed until 6 hours and continued to increase over time.
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Figure 4.14 Inhibition of capase-1.
Explants of (A) placenta, (B) choriodecidua and (C) amnion were treated with curdlan (100 pg/ml) in 
the presence or absence of the caspase-1 inhibitor Z-WEHD-FMK (5 pM; n=3) and IL-1(3 levels (pg/ml 
mean ± SEM) in tissue free supernatants were measured. Relative lactate dehydrogenase (LDH) levels 
in the (D) placenta, (E) choriodecidua and (E) amnion compared to the unstimulated control. Statistical 
significance was determined by Freidman’s test with Dunn’s posthoc test. No significant difference was 
observed.
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Figure 4.15 Inhibition of caspase-8.
Explants of (A) placenta, (B) choriodecidua and (C) amnion were treated with curdlan (100 pg/ml) in 
the presence or absence of the caspase-8 inhibitor Z-IETD-FMK (5 pM; n=3) and IL-1P levels (pg/ml 
mean ± SEM) in tissue free supernatants were measured. Relative lactate dehydrogenase (LDH) levels 
in the (D) placenta, (E) choriodecidua and (E) amnion compared to the unstimulated control. 
Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical 
significance compared to unstimulated are shown: * p < 0.05.
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Figure 4.16 Caspase-1 activity in the placenta and choriodecidua.
Tissue lysates prepared from (A) placenta and (B) choriodecidua with and without treatment with 
curdlan (100 pg/ml; n=3) at 3, 6 and 18 hours were assayed for Caspase-1 activity (OD 405 nm at 2, 
24, 48 and 72 hours; mean ± SEM). Caspase activity at TO was also examined.
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Figure 4.17 Caspase-8 activity in the placenta and choriodecidua.
Tissue lysates prepared from (A) placenta and (B) choriodecidua with and without treatment with 
curdlan (100 pg/ml; n=3) at 3, 6 and 18 hours were assayed for Caspase-8 activity (OD 405 nm at 2, 
24, 48 and 72 hours; mean ± SEM ). Caspase activity at TO was also examined.
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Figure 4.18 Caspase activity assay test.
Assay reagents (blank) and TO placental lysate were spiked with 1 unit (1U) of active (A) Caspase-1 or 
(B) Caspase-8 to determine validity of both activity assays (n=1). Caspase activity (OD 405 nm at 2, 
24, 48 and 72 hours).
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Figure 4.19 IL-1 p production in placental tissue lysates and tissue free supernatants.
IL-1 (3 levels (pg/ml mean ± SEM) in placental (A) tissue lysates (total protein) and in (B) tissue free 
supernatants in response to treatment with curdlan at 3, 6 and 18 hours (100 pg/ml; n=3). Statistical 
significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical significance 
compared to TO lysate is shown: ** p < 0.01.
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Figure 4.20 IL-1 (3 production in choriodecidual tissue lysates and tissue free supernatants.
IL-1 P levels (pg/ml mean ± SEM) in choriodecidual (A) tissue lysates (total protein) and in (B) tissue 
free supernatants in response to treatment with curdlan at 3, 6 and 18 hours (100 pg/ml; n=3). 
Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical 
significance compared to TO lysate is shown: * p < 0.05.
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4.4.5 Response of term non-laboured gestation-associated tissue 
explants to Candida albicans
While the work to date has utilised p-glucan agonists such as curdlan to examine
I the functional activity of Dectin-1, a whole array for other PRRs are involved in the
!
| recognition of Candida albicans (Table 4.1). As noted in Figure 4.1, transcripts for
l
CLRs and scavenger receptors involved in Candida recognition are expressed in the 
placenta, choriodecidua and amnion, and work presented in chapter 3, and implies 
functionally active TLRs in these tissues also. Based on this, these tissues likely 
would be able to mount an inflammatory response to Candida albicans.
To investigate the functional response to Candida albicans, in the placenta, 
choriodecidua and amnion, tissues were treated with both live and UV inactived 
Candida albicans strain SC5314 (Figure 4.21). The results are shown in Figures 
4.22 -  4.24. A general trend is observed that as the concentration of Candida 
increases, the amount of cytokine produced also increases. Additionally these a 
trend that the cytokine response to live Candida albicans is higher when compared 
to inactived Candida albicans, however this was only significant for IL-8 in the 
placenta at a concentration from 106 cells/ml and 107 cells/ml respectively and IL-1 (3 
in the placenta and amnion at 107 cells/ml.
In the placenta (Figure 4.22) a significant increase in both IL-1 (3 and IL-8 production 
is observed in response to live Candida albicans at a concentration of 106 cells/ml 
and higher, however a significant increase in IL-6 production is observed at a 
concentration of 107 cell/ml. A similar response is observed by the choriodecidua 
(Figure 4.23), In the amnion a significant increase in both IL-6 and IL-8 in response 
to live Candida albicans was observed a concentration 106 cells/ml, with a 
significant increase in IL-1 (3 at a concentration of 107 cell/ml (Figure 4.24).
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Figure 4.21 Inactive and live Candida albicans present in gestation associated tissue cultures
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Figure 4.22 Candida albican induced cytokine response in the term non-laboured placenta.
Cytokine production; (A) IL-6, (B) IL-8 and (C) IL-1 p (pg/ml; mean ±SEM) by the placenta in response 
to live and inactive Candida albicans (n=4). Statistical significance was determined by Freidman’s test 
with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * p < 0.05, ** p £ 
0.01. Statistical significance inactive vs life: # p < 0.05.
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Figure 4.23 Candida albican induced cytokine response in the term non-laboured 
choriodecidua.
Cytokine production; (A) IL-6, (B) IL-8 and (C) IL-1 p (pg/ml; mean ±SEM) by the choriodecidua in 
response to live and inactive Candida albicans (n=4). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 4.24 Candida albican induced cytokine response in the term non-laboured amnion.
Cytokine production; (A) IL-6, (B) IL-8 and (C) IL-1 (3 (pg/ml; mean ± SEM) by the amnion in response 
to live and inactive Candida albicans (n=4). Statistical significance was determined by Freidman’s test 
with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * p < 0.05, ** p < 
0.01.
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4.5 Discussion
One of the aims of this chapter was to examine the expression and function of C- 
type lectin receptors (CLRs) in the placenta, choriodecidua and amnion. Analysis of 
these tissues by PCR showed that transcripts of the CLRs - Dectin-1, Dectin-2, 
MINCLE, DC-SIGN, Galectin-3 and the Mannose Receptor - are expressed in these 
tissues. This includes the two described functional variants of Dectin-1 [325]; Dectin- 
1a and Dectin-1 b respectively. Additionally, transcripts for the scavenger receptors 
SCARF-1 and CD36 are also expressed. However protein expression of these 
receptors and their cellular source within these tissues is yet to been determined 
and is currently underway. To date only the expression of DC-SIGN has been 
reported in the placenta where it is expressed on Hofbauer cells (fetal 
macrophages) within the chorionic villi [214].
One of the most extensively studied CLR is the (3-glucan receptor Dectin-1 [197, 
205, 206]. The data shown here illustrate that stimulation of the placenta, 
choriodecidua and amnion with Dectin-1 agonists; curdlan and depleted zymosan is 
sufficient to elicit a significant increase in pro-inflammatory cytokine production in 
these tissues, implying functional dectin-1. While both agonists were used at the 
same concentration, on the whole a greater response in cytokine production was 
observed following curdlan treatment. This was most evident in the amnion, where 
no significant increase in cytokine production was observed following treatment with 
depleted zymosan compared with a 6-fold and 9-fold increase in IL-6 and IL-8 
respectively following curdlan treatment. While all |3-glucans are linear (3-glycosidic 1 
-»  3 linked glucose polymers, they differ in branching structure and length [326]. 
These characteristic differences in addition to the organism of origin have been 
shown in porcine leukocyte studies to have different immunomodulating activity 
[327, 328]. This indeed might explain the difference between depleted zymosan 
derived from Saccharomyces cerevisiae versus the Alcaligenes faecalis derived 
curdlan. The two isoforms of Dectin-1 are functionally different, which is suggested 
to play a role in the regulation of the cellular response to (3-glucans, likely via the N- 
linked glycosylation of Dectin-1 which has been shown to effect ligand binding and 
expression [329, 330]. While transcripts for both isoforms are expressed in the 
placenta, choriodecidua and amnion, the relative abundance of each is yet to be 
determined.
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To further investigate the role of (3-glucan mediated Dectin-1 activation by the 
gestation associated tissues, neutralisation/inhibition experiments utilising specific 
antibodies/inhibitors were performed to examine key components of the dectin-1 
signalling pathway; including Dectin-1, Syk and the transcription factor NF-kB. No 
consistent inhibition of Dectin-1 with a specific antibody was observed. This could be 
due to lack of access for the antibody to target cells within the explants, however 
similar experiment in subsequent chapter utilising neutralising antibodies to block 
other cell surface receptors have been successful. Alternatively the antibody might 
not be a neutralising antibody, and although it is supplied as such a lack of a
positive control leaves this unknown in our hands.
Following recognition of (3-glucans by Dectin-1, a Syk dependent pathway of
cytokine production via the transcription factor NF-kB is activated. The data
presented here, implies that both Syk and NF-kB are required for (3-glucans induced 
cytokine production in gestational tissues. However it should be noted that only 
partial inhibition was observed. This might relate to pre-incubation time of the 
inhibitor. While 30 minute pre-incubation was used here, based on previous 
experience within the research group, in comparison a 60 minute pre-incubation is 
used by others in explant models [286]. It’s also important to consider other 
downstream signalling events of Dectin-1 activation. While the Syk dependent 
pathway is the primary pathway activated, a Syk independent pathway signalling 
through Raf-1 has also been described. Raf-1 signalling ultimately feeds back into 
the Syk pathway for synergistic NF-kB activation [331]. In addition to NF-kB, other 
downstream events including the activation of MAPKs and NFAT play a role in 
Dectin-1 induced cytokine production [198, 200, 332].
In macrophages and dendritic cells, (3-glucan, specifically curdlan, induced 
activation of dectin-1 was associated with the production of IL-1 (3 [177, 314]. The 
mechanisms of IL-1 (3 production via the inflammasome recently have gained interest 
especially at the maternal fetal interface due to the association of intra-amniotic 
infection during pregnancy and elevated levels of IL-1 (3 present in the amniotic fluid 
[320]. To date little is known regarding inflammasome activation in the gestation 
associated tissues, with only limited examination of production of IL-1 (3 induced by 
uric acid crystals and the up-regulation of inflammasome gene expression by LPS in 
the trophoblast [238, 295, 333]. The data presented here illustrates that curdlan
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treatment is able to induce a significant increase in IL-1 (3 in the placenta, 
choriodecidua and amnion.
Dectin-1 mediated IL-1 (3 production in macrophages is associated with the 
generation of reactive oxygen species (ROS) and the activation of the 
NLRP3/caspase-1 inflammasome [199, 314]. More recently activation of a non- 
canonical capase-8 inflammasome has been described independent of NLRP3 and 
caspase-1 [177]. Since a role of ROS in IL-1 (3 production was not confirmed using 
the known ROS scavenger BHA, it would be prudent to measure ROS levels in the 
future. Examination of caspase-1 and caspase-8 using specific inhibitors implied 
both caspases contribute to IL-1 (3 production by gestation associated tissues. When 
the activity of both caspases was further examined using total protein lysates of the 
placenta and choriodecidua treated with curdlan, no discernible difference was 
observed, despite the proven validity of the assay. This would likely suggest that a 
minor cell population within these tissues, most likely a macrophage population, is 
responsible for the generation of IL-1 (3 induced by curdlan and that in a total protein 
colorimetric assay the signal would likely be below the limit of detection. While a 
more sensitive fluorescence assay might be appropriate, it might initially be more 
prudent to use an immunohistochemical approach to determine the specific cell type 
involved and purify out that cell population for further investigation. While these data 
demonstrates that both capase-1 and caspase-8 are involved in the production IL- 
1(3 induced by curdlan, it cannot conclusively confirm the involvement of the NLRP3 
inflammasome or the non-canonical caspase-8 inflammasome. Examination of 
putative pro-IL-1 (3 in tissue lysates, show an increase as early as 3 hours post 
treatment with curdlan in the placenta, with a corresponding increase observed IL- 
1 (3 in matched supernatants. The choriodecidua however, appear to require longer, 
with no increase in either putative pro-IL-1 (3 or IL-1 (3 until 6 hours post curdlan 
treatment. This warrants further investigation especially gene expression by 
quantitative PCR.
The role of MINCLE, a CLR primarily involved in the recognition mycobacterial cord 
factor but also in the antifungal response to Candida albicans was also examined 
[334, 335]. Stimulation of the placenta, choriodecidua and amnion with a synthetic 
analogue TDB, did not induce the production of either IL-6 or IL-8. In peripheral 
blood mononuclear cells, elevated levels of IL-8 was observed in response to TDB 
treatment. While IL-6 and IL-8 are induced by numerous agonists in these tissues,
TDB may not stimulate the production of these cytokines in these tissues. In murine 
bone marrow derived dendritic cells (BMDCs), TDB was able to induce IL-1 (3 
production via the NLRP3 inflammasome [336]. Examination of TDB stimulated 
placenta, choriodecidua and amnion showed that TDB was able to elicit significant 
IL-1 p production in the placenta and choriodecidua but not the amnion requiring 
further investigation (see Chapter 8.3 -  Figure 8.25).
While examination of single agonists provides insight into specifics of receptor 
activity and signalling, in response to a pathogen, in vivo, single PRR activation 
does not occur. This makes it important to investigate the immune response to 
whole organisms. Candida aibicans are able to grow as both budding yeast and 
hyphae [337]. The yeast form is able to colonise mucosal surfaces, while the 
primary role of the hyphae is host invasion [338]. Therefore the response to both 
live, which will be able to transition from yeast to hyphae, and inactivated Candida 
albicans were examined. The data shown here illustrates that culturing the placenta, 
choriodecidua and amnion in the presence of Candida albicans induces an 
inflammatory response in these tissue. Furthermore live Candida albicans were able 
induced a greater inflammatory response compared to UV inactivated Candida 
albicans. As Candida albicans switches between yeast and hyphael forms, different 
components of the cell wall are exposed. For example during budding, glucans and 
chitin are exposed, in contrast to being shielded by mannans and mannoproteins in 
the hyphae. As a result, different PRRs will be activated as the Candida changes 
forms [309, 339]. Additionally the switch from bud to hyphae formation trigger the 
activation of the NLRP3 inflammasome [340]. Therefore it’s not surprising that live 
Candida albicans would stimulate a greater inflammatory response. However this 
contrasts previously reported data in human PBMCs where both heat killed and UV 
irradiated Candida albicans induced a significantly higher inflammatory response 
compared to live Candida albicans, with the authors citing an increased exposure of 
p-glucan in the “killed” Candida as the reason [341]. However it should be noted that 
a different stain of Candida was used.
In summary the data contained in this chapter demonstrate the expression of 
transcripts in the placenta, choriodecidua and amnion for several CLRs and 
scavenger receptors involved in the innate immune response to Candida aibicans 
and other fungi. Furthermore these tissues produce an inflammatory response to 
Candida albicans. Detailed investigation of Dectin-1, demonstrates that the
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activation of this CLR in response to (3-glucans, induces an inflammatory response 
in gestation-associated tissues including activation of the inflammasome.
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Chapter 5
Flagellin induced inflammasome 
activation and IL-1 p at the maternal-
fetal interface
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5 Flagellin induced inflammasome activation and IL-1 p at the 
maternal-fetal interface
5.1 Introduction
lnterleukin-1 beta (IL-1 (3) is a pro-inflammatory cytokine that in response to 
pathogenic invasion can induce a local and systemic inflammatory response. 
Elevated levels of IL-1 (3 in amniotic fluid are a hallmark of intra-amniotic infection 
during pregnancy [320]. IL-1J3 is considered a major factor in the initiation of 
infection associated preterm labour by up-regulation of matrix metalloproteinase 
activity, prostaglandin production resulting in myometrial contractions, and 
membrane rupture and cervical ripening [19, 26, 75, 342]. Despite this little is known 
about the sources of IL-113 in these circumstances.
Production of IL-1 (3 is tightly regulated due to its potency as a pro-inflammatory 
mediator. Unlike many cytokines it is not constitutively expressed, with expression 
dependent on both exogenous and endogenous stimuli, resulting in the production 
of an inactive pro-IL-1 (3 precursor that must ultimately be cleaved into the bioactive 
mature IL-1 p, a process that is regulated by the inflammasome [343-345]. 
Inflammasomes are a cytosolic multi-protein complex typically including a member 
of the NLR family, that support the autocatalytic cleavage of pro-caspase-1 to active 
caspase-1, which in turn enables the processing of pro-IL-1 p (and pro-IL-18) and 
secretion of mature IL-1 p (and IL-18) [185, 346, 347].
In the previous chapter (Chapter 4), it was shown that the placenta, choriodecidua
and amnion are capable of producing IL-1 p in response to fungal stimuli. Parallel
work within the laboratory has demonstrated that these tissues can produce IL-1 p in
response to a wide variety of activators including the microbial toxin nigericin,
hemozoin produced by the parasite Plasmodium and monosodium urate (MSU)
crystals. The majority of these activators are associated with IL-1 p processing via
caspase-1 and the NLRP3 inflammasome, while the (3-glucan curdlan activates the
recently described non-canonical caspase-8 inflammasome ([177, 181, 348, 349]
and Chapter 4). Several other inflammasomes have been described including
NLRP1 and NLRC4, which are activated by MDP and flagellin, respectively. Both of
these inducers are components of bacteria; MDP is bioactive motif of peptidoglycan,
while flagellin is the major protein components of bacterial flagella [294, 350].
Several bacterial species associated with preterm labour are flagellated including
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Escherichia coli [49]. While transcripts for NLRC4 are expressed in the placenta, 
choriodecidua and amnion (Chapter 3), a functional role of NLRC4 is yet to be 
determined.
5.2 Aims
The aim of this chapter is to examine if flagellin can induce IL-1 p production by the 
term non-laboured human placenta, choriodecidua and amnion and to examine the 
signalling pathways that are involved in this process.
5.3 Methods
5.3.1 Samples
Healthy pregnant women scheduled for elective caesarean section (ESC) were 
approached in the antenatal day assessment unit at Singleton Hospital, Swansea, 
during their pre-anaesthetic assessment. Informed written consent was obtained 
upon explanation of the study. Following delivery, placenta and attached fetal 
membranes (n = 3 -12) from these women were collected and processed within 1.5 
hours of delivery.
5.3.2 Gestation-associated tissue explants
Placenta, choriodecidua and amnion tissue explants were cultured as described in 
Chapter 2.2. Cultures were stimulated with ultrapure flagellin isolated from 
Salmoneila typhimurium (100 ng/ml, endotoxin level: <0.05 EU/pg, Invivogen) for in 
vitro culture experiments. For inhibition/neutralisation experiments cultures were 
incubated for 30 minutes prior to the addition of flagellin with blocking antibodies or 
inhibitors as follows; anti-hTLR5 lgA2 (10 pg/ml, clone Q2G4; Invivogen), human 
lgA2 isotype control (10 pg/ml, clone T9C6; Invivogen), Z-W EHD-FMK (Caspase-1 
inhibitor, 5 pM; R&D Systems), Z-IETD-FMK (Caspase-8 inhibitor; 5 pM, R&D 
Systems). The anti-human TLR5 and isotype control antibodies were generated by 
combining the constant domains of human lgA2 with the variable domains of mouse 
IgG from mice immunised with either human TLR5 or, for the control, E. coli (3- 
galactosidase (Invivogen).
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5.3.3 Tissue lysates
Total protein was extracted from placenta and choriodecidua explants treated with 
flagellin after 3h, 6h and 18h. An unstimulated control at each time point and TO 
tissue was also included (see Chapter 2.5.1 for method). Total protein was 
estimated using the BCA assay (see Chapter 2.5.2 for method).
5.3.4 Cytokine production
IL-1 p, IL-6 and IL-8 in the tissue free supernatants of placenta, choriodecidua and 
amnion explant cultures collected after 24 h were measured using commercially 
available ELISA kits (DuoSet, R&D Systems) as per manufacturer’s instructions. IL- 
1(3 in tissue lysates and corresponding tissue free supernatants of placenta and 
choriodecidua collected after 3h, 6h and 18h were measured.
5.3.5 Cytotoxicity assay
As outlined in Chapter 2.2.4, cytotoxicity of all inhibitors was evaluated utilising a 
WST reagent for detection of LDH in tissue free supernatants (LDH-Cytotoxicity 
Assay Kit II, Abeam).
5.3.6 Caspase-1/8 activity
The activity of caspase-1 and caspase-8 was measured in tissue lysates at TO and 
after 3h, 6h and 18h of culture in the presence of absence of with flagellin using 
commercially available colorimetric kits (Caspase-1 Assay Kit and Caspase-8 Assay 
Kit, Both Abeam) as per manufacturer’s instructions (see Chapter 2.7 for method).
5.3.7 Statistical analysis
Agonist mediated cytokine production by non-laboured tissues was evaluated by 
Wilcoxon matched pairs signed rank test or Freidman’s test with Dunn’s posthoc test 
for multiple comparisons. A p-value of £ 0.05 was considered significant.
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5.4 Results
5.4.1 IL-1 p production by term non-laboured gestation-associated 
tissue explants in response to flagellin
To investigate if flagellin induced IL-1 (3 production in the placenta, choriodecidua 
and amnion an ultrapure form of flagellin isolated from Salmonella typhimurium was 
used at a pre-optimised concentration (Chapter 3) of 100 ng/ml (n=12). A significant 
increase in IL-1 (3 was observed in both the placenta and choriodecidua (Figure 5.1). 
IL-113 was not detectable in supernatants from amnion explant cultures.
5.4.2 The role of TLR5 in the production of IL-ip by term non-laboured 
gestation-associated tissue explants in response to flagellin
To determine if TLR5 played a role in the production of IL-1 p by the placenta and 
choriodecidua, neutralising anti-human TLR5 monoclonal antibody (10 pg/ml) was 
used; an appropriate isotype control was included (n=3). A decrease in flagellin- but 
not LPS-induced IL-1 (3, IL-6 and IL-8 production was observed in the placenta 
choriodecidua and amnion in the presence of anti-human TLR5 antibody but not 
isotype control (Figure 5.2 -  5.4). However this was not significant.
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Figure 5.1 Flagellin induced IL-1P production.
Explants of (A) placenta and (B) choriodecidua were treated with ultrapure flagellin (100ng/ml) and 
levels of IL-1 p production (pg/ml mean ± SEM) in tissue free culture supernatants measured (n=12). 
Statistical significance compared to unstimulated control as determined by Wilcoxon matched pairs 
signed rank test are shown: *** p < 0.001.
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Figure 5.2 Neutralisation of TLR5 in the placenta.
Levels of (A) IL-6, (B) IL-8 and (C) IL-1 (3 (pg/ml mean ± SEM) from explants of term non-laboured 
placenta (n=3) treated with flagellin (FLAG, 100 ng/ml) or LPS (10 ng/ml) alone or following 30 minutes 
pre-treatment with either anti-hTLR5-lgA or lgA2 isotype control (both 10 pg/ml). Statistical significance 
was determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown: * p £ 0.05, ** p < 0.01.
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Figure 5.3 Neutralisation of TLR5 in the choriodecidua.
Levels of (A) IL-6, (B) IL-8 and (C) IL-1 p (pg/ml mean ± SEM) from explants of term non-laboured 
choriodecidua (n=3) treated with flagellin (FLAG , 100 ng/ml) or LPS (10 ng/ml) alone or following 30 
minutes pre-treatment with either anti-hTLR5-lgA or lgA2 isotype control (both 10 pg/ml). Statistical 
significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical significance 
compared to unstimulated is shown: * p £ 0.05.
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Figure 5.4 Neutralisation of TLR5 in the amnion.
Levels of (A) IL-6 and (B) IL-8 (pg/ml mean ± SEM) from explants of term non-laboured amnion (n=3) 
treated with flagellin (FLAG, 100 ng/ml) or LPS (10 ng/ml) alone or following 30 minutes pre-treatment 
with either anti-hTLR5-lgA or lgA2 isotype control (both 10 pg/ml). Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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5.4.3 The role of caspase-1 and caspase-8 in the production of IL-1 p by 
term non-laboured gestation-associated tissue explants in 
response to flagellin
i
Since flagellin-induced IL-1 (3 production is associated with caspase-1 and NLRC4 
inflammasome activation [350], the role of capase-1 in pro-IL-1 (3 processing was 
examined using the caspase-1 inhibitor, Z-WEHD-FMK (5pM). A reduction in 
| flagellin-induced IL-1 (3 levels in both the placenta and choriodecidua (n=3) was
i
I observed, however this was not significant (Figure 5.5). Since caspase-8 has a role
| in IL-1 (3 production in response to curdlan, the role of capase-8 in flagellin induced
IL-1 [3 was examined using the caspase-8 inhibitor, Z-IETD-FMK (5pM). A reduction 
in IL-1 (3 was observed in the placenta, however this was not significant. Inhibiting 
caspase-8 had no effect on IL-1 (3 production in the choriodecidua (Figure 5.6). 
Monitoring LDH in the culture supernatants showed that there was no effect of the 
inhibitors on cell viability.
To examine specific caspase activity in these tissues, caspase-1 and caspsae-8 
activity was examined in tissue lysates prepared at 3, 6 and 18 hours following 
flagellin treatment (Figures 5.7 - 5.8). Caspase activity at TO was also examined. No 
discernible difference was observed in caspase-1 or caspase-8 activity regardless of 
time or flagellin stimulation. Examining activity at subsequent time points of 24, 48 
and 72 hours did not alter this. As shown in Chapter 4, both assays are indeed 
functional. When assayed for IL-1 (3, lysates showed an increase in putative pro-IL- 
1(3 production in both a flagellin and time dependent manner, which was also 
observed in corresponding supernatants (Figures 5.9 - 5.10). In the placenta, an 
increase in both putative pro-IL-1 (3 and IL-1 (3 was observed from 3 hours and this 
continued to increase over time, with a significant increase in putative pro-IL-1 p from 
6 hours. In the choriodecidua, an increase in both putative pro-IL-1 (3 and IL-1 (3 was 
not observed until 6 hours and this continued to increase over time, with a significant 
increase of putative pro-IL-1 (3 at 18 hours.
i
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Figure 5.5 Inhibition of capase-1.
Explants of (A) placenta and (B) choriodecidua were treated with flagellin (100 ng/ml) in the presence 
or absence of the caspase-1 inhibitor Z-WEHD-FMK (5 pM; n=3) and levels of IL-1p (pg/ml mean ± 
SEM) in tissue free supernatants measured. Relative LDH levels in the (C) placenta and (D) 
choriodecidua compared to the unstimulated control. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 5.6 Inhibition of caspase-8.
Explants of (A) placenta and (B) choriodecidua were treated with flagellin (100 ng/ml) in the presence 
or absence of the caspase-8 inhibitor Z-IETD-FMK (5 pM; n=3) and levels of IL-1 (3 (pg/ml mean ± 
SEM) in tissue free supernatants measured. Relative LDH levels in the (C) placenta and (D) 
choriodecidua compared to the unstimulated control. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 5.7 Caspase-1 activity in the placenta and choriodecidua.
Tissue lysates were prepared by homogenisation of explants of (A) placenta and (B) choriodecidua 
with and without treatment with flagellin (100 ng/ml; n=3) for 3, 6 an 18 hours. After determining total 
protein content, lysates were assayed for caspase-1 activity (OD 405 nm at 2, 24, 48 and 72 hours; 
mean ± SEM ). Caspase-1 activity at TO was also examined.
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Figure 5.8 Caspase-8 activity in the placenta and choriodecidua.
Tissue lysates were prepared by homogenisation of explants of (A) placenta and (B) choriodecidua 
with and without treatment with flagellin (100 ng/ml; n=3) for 3, 6 an 18 hours. After determining total 
protein content, lysates were assayed for caspase-8 activity (OD 405 nm at 2, 24, 48 and 72 hours; 
mean ± SEM). Caspase-8 activity at TO was also examined.
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Figure 5.9 IL-1 p production in placental tissue lysates versus issue free supernatants.
Explants of placenta were treated with flagellin (100 ng/ml; n=3) and then levels of IL-13 (pg/ml mean ± 
SEM) measured in (A) tissue lysates (total protein) and (B) tissue free supernatants. Statistical 
significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical significance 
compared to TO lysate is shown: * p s, 0.05, ** p s 0.01.
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Figure 5.10 IL-1 (3 production in choriodecidual tissue lysates versus tissue free supernatants.
Explants of choriodecidua were treated with flagellin (100 ng/ml; n=3) and then levels of IL-1 p (pg/ml 
mean ± SEM) measured in (A) tissue lysates (total protein) and (B) tissue free supernatants. Statistical 
significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical significance 
compared to TO lysate is shown: * p < 0.05.
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5.5 Discussion
Since IL-1 (3 is a key cytokine associated with intra-amniotic infection during 
pregnancy and a major factor in the initiation of infection associated preterm labour, 
identifying the key tissues involved in IL-1 (3 production at the maternal-fetal interface 
and the initiators of this process is of much interest. Chapter 4 demonstrated that 
the gestation-associated tissues are capable of producing IL-1 (3 in response to 
fungal (3-glucans, while work running in parallel in the research group demonstrated 
IL-1 (3 production in response to several other described agonists of the NLRP3 
inflammasome. In addition to NLRP3, transcripts for several other NLRs that are 
associated with the formation of an inflammasome are expressed by these tissues 
(Chapter 3). Therefore the aim of this chapter was to determine if flagellin, which is 
associated with the activation of the NLRC4 inflammasome [350], could induce IL- 
1(3 production in the term non-laboured placenta, choriodecidua and amnion.
The data generated shows that flagellin is able to induce the production of IL-1 p in 
both the placenta and choriodecidua, but not the amnion. The innate immune 
response to flagellin is traditionally associated with TLR5, while flagellin-induced IL- 
1 (3 is associated with the activation of the NLRC4 inflammasome. The expression of 
transcripts for TLR5 and NLCR4 within placenta, choriodecidua and amnion was 
shown in Chapter 3. However, protein expression of these receptors and their 
cellular source within these tissues has yet to been determined and is currently 
underway. It would be expected that TLR5 protein would be observed in all three 
tissue, as flagellin treatment induced elevated levels of IL-6 and IL-8 (Chapter 3). In 
contrast, since only the placenta and choriodecidua induced IL-1 (3 production, it 
would suggest that NLRC4 protein is not expressed by the amnion. However it’s 
entirely possible that NLRC4 protein might be expressed in the amnion, and the lack 
of IL-1 (3 results for defect in other inflammasome components.
To examine if TLR5 had a functional role in IL-1 [3 production, a TLR5 neutralising 
antibody was used. In the presence of anti-hTLR5 Ab, a reduction in IL-1 (3, IL-6 and 
IL-8 was observed in both the placenta and choriodecidua, suggesting that TLR5 is 
required for the production of IL-1 (3. It is probable that the flagellin-TLR5 interaction 
is the priming signal required for the initial production of pro-IL-1 (3, while 
simultaneous activation of the inflammasome occurs to process the pro-IL-1 [3 to IL- 
1 (3, but this needs to be investigated. Examination of placental tissue lysates
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demonstrate that by 3 hours there was a trend for increased level of putative pro-IL- 
1(3 occurs, with a corresponding increase of IL-1 (3 in the supernatant, suggesting a 
rapid and simultaneous response. The choriodecidua however, appear to require a 
longer prime, with no increase in either pro-IL-113 or IL-1 (3 until 6 hours post flagellin 
treatment. Regardless of the length of the priming event, replication of this 
experiment utilising the anti-hTLR5 Ab, might demonstrate no pro-IL-113 in the tissue 
lysate or IL-1 (3 in the supernatant, further implying a role for TLR5. Downstream of 
TLR5, production of pro-inflammatory cytokines is dependent on the MyD88 
dependent pathway and the activation of NF-kB and MAPKs [120]. While not 
examined here, it would be expected they signalling would be required for the 
production of pro-IL-1 (3.
Recognition of cytoplasmic flagellin by the NLRC4 inflammasome is associated with 
caspase-1 dependent cleavage of pro-IL-1 (3 to active IL-1 p. Inhibition of caspase-1 
using a caspase-1 specific inhibitor, resulted in lower levels of IL-1 p from flagellin 
treated placenta and choriodecidua. Recent work in a murine model has identified 
that NAIP5 and NAIP6 act as the direct sensors for flagellin and type three secretion 
systems signalling though NLRC4 [350, 351]. In humans only one NAIP protein is 
expressed and as shown in chapter 3 transcripts for NAIP are expressed in all three 
gestation-associated tissues. The human NLRC4-NAIP complex has not yet been 
extensively studied, however it has been shown to recognise a type three secretion 
system in human U937-derived macrophages in a NAIP dependent manner [352]. 
Therefore it is possible that human NAIP functions in a similar manner to murine 
NAIP5 and NAIP6, acting as a direct sensor for cytoplasmic flagellin, signalling 
through NLRC4 to activate caspase-1. In contract to NLRP3 which requires the 
adapter protein ASC, NLRC4 has been shown to directly interact with pro-caspase-1 
due the presence of CARD domain within its structure. However NLRC4-ASC  
dependent processes do occur [353, 354], therefore the exact role of for ASC within 
the NLRC4 inflammasome remains inconclusive.
A role for caspase-8 by macrophages in the processing of IL-1 (3 has been described 
[177]. Furthermore recent reports have shown that in a murine model a caspase-8 
dependent pathway is activated via NLRC4 in response to Salmonella infection 
inducing an ASC-caspase-8-caspase-1 complex [354]. Inhibition of caspase-8 
resulted in the reduction of IL-1 (3 production by the placenta and not the 
choriodecidua. As shown in chapter 4, caspase-8 is present in the choriodecidua
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and can be activating under certain conditions. It is therefore possible that gestation- 
associated tissue can utilise caspase-1 and caspase-8 in an agonist and tissue 
dependent manner. However at this time the mechanisms relating to this are 
unknown. Gestation-associated tissues might be utilising a caspase-1 dependent 
inflammasome e.g. NLCR4 or NLRP3 and the non-canonical caspase-8 
inflammasome independently or alternatively a caspase-8-caspsae-1 complex could 
be formed. Furthermore a role for caspase-8 in the processing of caspase-1 has 
been described [355]. A co-immunoprecipitation approach would likely assist in 
confirming what type inflammasome/caspase complexes are involved.
In summary the data contained in this chapter show that flagellin stimulates the 
production of IL-1 (3 by the placenta and choriodecidua, but not the amnion. There is 
a role for caspase-1 in IL-1 (3 production by both tissues but only placental IL-1 (3 
production in response to flagellin seems to utilise caspase-8. This contrasts with 
the response to curdlan shown in Chapter 4 where caspase-1 and caspase-8 were 
both involved in the curdlan stimulated IL-1 (3.
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Chapter 6
Use of anti-inflammatory cytokines 
to modulate the inflammatory 
response of gestation-associated
tissues
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6 Use of anti-inflammatory cytokines to modulate the inflammatory 
response of gestation-associated tissues
6.1 Introduction
Human labour and delivery has been well characterised as an inflammatory process 
with several pro-inflammatory cytokines produced by the gestation associated 
tissues involved in this process [10, 11, 14]. Work in this thesis and by others has 
shown that the gestation associated tissues are capable of producing an 
inflammatory response to an array of PAMPs via the activation of PRRs [233, 236, 
238, 242, 286, 287, 296]. While this response to microbial derived stimuli might offer 
an explanation of the mechanisms of infection associated preterm labour, it is 
possible that PRRs in response to endogenous stimuli play a role in term labour 
also. The ability to regulate the inflammatory response via PRRs in the gestation 
associated tissue might yield novel new approaches to the prevention of preterm 
labour and other adverse pregnancy outcomes.
To date treatment strategies for PTL have focused on inhibiting myometrial 
contractions utilising an array of compounds including cyclooxygenase inhibitors, 
oxytocin antagonists, magnesium sulphate and p-mimetics [356]. The potential 
benefits of progesterone treatments for PTL have also been examined [357]. While 
no significant change in the levels of progesterone are observed preceding labour, a 
functional withdrawal of progesterone activity in the uterus is associated with term 
and preterm labour [358, 359]. Several studies utilising progesterone in women have 
cautiously positive results [357, 360, 361], but indications from animal studies have 
shown an increased susceptibility to bacterial infection in the uterus [362, 363]. 
Regardless, progesterone supplementations was approved to prevent recurrent 
preterm birth in the United States in 2011 [357]. NF-kB has been suggested as 
another therapeutic target because of its role in both inflammation and labour. 
However considering its broad role, the identification of labour specific components 
is key in order to minimise toxicity [277].
A number of cytokines are well recognised for their anti-inflammatory activity, 
including IL-4, IL-10 and IL-13 [364]. IL-4 and IL-13 are shown to signal though a 
signal transducer and activator of transcription 6 (STAT6) dependent pathway 
(Figure 6.1), while IL-10 utilises STAT3 (Figure 6.2). During pregnancy anti­
inflammatory cytokines have been long associated with a protective role including
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maintaining the Th1:Th2 cytokine balance by decreasing the production of pro- 
inflammatory cytokines [365, 366]. The trophoblast, decidua and amnion have all 
been reported to produce IL-4, IL-10 and IL-13 contributing to the reported Th2 
cytokine bias of pregnancy [366]. Interestingly, IL-10 is increased in amniotic fluid 
from women in term labour and women with intra-amniotic infection at term and 
preterm, and is also increased in those without infection who delivered preterm 
rather than term [269]. A similar observation for IL-4 has been described [367]. 
Elevated anti-inflammatory cytokines in these circumstances might represent a 
compensatory mechanism that has failed.
Investigations into the use of anti-inflammatory cytokines therapeutically to prevent 
PTL have focused primarily on IL-10. Animal studies have shown that co­
administration of IL-10 and LPS decreased placental nitric oxide, TNF-a and 
apoptosis compared to LPS treatment alone [368]. Furthermore, intravenous IL-10 
administration was able to prevent PTB resulting from intrauterine LPS infusion in 
rats [369]. IL-10 has been shown to down-regulate LPS- and LTA (lipoteichoic acid)- 
induced cytokine and chemokine responses by the healthy term placenta [268]. In 
addition IL-10 can inhibit the production of IL-1 (3 and prostaglandin E2 production 
and inhibit COX-2 expression in intact term fetal membranes [370]. The anti­
inflammatory effects of IL-4 and IL-13 have also been noted. In human monocytes 
and human umbilical vein endothelial cells, IL-4 has been shown to inhibit LPS 
induced IL-13 and TNFa [371]. Furthermore IL-4 can down-regulate formyl 
methionyl leucyl phenylalanine (fMLP) induced IL-8 and TNFa in human 
polymorphonuclear leukocytes (PMNs) [372]. In monocytes and macrophages, IL-13 
has been shown to down-regulate the production of IL-1 (3, IL-8, MIP-1a and TNF-a  
[373-376]. It is therefore possible that other anti-inflammatory cytokines have effects 
similar to IL-10 in gestation associated tissues.
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Figure 6.1 Overview of IL-4/IL-13 signalling pathway.
There are two types of signalling receptors -  type I consisting of the common gamma chain (gc; 
CD132) and IL-4Ra; and type II consisting of IL-4Ra and IL-13Ra1. IL-4 first binds to IL-4Ra and can 
signal via both type I and type II, whereas IL-13 first binds to IL-13Ra1 and only signals via type II. IL- 
13Ra2 has been suggested to be a decoy. Activation of their receptors by IL-4 and IL-13 leads to 
transphosphorylation of non-receptor protein tyrosine kinases (JAKs) and STAT6 phosphorylation and 
dimerization, and translocation to the nucleus [377],
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Figure 6.2 Overview of the IL-10 signalling pathway.
Two copies of IL-10 receptor 1 (IL-1 OR) and IL-10 receptor 2 (IL-10R2), form a receptor complex. 
Association of JAK1 and Tyk2 occurs upon IL-10 binding to its receptor, resulting in the 
phosphorylation of the cytoplasmic tail of IL-10R1 facilitating the recruitment of STAT3. 
Homondimerisation of STAT3 occurs facilitating its release from IL-1 OR 1 and translocation into the 
nuclease [378, 379].
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6.2 Aims
The aim of this chapter is to examine if anti-inflammatory cytokines, notably IL-4 and 
IL-13, can regulate the LPS induced inflammatory response in the term non­
laboured human placenta, choriodecidua and amnion.
6.3 Methods
6.3.1 Samples
Healthy pregnant women scheduled for elective caesarean section (ESC) were 
approached in the antenatal day assessment unit at Singleton Hospital, Swansea, 
during their pre-anaesthetic assessment. Informed written consent was obtained 
upon explanation of the study. Following delivery, placenta and attached fetal 
membranes (n=3-9) from these women were collected and processed within 1.5 
hours of delivery.
6.3.2 PCR
RNA was extracted and cDNA produced from gestation associated tissue samples 
(placenta, choriodecidua and amnion) stored in TRI reagent (see Chapter 2.4 for 
method). PCR was performed for IL-4/13 receptor components; IL-4Ra, IL-13a1, IL- 
13a2 and CD132 (common gamma chain), the transcription factor STAT6 (see 
Chapter 2.4 for method and Table 6-1 for primer details).
Table 6-1 IL-4/13 receptor and STAT6 primer sequences.
Gene Primer
Mg2+
Cone
(nM)
Anneling
Temp
(°C)
Fragment 
Size (Bp)
Accession
Number
F 5' GACCTGGAGCAACCCGTATC
IL-4R 2.5 70 335 NM 000418
R 5' CATAGCACAACAGGCAGACG
F 5' ACGGGAACCCAGGAGACAGG
CD132 2 70 275 NM 000206
R 5' AGCGGCTCCGAACACGAAAC
F 5‘ GAGCTGACCAAAGTGAAGGA
IL-13Ra1 3 69 518 NM 001560
R 5' ATTG CACCTGCGACGATGACTG
F 5' GGCATAGGTGATCTTCTTGA
IL-13Ra2 2 60 559 NM 000640
R 5' GCCAGAAACGATGCAAAGTTT
F 5' AGAGGGGTTGCCGAGGTGA
STAT6 4 70 755 NM 001178078
R 5' TGTCCACCAGGCTTTCACAC
Sequences and optimum conditions for each pair of primers used for PCR.
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6.3.3 Gestation-associated tissue explants
Placenta, choriodecidua and amnion tissue explants were cultured as described in 
Chapter 2.2. Cultures were stimulated with previously optimised concentrations of 
cytokines and agonists as follows; ultrapure LPS (10 ng/ml; Invivogen), IL-4 (10 
ng/ml), IL-10 (10 ng/ml) and IL-13 (10 ng/ml). An unstimulated control was also 
included. Cytokines were added either pre- or post-LPS stimulation as detailed in 
the appropriate figure legends. Cultures were incubated for 24 hours. For 
inhibition/neutralisation experiments cultures were incubated for 30 minutes prior to 
the addition of cytokines/agonists with the following blocking antibodies: anti-hlL- 
4Ra lgG2A (1 pg/ml; R&D Systems), Mouse lgG2A isotype (1 pg/ml; R&D 
Systems).
6.3.4 Cytokine production
IL-1 (3 and MIP-1a in the tissue free supernatants of placenta, choriodecidua and 
amnion explant cultures collected after 24 h were measured using commercially 
available ELISA kits (DuoSet, R&D Systems) as per manufacturer’s instructions.
6.3.5 Western blotting
Total protein was extracted and quantified from gestation associated tissue samples 
(placenta, choriodecidua and amnion) treated with IL-4 for 0.5, 2 and 24 hours (see 
Chapter 2.5 for method). Immunoblotting was performed using 10 pg of protein for 
total and phosphorylated STAT6. Antibodies were used at the following dilutions; 
total STAT6 (rabbit polyclonal IgG; 1:1000; R&D systems), phospho-STAT6 (Y641; 
rabbit polyclonal IgG; 1:1000; R&D systems), GAPDH (rabbit polyclonal IgG; 
1:1000; santa cruz biotechnology); goat anti-rabbit IgG (secondary antibody; 1:2000; 
santa cruz biotechnology).
6.3.6 Statistical analysis
Agonist mediated cytokine production by non-laboured tissues was evaluated by 
Wilcoxon matched pairs signed rank test or Freidman’s test with Dunn’s posthoc test 
for multiple comparisons. A p-value of < 0.05 was considered significant.
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6.4 Results
6.4.1 Effect of IL-4 and IL-13 on the inflammatory response of term 
non-laboured gestation-associated tissues
To investigate the effect of IL-4 and IL-13 on the inflammatory response in the term 
non-laboured placenta, choriodecidua and amnion, tissues were pre-treated for 90 
minutes with previously optimised concentrations (10 ng/ml) of IL-4 or IL-13 prior to 
the addition of LPS (10 ng/ml). Results are represented as percentage decrease in 
cytokine production (IL-13 and MIP-1a) compared to LPS set at 100%. These 
cytokines were chosen because of their low constitutive production by gestation 
associated tissues (see Chapter 8.3, Figure 8.26), because of this only the data 
from LPS treated samples are shown. As shown in Figure 6.3, pre-treatment with IL- 
4 decreases LPS induced IL-1 (3 and MIP-1a production in all three tissues. IL-13 
pre-treatment had the same effect (Figure 6.4). However, a varied effect is seen 
across the three tissues: the greatest impact of IL-4 /13 pre-treatments was on the 
placenta with the least impact on the amnion. Additionally a greater impact on IL-13 
than MIP-1a was observed.
While pre-treatment with either IL-4 or IL-13 was able to reduce LPS induced 
cytokine levels, this does not mimic the typical clinical setting. Therefore the ability 
of both IL-4 and IL-13 to modulate cytokine production post-LPS exposure was 
examined. To investigate this term non-laboured placenta, choriodecidua and 
amnion were treated with LPS and IL-4 or IL-13 either concurrently, 90 minute or 
240 minute post-LPS treatment. Pre-treatment (90 minutes) was also performed to 
provide a base line response for IL-4/IL-13. Results are represented as percentage 
decrease in cytokine production compared to LPS set at 100%. As shown in Figure 
6.4, the inhibitory effect of IL-4 diminishes over time post LPS treatment. A similar 
effect is observed for IL-13 (Figure 6.5).
Since the effect of both IL-4 and IL-13 diminishes post exposure to LPS, it was 
decided to examine whether co-treatment with both cytokines would enhance their 
anti-inflammatory effect. To investigate this term non-laboured placenta, 
choriodecidua and amnion, tissues were treated with IL-4 alone, IL-13 alone or a co­
treatment of IL-4 and IL-13 at 90 and 240 minutes post-LPS exposure. The results 
are shown in Figure 6.6. IL-4 and IL-13 co-treatment did not enhance the ability of 
these cytokines to down regulate the LPS response.
144
A
150
125 -
LPS LPS + IL-4
B
150 i
125 ■
LPS LPS + IL-4
c
150 i
125 -
LPS LPS + IL-4
Figure 6.3 Effect of IL-4 on LPS induced cytokine production by term non-laboured gestation 
associated tissues.
Cytokine levels (IL-1 (3 & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to treatment with IL-4 (10 ng/ml) 90 minutes prior to treatment with LPS (10 ng/ml). Data 
shown as percentage of response to LPS alone (n=9); error bars represent SEM. Statistical 
significance compared to unstimulated LPS as determined by Wilcoxon matched pairs signed rank test 
are shown: ** p < 0.01.
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Figure 6.4 Effect of IL-13 on LPS induced cytokine production by term non-laboured gestation 
associated tissues.
Cytokine levels (IL-1 (3 & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to treatment with IL-13 (10 ng/ml) 90 minutes prior to treatment with LPS (10 ng/ml). Data 
shown as percentage of response to LPS alone (n=9); error bars represent SEM. Statistical 
significance compared to LPS as determined by Wilcoxon matched pairs signed rank test are shown: **
p<0 .01 .
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AFigure 6.5 Effect of IL-4 treatment over time on LPS induced cytokine production by term non- 
laboured gestation associated tissues.
Cytokine levels (IL-1 (3 & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to LPS (10 ng/ml) in the presence of IL-4 (10 ng/ml) added 90 minutes prior to LPS (T-90), at 
the same time as LPS (TO), or 90 minutes (T+90) or 4 hours (T+240) after LPS (n=3). Data are shown 
as percentage of response to LPS alone; error bars represent SEM. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to LPS is 
shown: * p < 0.05, ** p < 0.01.
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AFigure 6.6 Effect of IL-13 treatment over time on LPS induced cytokine production by term non- 
laboured gestation associated tissues.
Cytokine levels (IL-1 (B & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to LPS (10 ng/ml) in the presence of IL-13 (10 ng/ml) added 90 minutes prior to LPS (T-90), 
at the same time as LPS (TO), or 90 minutes (T+90) or 4 hours (T+240) after LPS (n=3). Data are 
shown as percentage of response to LPS alone; error bars represent SEM. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to LPS is 
shown: * p < 0.05, ** p < 0.01.
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Figure 6.7 Combined effect of IL-4 and IL-13 treatment on LPS induced cytokine production by 
term non-laboured gestation associated tissues.
Cytokine levels (IL-1 (3 & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to LPS (10 ng/ml) in the presence of IL-4, IL-13 or IL-4 + IL-13 (bothIO ng/ml) added 90 
minutes (T+90) or 4 hours (T+240) after LPS (n=3). Data are shown as percentage of response to LPS 
alone; error bars represent SEM. Statistical significance was determined by Freidman’s test with 
Dunn’s posthoc test. Statistical significance compared to LPS is shown: * p < 0.05, ** p < 0.01.
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6.4.2 The IL-4/IL-13 signalling pathway
IL-4 and IL-13 share a number of functional characteristics. Both IL-4 and IL-13 
utilise the receptor component IL-4Ra and activate a common signalling pathway; 
the JAK/STAT pathway to activate signal transducer and activator of transcription 6 
(STAT6). An overview of IL-4 and IL-13 signalling is shown in Figure 6.1.
6.4.2.1 Expression of transcripts for IL-4/IL-13 signalling pathway by 
gestation-associated tissues
To investigate whether transcripts for components of the IL-4/IL-13 signalling 
pathways, including IL-4 receptor (IL-4Ra), the common gamma chain (CD132), IL- 
13 receptor alpha 1 (IL-13Ra1), IL-13 receptor alpha 2 (IL-13Ra2) and STAT6 are 
expressed in gestation associated tissues, PCR was performed using five individual 
samples of each tissue type (placenta, choriodecidua and amnion). Three of these 
five samples are shown in Figure 6.8. Transcripts for each component examined 
were present in all five samples of each of the tissues, with the exception of IL- 
13Ra2, which showed varied expression in the amnion across all 5 samples, from 
no expression to strong expression.
6.4.2.2 IL-4Ra neutralisation
To confirm that both IL-4 and IL-13 utilise their classically described signalling 
pathway in the gestation associated tissues, IL-4Ra, as a common receptor 
component to both IL-4 and IL-13 signalling was examined. Term non-laboured 
tissues were pre-treated for 90 minutes with either IL-4 or IL-13 prior to the addition 
of LPS in the presence and absence of a neutralising Mouse lgG2A anti-hlL-4R (1 
pg/ml; n=3). Mouse lgG2A isotype (1 pg/ml) was used as a control. The results are 
shown in Figures 6.9 -  6.11. In the presence of the anti-IL-4Ra antibody, the effect 
of IL-4/IL-13 on LPS-induced IL-1 (3 and MIP-1a is abrogated, with no effect of 
isotype control.
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Figure 6.8 Expression of transcripts of the IL-4/13 signalling pathway by gestation-associated 
issues.
PCR for each of the receptor chains involved in IL-4 and IL-13 signalling as well as the main 
transcription factor STAT6. Three representative examples of a total of 5 are shown; placenta (P), 
choriodecidua (C) and amnion (A). Human spleen (S) was used as a positive control and UBE2D2 was 
used as a housekeeping gene. L = 100 base pair ladder and the negative control (-ve) was with water 
replacing cDNA in the reaction mix.
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Figure 6.9 Neutralisation of IL-4 receptor in the placenta abrogates the anti-inflammatory effects 
of IL-4 and IL-13.
Cytokine levels (IL-13 & MIP-1a) from explants of placenta in response to LPS (10 ng/ml) pre-treated 
for 90 minutes with (A) IL-4 and (B) IL-13 (both 10 ng/ml) in the presence or absence of mouse lgG2a 
anti-human IL-4R antibody or mouse lgG2a isotype. Data are shown as % of LPS alone (n = 3); error 
bars represent SEM. Statistical significance was determined by Freidman’s test with Dunn’s posthoc 
test. No significant difference was observed.
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Figure 6.10 Neutralisation of IL-4 receptor in the choriodecidua abrogates the anti-inflammatory 
effects of IL-4 and IL-13.
Cytokine levels (IL-1 (B & MIP-1a) from explants of choriodecidua in response to LPS (10 ng/ml) pre­
treated for 90 minutes with (A) IL-4 and (B) IL-13 (both 10 ng/ml) in the presence or absence of mouse 
lgG2a anti-human IL-4R antibody or mouse lgG2a isotype. Data are shown as % of LPS alone (n = 3); 
error bars represent SEM. Statistical significance was determined by Freidman’s test with Dunn’s 
posthoc test. No significant difference was observed.
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Figure 6.11 Neutralisation of IL-4 receptor in the amnion abrogates the anti-inflammatory effects 
of IL-4 and IL-13
Cytokine levels (IL-1p & MIP-1a) from explants of amnion in response to LPS (10 ng/ml) pre-treated for 
90 minutes with (A) IL-4 and (B) IL-13 (both 10 ng/ml) in the presence or absence of mouse lgG2a anti­
human IL-4R antibody or mouse lgG2a isotype. Data are shown as % of LPS alone (n = 3); error bars 
represent SEM. Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. 
No significant difference was observed.
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6 .4 .2 .3  STA T6 phosphory la tion
To confirm that both IL-4 and IL-13 induce STAT6 phosphorylation in these tissues, 
lysates of placenta were prepared at 0.5, 2 and 24 hours in the presence or absence 
of cytokine treatment. Phosphorylation at TO was also examined. Figure 6.12 shows 
the effect of IL-4 (10 ng/ml and 100 ng/ml) on STAT6 phosphorylation compared to 
total STAT6 in the placenta. It would appear IL-4 treatment does result in 
phosphorylation of STAT6; however this result was not reproducible. Therefore the 
validity is questionable.
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Figure 6.12 STAT6 phosphorylation in the placenta
Tissue lysates were prepared fromplacental explants treated with IL-4 (10 ng/ml and 100 ng/ml) for 0.5, 
2 and 24 h and STAT6 phosphorylation examined. IL-4 treatment appeared to result in phosphorylation 
of STAT6, however this result was not reproducible.
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6.4.3 Can simultaneous treatment with IL-10 augment the anti­
inflammatory effect of IL-4?
Since IL-10 has been shown previously to inhibit cytokine production in the term 
placenta and fetal membranes, it was decided to examine whether co-treatment with 
IL-10 could enhance the inhibitory effect of IL-4 post-LPS stimulation. Initial 
investigations were performed to confirm the inhibitory effect of IL-10 on LPS 
induced cytokine production. Term non-laboured placenta, choriodecidua and 
amnion, tissues were pre-treated for 90 minutes with previously optimised 
concentration (10 ng/ml) of IL-10 prior to the addition of LPS. Results are 
represented as percentage decrease in cytokine production (IL-1|3 and MIP-1a) 
compared to LPS set at 100%. As shown in Figure 6.13, treatment with IL-10 was 
able to decrease LPS-induced IL-1 (3 and MIP-1a production in all three tissues.
To investigate the effects of co-treatment with IL-10 and IL-4 on term non-laboured 
placenta, choriodecidua and amnion, tissues were treated with IL-4 alone, IL-10 
alone or a combination of IL-4 and IL-10 at 90 and 240 minutes post-LPS exposure. 
The results are shown in Figure 6.13. In the placenta, while a reduction in both IL-1p 
and MIP-1a was observed at 90 minutes post-LPS in response to the combination of 
IL-4 and IL-10 compared to IL-4 or IL-10 alone this was not significant. In the 
choriodecidua, there was a significant reduction in MIP-1a at 90 minutes post-LPS 
in the presence of both IL-4 and IL-10 compared to IL-4 alone. Additionally at 240 
minutes post-LPS, a significant reduction in IL-1(3 and MIP-1a was observed 
compared to IL-10 and IL-4 alone, respectively. A significant reduction in MIP-1a at 
240 minutes was observed compared to IL-4 and IL-10 alone in the amnion. 
Additionally a reduction in IL-1(3 at 240 minutes post-LPS was observed compared 
to IL-4 alone. These data would imply that co-treatment of IL-4 and IL-10 may have 
a greater effect than either cytokine individually.
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Figure 6.13 Effect of IL-10 on LPS induced cytokine production by term non-laboured gestation 
associated tissues
Cytokine levels (IL-ip & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to treatment with IL-10 (10 ng/ml) 90 minutes prior to treatment with LPS (10 ng/ml). Data are 
shown as % of response to LPS alone (n=6); error bars represent SEM. Statistical significance 
compared to LPS as determined by Wilcoxon matched pairs signed rank test. No significant difference
was observed.
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Figure 6.14 Effect of simultaneous treatment with IL-4 and L-10 on LPS-induced cytokine 
production by term non-laboured gestation associated tissues.
Cytokine levels (IL-1P & MIP-1a) from explants of (A) placenta (B) choriodecidua and (C) amnion in 
response to LPS (10 ng/ml) in the presence of IL-4, IL-10 or IL-4 + IL-10 (both10 ng/ml) added 90 
minutes (T+90) and 4 hrs (T+240) after LPS treatment. Data are shown as % of LPS alone (n=3); error 
bars represent SEM. Statistical significance was determined by Freidman’s test with Dunn’s posthoc 
test. Statistical significance compared to LPS is shown: * p < 0.05, ** p < 0.01.
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6.5 Discussion
The cytokines IL-4, IL-10 and IL-13 have anti-inflammatory activity in a number of 
experimental settings [372-376]. Anti-inflammatory cytokines are also associated 
with a protective role during pregnancy [365, 366]. Studies to date have 
demonstrated that IL-10 can down-regulate LPS- and LTA-induced 
cytokine/chemokine and prostaglandin production, in addition to COX-2 expression 
by the healthy term placenta and intact term fetal membranes [268, 370]. However, 
it is unknown if other anti-inflammatory cytokines such as IL-4 and IL-13 have similar 
effects. The data presented here show that IL-4 and IL-13 pre-treatment of the 
placenta, choriodecidua and amnion reduced the production of the pro-inflammatory 
cytokines IL-1(3 and MIP-1a in response to LPS. The effect of IL-4 and IL-13 
treatment after LPS stimulation was also considered as this was postulated to better 
mimic the clinical scenario. The anti-inflammatory effect of these cytokines was 
diminished when the cytokines were treated post-LPS exposure. Co-treatment with 
both IL-4 and IL-13 did not enhance the anti-inflammatory effects of either cytokine 
alone post-LPS exposure.
Two types of IL-4 signalling pathways have been described; type I signalling and 
type II signalling [377]. The type I signalling consists of a receptor complex between 
the common gamma chain (gc; CD132) and IL-4Ra; and type II consisting of IL-4Ra 
and IL-13Ra1. IL-4 can signal via both type I and type II, whereas IL-13 first binds to 
IL-13Ra1 and can only signal via type II. Analysis of the placenta, choriodecidua 
and amnion by PCR showed transcripts for both type I and type II receptor 
components (IL-4Ra, CD132 and IL-13Ra1), the IL-13 decoy receptor IL-13Ra2 and 
the transcription factor STAT6. However the expression of IL-13Ra2 varied in the 
amnion. Furthermore neutralisation of IL-4Ra, which is required for both type I and 
type II, was able to block the effects of both IL-4 and IL-13 in these tissues. IL-4 
induced phosphorylation of STAT6 was also examined, but was not reproducible i.e. 
no phospho-STAT6 or total STAT6 was observed under the same conditions or with 
alternative antibodies. Examination of STAT6 phosphorylation utilising a plate based 
assay may overcome this, however similar issues to the capase-1/8 activity assays 
in Chapter 4 and 5 may occur. Immunoprecipitation of STAT6 prior to blotting might 
also overcome the detection problems.
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When comparing the anti-inflammatory effect of IL-4 and IL-13, it was generally 
observed that IL-4 had a great effect in reducing the LPS induced cytokine 
production. The ability of IL-4 to utilise both type I and type II might account for 
these differences as there are more target receptors for it to bind. Similarly this 
would explain why there was no enhancement of the anti-inflammatory effect of 
these cytokine with co-treatment as in this situation both IL-4 and IL-13 would be 
competing for the type II receptor complex. This highlight the need to further 
examine the function of other receptor chains notably IL-13Ra1.
As IL-10 has already been reported to have anti-inflammatory effects on gestation 
associated tissues, investigation into whether co-treatment of IL-10 could enhance 
the anti-inflammatory effect of IL-4, which had a greater effect than IL-13, was 
undertaken. Simultaneous treatment with IL-4 and IL-10 was able to enhance the 
down-regulation of LPS-induced cytokine response by IL-4 or IL-10 alone. IL-4 has 
been shown to both up-regulate and inhibit IL-10 production [380, 381] and as LPS 
can also induce IL-10 production in gestation-associated tissues [233, 382], it would 
be worthwhile measuring IL-10 in supernatants from LPS/IL-4 treated tissues 
explants. It is likely that the effect observed by addition of IL-10, results from the 
activation of a second distinct signalling pathway or enhancing its effect.
These results suggest that further investigation of the therapeutic potential of IL-4 
and IL-10 is warranted. Targeting the receptor with small peptides would be worth 
pursuing. Understanding the signalling mechanisms might also reveal therapeutic 
targets. The mechanisms of how IL-4 and IL-13 inhibit LPS induced pro- 
inflammatory cytokine production might relate to the down-regulation of TLR4 
expression and function [383]. However, this may result in an undesired impaired 
innate immune response [384]. Activation of TLR4 by LPS has been shown to 
directly up-regulated suppressor cytokine signalling 1 (SOCS1) expression, a 
negative regulator of both TLR and JAK/STAT signalling pathways [377, 385]. 
SOCS1 is also up-regulated by IL-4, but it has been suggested that SOCS1 does 
not mediate the anti-inflammatory effects of IL-4 [386], Therefore it’s possible that 
the diminished effect of IL-4 and IL-13 post LPS treatment is mediated by SOCS1 
induced by LPS.
An overview of the IL-10 signalling pathway is shown in Figure 6.2. Activation of 
STAT3 is key in mediating the anti-inflammatory effects of IL-10 [387], however the
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exact mechanisms of how this occurs remain unclear but might result from the 
induction of SOCS3 [388]. The potential of IL-10 to inhibit NF-kB activation has been 
examined, with several, contradictory reports in the literature. Some have reported 
the inhibition of NF-kB activation by IL-10 [389, 390], while negligible effects have 
been suggested by others [391, 392]. However, IL-10 has been shown to induce the 
expression of Bcl-3 in macrophages [393], a suggested negative regulator of NF-kB 
[394, 395]. Both IL-10 and IL-4 have been shown to enhance the expression of IL-1 
receptor antagonist (IL-1Ra) [396], a potent anti-inflammatory cytokines involved in 
the inhibition of IL-1 a and IL-1 (3 [364].
While LPS is a classically used agonist to induce inflammation and to initiate 
infection associated preterm labour in animal models, the work in this thesis has 
demonstrated that gestation associated tissues can response to a wide variety of 
agonists of bacterial, viral and fungal origin. Whether the effects of IL-4, IL-10 and 
IL-13 shown in this chapter, apply to other agonist or indeed other cytokines is yet to 
be determined. However based on the ability of IL-10 to down-regulate LTA (TLR2 
agonist)-induced cytokine production in healthy term placenta [268], it is possible 
this maybe also be the case for cytokine production induced by other agonists.
In summary the data contained in this chapter demonstrate that both IL-4 and IL-13 
are able to down-regulate LPS induced cytokine production in the placenta, 
choriodecidua and amnion likely functioning via their classically described pathways. 
Furthermore co-treatment of IL-4 and IL-10 results in a greater down-regulation of 
LPS induced cytokine production.
161
Chapter 7
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7 General discussion and directions for further work
7.1 Overview
Increased interest in the innate immune response and its receptors at the maternal- 
fetal interface has arisen because of the association between intrauterine infection, 
inflammation and certain adverse pregnancy outcomes. However, the study of PRR 
expression and activity by gestation-associated tissues is still in its infancy. While 
ultimately an improved understanding of these receptors and the signal transduction 
cascades they initiate might offer an explanation as to why some pregnancies are 
complicated by PTL and PPROM whereas others are only affected by PPROM, this 
is beyond the scope of this current study. Here the focus was to examine PRR 
expression and activity in term non-laboured tissues, providing a baseline 
comparison and greater understanding of these receptors in gestational tissues, to 
aid in examining any potential role they may play in normal term labour but also in 
preterm labour and other adverse pregnancy outcomes in the future.
7.2 Expression and activity of PRRs by gestation associated tissues.
At the outset of this work, investigation into Toll-like receptors (TLRs) in the 
gestation associated tissues was the primary focus. However during the early 
months of research , it became clear as the literature surrounding PRRs evolved 
that the scope of the work should be expanded to include other PRR families, 
including Nod-like receptors (NLRs), RIG-l-like receptors (RLRs) and C-type lectin 
receptors (CLRs). Initial investigations were performed to determine the expression 
profile of PRRs by the placenta, choriodecidua and amnion. Transcripts for all PRRs 
examined were shown to be expressed in these tissues, corresponding to some 
previously published reports (including TLRs 1-10 [233] and the NLRs, NOD1 and 
NOD2 [60, 288]), while demonstrating the expression of others for this first time 
notably Dectin-1, Dectin-2 and MINCLE.
Following this, the placenta, choriodecidua and amnion were treated with a wide
variety of agonists shown to bind and activate specific PRRs to determine if these
receptors were functional in these tissues. An increase in IL-6 and/or IL-8 in
response to stimulation of all three tissues with receptor specific agonists, implied a
functional role for TLRs 1-8, NOD1, NOD2, RIG-I/MDA5 and Dectin-1. Detailed
investigation of the Dectin-1 signalling pathway, demonstrated that p-glucans, a
primary component of the Candida albicans cell wall was able to elicit a robust
163
inflammatory response in a spleen tyrosine kinase and NF-kB dependent manner. 
Furthermore exposure of these tissues to Candida albicans resulted in an increase 
in IL-6 and IL-8 production. Of all PRRs examined, TLR9 and MINCLE agonists 
appeared not to elicit a response suggesting that either that these receptors are not 
functional in these tissues or that a broader screen of cytokines is required. It has 
been previously reported that fetal membranes treated with a TLR9 agonist 
significantly increased MCP-1 production, while significantly inhibiting the 
constitutive production of G-CSF, IFNy, MIP-1a, M IP -ip , RANTES and VEGF [288]. 
Additionally, further examination of placenta and choriodecidua treated with the 
MINCLE agonist TDB, based on reports that in may activate the NLRP3 
inflammasome [336], resulted in an increase in IL-1 (3 production (Chapter 8 -  Figure 
8.25).
An increase in the local production of pro-inflammatory cytokines at the maternal- 
fetal interface has been long associated with initiating the physiological processes of 
labour; remodelling of the cervix, weakening and rupture of the membranes and the 
initiation of uterine contractions [11]. These processes are facilitated by the activity 
of matrix metalloproteinases (MMPs), the expression of which are augmented by 
pro-inflammatory cytokines [11, 356]. Based on the knowledge that PRRs are 
expressed and are functional in the placenta, choriodecidua and amnion it is likely 
that the activation of PRRs might lead to the production of MMPs. Indeed activation 
of TLRs in various cell types including monocytes, keratinocytes and fibroblasts has 
been shown to induce the expression of several MMPs [397-399]. Examinations of 
PRR induced MMP expression in gestation associated tissues is rather limited and 
has notably focused on the amnion. Murine studies have shown activation of MMP-1 
and MMP-9 in a TLR4 dependent manner [400]. Examination of human amniotic 
epithelial cells and amnion explants has noted the induction of MMP-9 via TLR5 and 
TLR2/6 and in response to LPS [287, 401]. Additionally induction of MMP-9 has 
been reported in fetal membranes in response to a mixed bacterial population and in 
response to NOD1 agonist iE-DAP and NOD2 agonist MDP [286, 402]. Furthermore 
LPS induced secretion of MMP-9 by human chorion trophoblasts and placental 
syncytiotrophoblast has been reported, however no significant effect was observed 
on TIMP-1, an inhibitor of MMPs [403].
Since PRRs utilise a number of microbial derived agonists, it’s easy to understand 
how PRRs may play a role in the pathogenesis of infection associated preterm
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labour and birth. However PTB has multiple etiologies, with several risk factors 
identified including extremes of maternal body mass index (BMI), hypertension, 
multiple gestations, uterine anomalies and adverse behaviours (smoking and 
alcohol consumption) among others [41]. PRRs have been implicated in the 
recognition of endogenous danger signals released by the host; referred to as both 
DAMPs or alarmins. These include HMGB1, fibronectin and heat shock proteins 
(HSPs) [101, 404]. HMGB1 mediates its activity though multiple TLRs including 
TLR2, TLR4 and TLR9 and the receptor for advanced glycation end products 
(RAGE) [405-407]. HMGB1 localised to amnion epithelial cells is associated with 
membrane rupture with elevated levels present in the amniotic fluid of women in 
PTL with PPROM compared to women in PTL with intact membranes [408]. Fetal 
fibronectin (fFN) present in vaginal secretions has long been suggested as a marker 
for PTL [22, 409]. Murine studies have shown the ability of fFN to activate NF-kB 
and ERK1/2 in a TLR4 dependent manner in amnion mesenchymal cells, resulting 
in several downstream effects including increased COX-2 mRNA, PGE2 
biosynthesis, and enzymatic activity of MMP-1 and MMP-9 [400] Elevated levels of 
alarmins (HMGB1 and HSP70) in the amniotic fluid are also associated with intra- 
amniotic infection [408, 410]. Therefore it is possible that alarmins at the maternal- 
fetal interface play a role in preterm labour with and without the presence of 
infection.
7.3 IL-1 p production and inflammasome activation by gestation 
associated tissues
IL-1 (3 is tightly regulated due to its potency as a pro-inflammatory mediator. Initially 
expressed as an inactive pro-IL-1(3 precursor it requires caspase activity mediated 
by several described inflammasomes to be processed into mature IL-1 (3 [185, 343- 
347].
The data presented in this thesis, demonstrates production of IL-1 (3 in response to 
the [3-glucan curdlan and bacterial flagellin in both the placenta and choriodecidua. 
Parallel work within the laboratory has demonstrated that these tissues can produce 
IL-1 (3 in response to a wide variety of inflammasome activators including nigericin, 
hemozoin and monosodium urate (MSU) crystals. Studies of (3-glucan induced IL-1 (3 
in macrophages and dendritic cells have yielded evidence of activation of both 
NLRP3/capase-1 and a non-canonical capase-8 inflammasome respectively [177, 
314]; flagellin induced IL-1 (3 is associated with the activation of caspase-1 and the
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NLRC4 inflammasome [350]. Investigation into these pathways using specific 
inhibitors, yielded evidence that both caspase-1 and caspase-8 are required for 
curdlan and flagellin induced IL-1 p production in the placenta. A similar observation 
is seen the choriodecidua for curdlan induced IL-1 (3; however flagellin induced IL-1 (3 
in this tissue was dependent on caspase-1 only. Despite showing a role for 
caspase-1 and capase-8 in IL-1 [3 production in these tissues, the results cannot 
confirm conclusively the involvement of the NLRP3 inflammasome, the non- 
canonical caspase-8 inflammasome or the NLRC4 inflammasome and these should 
be the focus of further investigation utilising a co-immunoprecipitation approach.
It has been well documented that IL-1 (3 is a major factor in the initiation of both term 
and preterm labour via its ability to up-regulate MMP activity and prostaglandin 
production which facilitate the physiological processes of labour [19, 26, 75, 342]. 
Additionally, elevated levels of IL-1 (3 in amniotic fluid is a hallmark of intra-amniotic 
infection during pregnancy [320]. Although gestation associated tissues produce IL- 
1(3, it’s not known whether IL-1 (3 acts in either an autocrine or paracrine manner or 
both at the maternal-fetal interface. IL-1 [3 signals through the IL-1 receptor (IL-1 R) 
[411]. Examination of IL-1 R expression by gestational tissues has not been 
investigated; however it would be highly unlikely that IL-1 R is not expressed by 
some component of the maternal-fetal interface due to the highlighted role of IL-1 (3 
in term and preterm labour. Furthermore the IL-1 signalling pathway utilises several 
signalling molecules associated with TLR signalling [412], which are functional in 
gestation-associated tissue, further suggesting a functional IL-1 signalling pathway. 
Activation of the IL-1 pathway by IL-1 (3 is associated with the production of a 
number of pro-inflammatory cytokines including IL-6 [413, 414]. Furthermore, IL-1 p 
has been shown to induce the expression of several DAMPs including HMGB1 and 
HSP70, by cortical astrocytes and islet beta cells respectively [415, 416]. Therefore, 
IL-1 (3 production by gestation-associated tissues might contribute to sustained 
inflammation at the maternal-fetal interface.
Activation of the inflammasome and the production of IL-1 (3 have gained extensive 
interest as a link between inflammation and metabolic disorders including obesity 
[417]. The inflammatory state during obesity is linked to the activation of adipose 
tissue macrophages by lipids including ceramide and palmitate, which have been 
shown drive the activation of NLRP3 and caspase-1 and the production of IL-1 (3, 
mediating insulin resistance [417-419]. This occurs due to the down-regulation of
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AMP-activated kinase (AMPK) activity, a regulator of cellular energy status, resulting 
in enhanced reactive oxygen species (ROS) production from accumulated 
dysfunctional mitochondria, promoting the activation of NLRP3 [418].
Because of the obesity epidemic there are an increased number of obese pregnant 
women, and maternal obesity is associated with increased risk of PTL [420-425]. 
Since the placenta and attached membranes are the interface between the maternal 
and fetal environment, it is likely to have a central role in the impact of maternal 
obesity on adverse pregnancy outcomes and the short and long term health of the 
offspring [426]. Examinations of the impact of maternal obesity on the placenta have 
demonstrated elevated oxidative and nitrative stress, pro-inflammatory cytokine 
gene expression and placental lipotoxicity [426-428]. An association of increased 
risk of PTL with low BMI also has been reported [429]. Since caloric restriction is 
associated with AMPK activation [430], adverse pregnancy outcomes such as PTL 
at the lower extremes of maternal BMI, may be associated with increased oxidative 
phosphorylation.
While the work here examined the production of IL-1 (3 by gestation-associated 
tissues, inflammasome activation is also associated with processing of pro-IL-18 to 
mature IL-18. To date, IL-18 production in response to inflammasome stimuli by 
gestation associated tissue has not been examined; evidence however of IL-18 at 
the maternal-fetal interface has been described. IL-18 is constitutively expressed in 
human chorion and decidua [431]. Furthermore significant amniotic fluid 
concentrations of IL-18 are observed following microbial invasion of the amniotic 
cavity in patients with intact membranes and PPROM at term and preterm [431, 
432]. Elevated placental IL-18 is associated with preeclampsia [433]. Similar to IL- 
1(3, IL-18 mediates its pro-inflammatory effect by stimulating the production of a 
variety of cytokine including IL-1 (3 and TNFa [434, 435], both of which facilitate the 
physiological processes of labour. Therefore is likely that IL-18 may play a role in 
the onset of labour and in adverse pregnancy outcomes.
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7.4 Modulating the inflammatory response in gestation associated 
tissues
With preterm labour, regardless of infection status, characterised by an increase of 
pro-inflammatory cytokines at the maternal-fetal interface, resolution of this 
inflammatory response might be beneficial in prolonging the pregnancy and 
providing a better outcome for the fetus [1, 15, 436]. For immune homeostasis, 
several endogenous resolving and anti-inflammatory mediators have been 
described, including; anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF-(3), 
bioactive lipids (lipoxins, protectins), glucocorticoids, neuropeptides (ghrelin) and 
resolution associated molecular patterns (RAMPs; HSP10, HSP27) [266].
At the maternal-fetal interface anti-inflammatory cytokines, have been long 
associated with a protective role, maintaining the Th1:Th2 cytokine balance by 
decreasing the production of pro-inflammatory cytokines [365, 366]. The potential 
benefits of anti-inflammatory cytokine treatment on PRR induced inflammation by 
the placenta, choriodecidua and amnion was considered. Firstly IL-4 and IL-13 were 
used. While pre-treatment with both cytokines was able to reduce LPS induced 
cytokine production, utilising classically described signalling receptors; this effect 
was diminished post-treatment. Further investigation with IL-10 demonstrated that 
simultaneous treatment with IL-4 and IL-10 was able to enhance the down- 
regulation of LPS-induced IL-1 (3 and MIP-1a by IL-4 or IL-10 alone. The 
mechanisms of how these cytokines might have their effect are yet to be determined 
but might relate to the down regulation of PRRs themselves, induction of suppressor 
of cytokine signalling (SOCS) proteins or negative regulation of NF-kB [383, 388, 
395]. While these anti-inflammatory cytokines were able to down-regulate IL-1 (3 and 
MIP-1a, it would be worthwhile examining whether this effect applies to other 
pathogenic stimuli, whole organisms or indeed other pro-inflammatory cytokines. 
While anti-inflammatory cytokine treatments in vitro may have a positive effect in 
relation to reducing PAMP induced cytokine response, in order to determine any 
potential benefit for the treatment of PTL in vivo studies would be required.
Maternal nutrition has been shown to influence fetal development and pregnancy 
outcomes, with poor maternal nutrition linked to adverse pregnancy outcomes [437- 
441]. Some reports have implicated that women following a Mediterranean-type diet 
during pregnancy may reduce the risk of PTB [442, 443]. However no benefit was 
observed by others [444]. Regardless a Mediterranean-type diet contains high levels
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of phytonutreints. Plant derived phytonutrients or phytochemicals, have gained 
clinical interest due to their anti-oxidant and anti-inflammatory properties [445-447]. 
Evidence now exists that phytonutrients can inhibit PRR mediated inflammation by a 
variety of mechanisms including inhibition of receptor dimerisation, MyD88- 
independent signalling and NF-kB activation [448]. Additionally several 
phytonutrients including curcumin, capsaicin and quercetin have been shown to 
activate AMPK in 3T3-L1 adipocytes and MCF-7 breast cancer cells [449-452]. It is 
therefore possible that phytonutreints might impact the PRR mediated inflammatory 
response by gestation-associated tissues at the maternal-fetal interface. To date, 
there are only a limited number of conflicting reports examining the impact of 
phytonutreints on adverse pregnancy outcomes. High plasma concentrations of 
several carotenoids, including (3-carotene and lycopene were associated with 
reduced risk of preterm birth [453]. Low carotenoid levels in placental tissue are 
associated with preeclampsia [454]. However, others have reported that lycopene 
was associated with increased risk of preterm birth and low birth weight [455]. 
Therefore further investigations into the impact of phytonutreints on pregnancy 
outcomes are required.
7.5 Limitations
Many of the experiments performed in this study had a limited sample size, resulting 
in no significant outcomes for many of the experiments. This was notably evident 
with inhibition experiments, where a reduction in cytokine output was observed 
however the results were typically not significant. This is even more problematic with 
primary human material, due to the variation in response between donors. It would 
have been beneficial initially for a power calculation to be performed to determine 
sample numbers that would be required. However, when working with human 
samples it’s often difficult to achieve high sample numbers, which can be 
complicated further depending on the nature of the experiments to be performed.
Hetergeneity within the small sample population is likely to be another contributing 
factor to the lack of significance observed. While all the tissue used in this study was 
from healthy pregnant women and therefore the data derived is not impacted by the 
presence of infection, severe medical conditions or adverse pregnancy outcomes; 
there are other factors that may impact the results. For example it’s now been 
established that BMI can impact immune function [456], however this was not 
accounted for during this study, and therefore the maternal BMI of the pregnant
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women recruited would likely add to the heterogeneity observed. Other demographic 
factors including age and ethnicity may also play a role.
7.6 Future Directions
The work presented here was all performed on term non-laboured gestation 
associated tissues; however it’s important to consider how PRR expression and 
function might differ in term laboured tissue and preterm tissues in order to asses 
any potential therapeutic targets for PTL. Murine studies have implicated functional 
TLRs associated with PTB. Functional TLR4 has been implicated in preterm labour 
triggered by administration of heat killed E.coli [92], while intraperitoneal injection of 
poly l:C, caused preterm delivery within 24 hours [257]. In humans, it has been 
previously shown that labour can impact the expression and function of TLRs in the 
placenta, with labour associated with increased TLR2 and TLR5 expression, while 
increase TNFa production was observed in response to TLR4 and TLR7/8 agonists 
[233]. Elevated TLR2 and TLR4 expression in chorioamniotic membranes following 
preterm birth compared to membranes without chorioamnionitis has been 
documented [59]. While the knowledge and understanding in this area is ever 
expanding, much of relates to TLRs and not the wider array PRRs described here, 
highlighting a knowledge grab in this area.
There is also an increasing interest in the role of sterile inflammation as a cause of 
PTL. Recently it has been reported that sterile intra-amniotic inflammation is a more 
frequent cause of PTL than infection associated intra-amniotic inflammation [457]. 
While the exact mechanisms for this are currently unknown, DAMPs/alarmins 
including HMGB1 and IL-1 receptor antagonist (IL-1Ra) have been suggested as 
key to this process, with elevated levels observed in the amniotic fluid and 
circulation of women with high risk pregnancies [408, 410, 458]. HMGB1 is one of 
the most extensively studied DAMPs and has been shown to signal via TLR2, TLR4 
and RAGE (see chapter 7.2), while IL-1Ra functions as a negative regulator of IL- 
10, by binding to the IL-1 R [343]. However the mechanism of action for many 
DAMPs has not been determined. Furthermore, how gestation-associated tissue 
respond to an array of DAMP has yet to be determined and may occur via PRR 
activation. However, if they act in a different manner to PAMPs, it might highlight the 
possible need for different treatment/prevention strategies for intra-amniotic 
inflammation in the presence or absence of infection.
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A link between inflammation and metabolism is becoming increasingly apparent. 
Glucose and fatty acids are the main energy substrates used by cells through 
oxidative metabolism and glycolysis to generate the ATP needed to power cellular 
activity [430]. Studies have shown evidence of a metabolic shift in activated 
macrophages, from oxidative phosphorylation to aerobic glycolysis, the so called 
Warburg effect, to provide the energy needed during host defence [418, 430]. 
Considering that gestation-associated tissues have a highly inflammatory nature 
both in term and preterm labour little is known about the energy substrate 
requirement of these tissues. Understanding this might offer an explanation why 
women at the extremes of BMI are at greatest risk of preterm birth: women with low 
BMI of spontaneous preterm labour and women in obese classes II of PPROM  
[429].
7.7 Final Summation
In summary the work detailed here clearly demonstrates that human term gestation- 
associated tissues express transcripts for a variety of PRRs, including TLRs, NLRs, 
RLRs and CLRs. Furthermore an implied functional role for TLRs 1-7, NOD1, 
NOD2, RIG-I/MDA5 and Dectin-1 was determined by an increase in the production 
of IL-6 and IL-8 following stimulation with receptor specific agonists. Inflammasome 
activity, noted by an increase in IL-1 (3 levels was observed for the placenta and 
choriodecidua in response to [3-glucan and flagellin. Evidence that both caspase-1 
and caspase-8 are involved in this was found. Modulation of LPS-induced cytokine 
production in the placenta, choriodecidua and amnion was observed with treatment 
of these tissues with the anti-inflammatory cytokines IL-4 and IL-13, likely 
functioning via their classically described pathways. Furthermore co-treatment of IL- 
4 and IL-10 resulted in a greater down-regulation of LPS-induced cytokine 
production.
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8 Appendices
8.1 Study Information and Consent Forms
Preterm Birth Study 
Participant Information Sheet
REC No: 11/WA/0060 Version 2,
23/03/12
You are being invited to take part in a research study. We appreciate that this is a 
distressing time for you but we are doing research to determine why preterm birth 
occurs. Before you decide it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully, discuss it with your friends and relatives if you wish and 
decide whether or not you want to take part.
What is the purpose of the study?
Around 10% of pregnant women will deliver their baby before full term. We are trying 
to understand why preterm birth occurs. We particularly want to study the 
inflammatory response in the mother, baby and placenta to see if this might 
contribute to preterm labour and/or birth.
Why have I been chosen?
We are approaching pregnant women who are at risk of delivering their baby 
prematurely and inviting them to be part of this study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you or your baby receives.
What will happen to me if I take part?
If you agree to help with this research, we will take some blood (up to two
tablespoonfuls) from you at the same time as blood is taken for the tests that are
part of your normal care. If you do not need a blood test for other reasons, we will
173
Swansea University 
Prifysgol Abertawe
ask to take a sample specifically for our research. When your baby is born, we will 
collect a sample of blood from the discarded placenta after the delivery. This will not 
harm you or your baby. W e will ask you questions about you general health, any 
medicine you have taken, smoking and diabetes. Your hospital notes will be read to 
gain information about you and your newborn baby, such as birth weight and 
whether you had a boy or a girl.
The samples of blood and placenta will be studied in the laboratory to find out how 
many and what type of immune cells they contain and how these react in various 
tests. Samples will be kept for ten years and may be used for other tests in the 
future.
What are the side-effects of taking part?
Taking the blood sample from you may cause some minor discomfort. There is no 
discomfort for your baby.
What are the possible benefits of taking part?
There are no immediate benefits of taking part in this study.
What if something goes wrong?
We hope that any problems can be sorted out easily and quickly, at the time they
arise and with the person concerned. If the problem cannot be sorted out in this way
and you wish to make a complaint the normal National Health Service and Swansea 
University complaints mechanisms are available to you. You may have grounds for 
a legal action but you may have to pay for it.
Will my taking part in this study be kept confidential?
All information which is collected about you and your baby during the course of the 
research will be kept strictly confidential. You will be given a unique identifying 
number and this will be used for labelling of samples and all analyses undertaken 
using the samples you provide.
What will happen to the results of the research study?
Results will be presented at scientific meetings and published in scientific journals. 
You will not be identified in any report/publication. Some of the samples might be
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used by research students who will present results in their dissertation. Each year 
we will prepare a summary of the progress/results of the study which we can send to 
you if requested.
Who has reviewed the study and who is funding the research?
This study has been reviewed by and given a favourable opinion bv South West 
Wales Research Ethics Committee and is organised by the College of Medicine, 
Swansea University.
Further information
If you want more information about this study please contact Cathy Thornton 
(College of Medicine, Swansea University, Swansea, SA2 8PP or 01792 602122).
Thank you for taking the time to read this, and please feel free to ask any questions.
i
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Swansea University 
Prifysgol Abertawe
PARTICIPANT CONSENT FORM (Version 1, 28/11/11; REC No:
11/W A/0060)
Participant identification number for this study................................
N.B. Two copies should be made for (1) participant, (2) researcher
Title of project: Preterm birth study
Name of researcher: Catherine Thornton, PhD
Contact telephone number: 01792 602122
Please initial box
1. I confirm that I have read and understood the information sheet
for the above study and have had the opportunity to ask questions. ------
2. I understand that my participation is voluntary and that I am free---------------- ------
to withdraw at any time, without giving any reason, without my ___
medical care or legal rights being affected.
3. I understand that sections of any of my or my baby’s medical notes ------
may be looked at by responsible individuals from Swansea University ___
where it is relevant to my taking part in research. I give permission
for these individuals to have access to my records.
4. I agree to take part in the above study.
Name of Participant Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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Preterm Birth Study
Swansea University 
Prifysgol Abertawe
Maternal Questionnaire (Version 1, 30/11/11; r e c  no: 11/WA/0060)
Study ID ID number
Date of questionnaire dd
m vpar
Date of birth 
..............years
dd mm vear Age
Gestation Estimated due date dd m
Reason for preterm birth if known:
Additional information:
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Number of pregnancies (including this one):
How many older siblings will your newborn have?
Have you had a previous preterm delivery? 
Yes/No
Reason for previous preterm birth (if known): 
Additional information:
Are you taking any medication? Yes/No 
If yes,
what?.....................................................................
Do you smoke cigarettes at the moment? 
Yes/No
If yes, How many cigarettes per day?
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If no, Did you smoke before you were
pregnant?
Did you smoke at any time during this pregnancy?
If yes, When did you smoke?............................
How many cigarettes per day?
Does anyone else in your household smoke?
If yes, How many cigarettes per day?
Have you ever been diagnosed with diabetes?
Yes/No
If yes, what type of diabetes? Type 1/ Type
2/Gestational
Were you tested for gestational diabetes in
(i) this pregnancy?
Yes/No
(ii) a previous pregnancy?
Yes/No
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Height
Weight
BMI
The Immune Response at Birth
Participant Information Sheet REC No: 11/WA/0040
Version 2,12/07/11
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully, discuss it with 
your friends and relatives if you wish and decide whether or not you want to take 
part.
What is the purpose of the study?
The immune response made by healthy pregnant women and babies is very 
different to that of non-pregnant women or men. Differences in the immune 
response of babies might relate to the later health of the child. W e want to study why 
the immune response of pregnant women and babies is different. W e also want to 
study if common health issues in pregnant women such as allergy, smoking, 
diabetes or obesity affect the immune response of mother or baby.
Why have I been chosen?
We are approaching pregnant women and inviting them to be part of this study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you or your baby receives.
What will happen to me if I take part?
If you agree to help with this research, we will take some blood (up to two 
tablespoonfuls) from you at the same time as blood is taken for the tests that are 
part of your normal care in pregnancy. If you do not need a blood test for other
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reasons, we will ask to take a sample specifically for our research. When your baby 
is born, we will collect a sample of blood from the umbilical cord and will take the 
placenta. This will not harm you or your baby. The cord and placenta would 
otherwise be disposed of by the hospital.
W e will ask you questions about any allergies you have, medicine you have taken, 
smoking and diabetes. Your hospital notes will be read to gain information about you 
and your newborn baby, such as birth weight and whether you had a boy or a girl. 
The samples of blood and placenta will be studied in the laboratory to find out how 
many and what type of immune cells they contain and how these react in various 
tests. Samples will be kept for ten years and may be used for other tests in the 
future.
What are the side-effects of taking part?
Taking the blood sample from you may cause some minor discomfort. There is no 
discomfort for your baby.
What are the possible benefits of taking part?
There are no immediate benefits of taking part in this study.
What if something goes wrong?
W e hope that any problems can be sorted out easily and quickly, at the time they 
arise and with the person concerned. If the problem cannot be sorted out in this way 
and you wish to make a complaint the normal National Health Service and Swansea 
University complaints mechanisms are available to you. You may have grounds for 
a legal action but you may have to pay for it.
Will my taking part in this study be kept confidential?
All information which is collected about you and your baby during the course of the 
research will be kept strictly confidential. You will be given a unique identifying 
number and this will be used for labelling of samples and all analyses undertaken 
using the samples you provide.
What will happen to the results of the research study?
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Results will be presented at scientific meetings and published in scientific journals. 
You will not be identified in any report/publication. Some of the samples might be 
used by research students who will present results in their dissertation. Each year 
we will prepare a summary of the progress/results of the study which we can send to 
you if requested.
Who has reviewed the study and who is funding the research?
This study has been reviewed by the Local Research Ethics Committee and is 
organised by the College of Medicine, Swansea University.
Further Information
If you want more information about this study please contact Cathy Thornton 
(College of Medicine, Swansea University, Swansea, SA2 8PP or 01792 602122).
Thank you for taking the time to read this, and please feel free to ask any questions.
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PARTICIPANT CONSENT FORM (Version 1, 23/02/11; REC No:
11/W A/0040)
Participant identification number for this study................................
N.B. Two copies should be made for (1) participant, (2) researcher
Title of project: The immune response at birth
Name of researcher: Catherine Thornton, PhD
Contact telephone number: 01792 602122
Please initial box
1. I confirm that I have read and understood the information sheet 
for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.
3. I understand that sections of any of my or my baby’s medical notes 
may be looked at by responsible individuals from Swansea University 
where it is relevant to my taking part in research. I give permission 
for these individuals to have access to my records.
4. I agree to take part in the above study.
Name of Participant Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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The immune response at birth 
Maternal Questionnaire (version 1, 23/02/11; r e c  no: 11/WA/0040)
Study ID ID number
Date of questionnaire dd m vpar
Date of birth dd
mm vear
Age
.years
Gestation Estimated due date dd m
Number of pregnancies (including this one) r
How many older siblings will your newborn have? c
Do you suffer from Eczema?
Asthma?
Hayfever/Rhinitis?
Yes/No
Yes/No
Yes/No
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Have you ever had allergy/asthma diagnosed by your doctor? 
Yes/No
If yes to any of the above, what are you allergic to?
Are you taking any medication? Yes/No
If yes,
what?..............................................................................................
Do you smoke cigarettes at the moment?
Yes/No
If yes, How many cigarettes per day? —
If no, Did you smoke before you were —
pregnant?
Did you smoke at any time during this pregnancy? —
If yes, When did you smoke?...................................
How many cigarettes per day? —
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Does anyone else in your household smoke?
If yes, How many cigarettes per day?
Have you ever been diagnosed with diabetes?
Yes/No
If yes, what type of diabetes? Type 1/ Type
2/Gestational
Were you tested for gestational diabetes in
(i) this pregnancy?
Yes/No
(ii) a previous pregnancy Yes/No
Height .................................. cm
Weight .................................. kg
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The Immune Response at Birth ■ Mother 
and Baby Data
Mother:
Study number assigned: Date consent
taken:
Hospital number: DOB:
Name:
Age: BMI:
Smoking whilst pregnant: Yes / No
Gravidity/Parity: G /P
Any other information:
Baby:
DOB: Gender: Male/Female
Birth Weight: (grams) Mode of delivery:
Gestation: Apgar@1: Apgar@5:
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Time of delivery:
Other:
Placental weight: (grams)
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Peanut, tree nut and sesame seed allergy
LREC No: 04/WMW02/68 Version 1
(20/09/04)
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully, discuss it with your friends and 
relatives if you wish and decide whether or not you want to take part. Ask us if anything 
is not clear or if you want more information. Consumers for Ethics in Research 
(CERES) publish a leaflet entitled “Medical Research and You”. The researchers have 
copies of this leaflet that gives you more information about medical research.
What is the purpose of the study?
Allergy to peanuts, other nuts such as cashews and almonds, and sesame seeds 
occurs in some children and adults. These allergies make some people very ill and we 
are trying to work out what parts of the nuts and seeds cause this illness.
Why I have been chosen?
We are approaching healthy adults with and without allergies and inviting them to be 
part of this study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason.
What will happen to me if I take part?
If you agree to participate we will ask you some questions about your general health 
and whether or not you suffer from any allergies. We will also take some blood ( 1 - 2  
tablespoonfuls) from you. The blood sample we collect will be used to study the effect 
of extracts of various nuts and seeds on immunological responses by your white blood 
cells. We plan to store any unused samples for up to 10 years for further studies that
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arise from our initial research but any additional studies would still relate only to nut and 
seed allergies.
What are the side-effects of taking part?
Taking the blood samples from you may cause some minor discomfort.
What are the possible benefits of taking part?
There are no immediate benefits of taking part in this study. In the unlikely event that 
your blood sample or the questions we ask you indicate that something else is wrong 
with you, we will discuss this with you and make sure the right treatment is made 
available to you.
What if something goes wrong?
If you are harmed by a mistake made by the researchers or by chance you can seek 
compensation but you may have to pay the legal costs. Regardless of this, if you wish 
to complain about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms 
may be available to you.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be 
kept strictly confidential. You will be given a unique identifying number and any 
information about you will have your name and address removed so that you cannot be 
recognised from it.
What will happen to the results of the research study?
Results will be presented at scientific meetings and published in scientific journals. You 
will not be identified in any report/publications. Each year we will prepare a summary of 
the progress/results of the study which can send to you if requested.
Who has reviewed the study and who is organising the research?
191
This study has been reviewed by the Local Research Ethics Committee.
Further Information
If you want more information about this study please contact Cathy Thornton (Institute 
of Life Science, Swansea University, SA2 8PP, Tel: 01792 602122).
Thank you for taking time to read this, and please feel free to ask any questions.
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Peanut, tree nut and sesame seed allergy
QUESTIONNAIRE (Version 1, 20/09/04, LREC No. 04/WMW02/68)
Patient identification for this trial
Date of questionnaire
Date of birth 
Age
day month year
day month year
Gender
Do you suffer from Eczema?
Asthma?
Hayfever/ Rhinitis?
Have you ever had allergy/asthma diagnosed by your doctor?
If yes to any of the above, what are you allergic to?
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Are you taking any medication?
If yes, what? ............................................................................... .
Do you smoke cigarettes at the moment?
If yes, How many cigarettes per day?
If no, Have you ever been a smoker?
If you used to be a smoker:
How long ago? .....................................................
How many cigarettes per day?
Would you be happy to be invited back for follow-up study?
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CONSENT FORM (version 2,17/03/05, LREC No. 04/WMW02/68)
Patient identification for this trial......................................
N.B. Two copies should be made for (1) patient and (2) researcher.
Title of Project: Peanut, tree nut and sesame seed allergy.
Person in charge of the study: Catherine Thornton, PhD 
Contact telephone numbers: 01792 602122
Pleas
e
initial
box
1. I confirm that I have read and understood the information sheet for 
the above study and have had the opportunity to ask questions.
2 . I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reasons, without my 
medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked 
at by responsible individuals from of Abertawe Bro Morgannwg 
University NHS Trust or from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these 
individuals to have access to my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date
Signature
Researcher Date Signature
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8.2 Supplementary data
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Figure 8.1 TLR2 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the placenta (n=3) in response to varying 
concentrations of (A-B) Pam3CSK4, (C-D) FSL-1 and (E-F) HKLM. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown: * p < 0.05.
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Figure 8.2 TLR2 agonist induced cytokine response by the term non-laboured choriodecidua.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the choriodecidua (n=3) in response to varying 
concentrations of (A-B) Pam3CSK4, (C-D) FSL-1 and (E-F) HKLM. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown: * p £ 0.05.
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Figure 8.3 TLR2 agonist induced cytokine response by the term non-laboured amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the amnion (n=3) in response to varying 
concentrations of (A-B) Pam3CSK4, (C-D) FSL-1 and (E-F) HKLM. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown: * p < 0.05.
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Figure 8.4 TLR3 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the placenta in response to varying concentrations of 
(A-B) Poly(l:C)HMW and (C-D) Poly(l:C)LWM (n=3). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.5 TLR3 agonist induced cytokine response by the term non-laboured choriodecidua.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the placenta in response to varying concentrations of 
(A-B) Poly(l:C)HMW and (C-D) Poly(l:C)LWM (n=3). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.6 TLR3 agonist induced cytokine response by the term non-laboured amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the amnion in response to varying concentrations of 
(A-B) Poly(l:C)HMW and (C-D) Poly(l:C)LWM (n=3). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p < 0.05.
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Figure 8.7 TLR5 induced cytokine response by the term non-laboured placenta, choriodecidua 
and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion in response to varying concentrations of flagellin (n=3). Statistical significance was determined 
by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is 
shown: * p < 0.05.
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Figure 8.8 TLR7/8 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the placenta in response to varying concentrations of 
(A-B) imiquimod and (C-D) ssRNA40 (n=3). Statistical significance was determined by Freidman’s test 
with Dunn’s posthoctest. Statistical significance compared to unstimulated is shown: * p < 0.05.
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Figure 8.9 TLR7/8 agonist induced cytokine response by the term non-laboured choriodecidua.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the choriodecidua in response to varying 
concentrations of (A-B) imiquimod and (C-D) ssRNA40 (n=3). Statistical significance was determined 
by Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.10 TLR7/8 agonist induced cytokine response by the term non-laboured amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the amnion in response to varying concentrations of 
(A-B) imiquimod and (C-D) ssRNA40 (n=3). Statistical significance was determined by Freidman’s test 
with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.11 NOD1/2 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml ± SEM) by the placenta in response to varying concentrations of (A-B) 
Tri-DAP and (C-D) MDP (n=3). Statistical significance was determined by Freidman’s test with Dunn’s 
posthoc test. Statistical significance compared to unstimulated is shown: * p £ 0.05, **p£ 0.01.
206
B
80000
60000
E 40000 
"Ss
20000
100000 n
80000 -
«£> 60000 -
?■ 40000 -
20000 -
500000 -i
400000 -
2 300000 -
£  200000 -
100000 -
0 0.1 1 10
Tri-DAP iig/ml Q Tri-DAP ng/ml
500000
400000
2  300000
a- 200000
100000
0 0.1 1 10 
MDP pg/ml MDP iig/ml
Figure 8.12 NOD1/2 agonist induced cytokine response by the term non-laboured 
choriodecidua.
IL-6 and IL-8 production (pg/ml ± SEM) by the choriodecidua in response to varying concentrations of 
(A-B) Tri-DAP and (C-D) MDP (n=3). Statistical significance was determined by Freidman’s test with 
Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * p < 0.05.
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Figure 8.13 N0D1/2 agonist induced cytokine response by the term non-laboured amnion.
IL-6 and IL-8 production (pg/ml ± SEM) by the amnion in response to varying concentrations of (A-B) 
Tri-DAP and (C-D) MDP (n=3). Statistical significance was determined by Freidman’s test with Dunn’s 
posthoc test. Statistical significance compared to unstimulated is shown: * p < 0.05.
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Figure 8.14 RIG-I/MDA5 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion in response to varying concentrations of Poly(l:C)LyoVec (n=3). Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown: * p £ 0.05.
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Figure 8.15 CpG ODN induced cytokine response by the term non-laboured placenta, 
choriodecidua and amnion.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion following stimulation with 5 pM of CpG ODN (n=3). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.16 NOD1/2 agonist induced IL-1p by the term non-laboured placenta and choriodecidua
Explants of (A) placenta and (B) choriodecidua were treated with either Tri-DAP or MDP (both 10 
pg/ml) and levels of IL-1 p production (pg/ml mean ± SEM) in tissue free culture supernatants measured 
(n=3). Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. No 
significant difference was observed.
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Figure 8.17 Dectin-1 agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml ± SEM) by the placenta in response to varying concentrations (n=3) of 
(A-B) depleted zymosan (DZYM) and (C-D) curdlan. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p < 0.05, ** p < 0.01.
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Figure 8.18 Dectin-1 agonist induced cytokine response by the term non-laboured 
choriodecidua.
IL-6 and IL-8 production (pg/ml ± SEM) by the choriodecidua in response to varying concentrations 
(n=3) of (A-B) depleted zymosan (DZYM) and (C-D) curdlan. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p < 0.05.
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Figure 8.19 Dectin-1 agonist induced cytokine response by the term non-laboured amnion.
IL-6 and IL-8 production (pg/ml ± SEM) by the amnion in response to varying concentrations (n=3) of 
(A-B) depleted zymosan (DZYM) and (C-D) curdlan. Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown: * 
p £ 0.05.
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Figure 8.20 MINLCE agonist induced cytokine response by the term non-laboured placenta.
IL-6 and IL-8 production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E-F) 
amnion in response to varying concentrations of TDB (n=4). Statistical significance was determined by 
Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.21 Optimisation of the Syk Inhibitor Piceatannol.
Explants of (A) placenta, (B) choriodecidua, and (C) amnion were stimulated with depleted zymosan 
(100 pg/ml) in the presence or absence of varying concentrations of the Syk inhibitor piceatannol (n=3) 
and IL-6 (pg/ml; mean ± SEM) in tissue free supernatants measured. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. Statistical significance compared to 
unstimulated is shown as: * p ^ 0.05. Statistical significance compared to curdlan is shown as: # p < 
0.05.
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Figure 8.22 Optimisation of the NF-kB Inhibitor BAY11-7082
Explants of (A) placenta, (B) choriodecidua, and (C) amnion were stimulated with LPS (10 ng/ml) in the 
presence or absence of varying concentrations of the NF-kB inhibitor BAY11-7082 (n=3) and IL-6 
levels (pg/ml mean ± SEM) in tissue free supernatants measured. Explants of (D) placenta, (E) 
choriodecidua, and (F) amnion following stimulation with LPS (10 ng/ml) in the presence or absence of 
50 pM BAY11-7082 (n=3) and IL-6 levels (pg/ml mean ± SEM) in tissue free supernatants measured. 
Statistical significance was determined by Freidman’s test with Dunn’s posthoc test. Statistical 
significance compared to unstimulated is shown as: * p £ 0.05. Statistical significance compared to 
LPS is shown as: # p £ 0.05.
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Figure 8.23 Caspase-1 Inhibitor optimisation
Explants of (A) placenta, (B) choriodeicuda and (C) amnion were treated with LPS (10 ng/ml) + 
Nigericin (1 pM) in the presence or absence of the caspase-1 inhibitor Z-WEHD-FMK (n=3) and IL-1 p 
production (pg/ml mean ± SEM) in tissue free supernatants measured. Statistical significance was 
determined by Freidman’s test with Dunn’s posthoc test. No significant difference was observed.
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Figure 8.24 Caspase-8 Inhibitor Optimisation
Explants of (A) placenta, (B) choriodeicuda and (C) amnion were treated with curdlan (100 pg/ml) in 
the presence or absence of the caspase-8 inhibitor Z-IETD-FMK (n=3) and IL-1p production (pg/ml 
mean ± SEM) in tissue free supernatants measured. Statistically significant differences compared to 
curdlan are shown: * p £ 0.05, ** p < 0.01. Statistical significance was determined by Freidman’s test 
with Dunn’s posthoc test. Statistical significance compared to unstimulated is shown as: * p s 0.05.
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Figure 8.25 TDB induced IL-1p by the term non-laboured placenta and choriodecidua
Explants of (A) placenta and (B) choriodecidua were treated with either TDB (both 100 pg/ml) and 
levels of IL-1P production (pg/ml mean ± SEM) in tissue free culture supernatants measured (n=9). 
Statistical significance compared to unstimulated control as determined by Wilcoxon matched pairs 
signed rank test are shown: ** p < 0.01.
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Figure 8.26 LPS induced cytokine response by the term non-laboured placenta, choriodecidua 
and amnion.
IL-1(3 and MIP-1a production (pg/ml mean ± SEM) by the (A-B) placenta, (C-D) choriodecidua, and (E- 
F) amnion following stimulation with 10 ng/ml of LPS (n=9). Statistical significance compared to 
unstimulated control as determined by Wilcoxon matched pairs signed rank test are shown: ** p < 0.01.
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8.3 Conference presentations and publications
8.3.1 Conference posters
1. European Congress of Immunology (2012) -  Poster titled: Modulation of the 
inflammatory response in gestation associated tissues by IL-4.
2. International Congress of Immunology (2013) -  Poster titled: Fungal 
stimulated inflammatory response of gestation associated tissues.
8.3.2 Publications
1. Aled H. Bryant and Catherine A. Thornton (2012). Cytokines and the Innate 
Immune Response at the Materno-Fetal Interface, Recent Advances in 
Research on the Human Placenta, Dr. Jing Zheng (Ed.), ISBN: 978-953-51- 
0194-9, InTech, DOI: 10.5772/33219. Available from:
http://www.intechopen.com/books/recent-advances-in-research-on-the- 
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